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ABSTRACT 
NNEKA IJOMA EMENYONU: Barriers to HIV Care in Rural Uganda 
(Under the direction of Sandra Greene, DrPH) 
 
More than 70% of HIV infections occur in sub-Saharan Africa, where the 
epidemic continues to have a profound impact on public health and economic growth (1-
3). Significant progress has been made over the last decade with the introduction of 
antiretroviral treatment, which has resulted in an increased number of people living with 
HIV, and a decreased number of AIDS-related deaths. Many studies have looked at 
retention in HIV clinics in Africa (4-16) as well as HIV treatment outcomes (17-26), and 
have concluded that low retention in care threatens the sustainability of the early success 
of treatment programs in resource limited settings (RLS).   
The purpose of this study was to identify barriers to HIV care in rural Uganda and 
determine the impact of these barriers on HIV treatment outcomes. The study comprised 
a two part, mixed method approach, including data from the two separate sources 
analyzed concurrently. A cross-sectional qualitative study was conducted with key 
informant interviews of healthcare providers and patients at the Mbarara ISS Clinic in 
Uganda. A sub-study comprised quantitative analysis of secondary data from the Uganda 
Antiretroviral Rural Treatment Outcomes (UARTO) cohort collected over the first 12 
months of enrollment in UARTO.
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Findings from the qualitative analysis show that stigma, financial constraints, and 
inflexible clinic schedules present barriers to patients accessing and sustaining care. The 
availability of antiretroviral therapy, treatment success, trust in the healthcare providers, 
social support, and a strong reliance on spirituality emerged as strong facilitators to care. 
For the Quantitative study, results from the survival analysis showed that travel time to 
clinic longer than 45 minutes was associated with mortality as was being male.  Being 
male was also associated with increased odds of treatment failure (odds ratio (OR) =  0.5, 
95% CI 0.28-0.89). Age was associated with being lost to follow up (OR = 1.00 95% CI 
0.98-1.03). Higher levels of internalized stigma were associated with lower MEMS 
adherence (OR = 0.90 95% CI 0.81-0.99). Having a lower asset index predicted treatment 
interruptions lasting 7 days or shorter (OR = 0.74 95% CI 0.61-0.91) and increased travel 
time to clinic predicted a decreased odds of treatment interruptions lasting 30 days or 
longer (OR = 0.98 95% CI 0.96-1.00). There were no significant associations between the 
predictor variables of stigma or social support and the outcome variables of loss to follow 
up, treatment failure and mortality. While the quantitative data did not support the 
hypothesis that social support mitigates structural and economic barriers to care, the 
findings suggest points of intervention that are targeted towards reduction of stigma at the 
individual level.  
The study concluded that barriers to sustained HIV care in a rural resource limited 
setting include a combination of factors that are structural, economic, and social, which 
act independently or through complex interactions. Strategies to improve HIV care in 
resource limited settings should aim at targeting all three components of these barriers, 
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while strengthening health care systems and building local leadership remain the 
foundation for sustained success. 
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CHAPTER 1: INTRODUCTION 
 
A. Statement of the Issue  
 
The Joint United Nations Program on HIV/AIDS (UNAIDS) estimates that 34 
million people worldwide are infected with HIV/AIDS(1). Of this number, 70% are 
estimated to be in sub-Saharan Africa where 72% of the AIDS-related deaths in 2009 
were reported (1). Since the onset of the epidemic in the early 1980s, over 25 million 
people have died of HIV/AIDS, and sub-Saharan Africa continues to be 
disproportionately affected by the disease (1). Disease management through viral 
suppression with antiretroviral therapy (ART) and prevention of new infections remains 
the most effective course of action in controlling the pandemic. In the absence of a cure, 
current public health strategies aim at expanding the availability of ART and preventing 
new infections through risk reduction and behavior change. 
 Significant progress has been made over the last decade with the introduction of 
ART(1, 24), which has resulted in an increase in the number of people living with 
HIV/AIDS, and a decrease in the number of AIDS related deaths. In 2010, there were 1.8 
million deaths related to AIDS, as compared to previous years with death tolls above 2 
million(1). This trend of decline in AIDS-related deaths, coupled with people living 
longer with the disease, has been consistent in most sub-Sahara African countries since 
2004 when the expansion of ART began in the region. Nonetheless, the long-term 
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effectiveness of ART is dependent on the patients’ life-long adherence to a regimen (27), 
concurrent with routine follow up in care. While the success of ART is evident (24, 28), 
issues of access and availability continue to present challenges in rural and resource 
limited settings in sub-Saharan Africa (29-32), where 90% of the disease burden lies (1, 
33).  
Many studies have looked at retention in HIV clinics in Africa (4-16) as well as 
HIV treatment outcomes (17-26), and have concluded that low retention in care threatens 
the sustainability of the early success of treatment programs in resource limited settings 
(RLS). More recent studies have examined barriers to HIV care in RLS and have 
highlighted the following target points where barriers are most evident; HIV testing, 
entry into care, treatment acceptance, treatment adherence, and retention in care (34, 35). 
These studies suggest the need for targeted interventions at specific time points where 
retention or linkage in care, are likely to be compromised. These targeted interventions 
could mitigate the poor treatment outcomes associated with low retention in care by 
strengthening linkage in care from a patient-centered angle. A recent intervention study 
by Gardner et al..., assessed the effects of exposing patients in 6 different RLS HIV 
clinics to brochures, posters and messages emphasizing the importance of retention in 
care, versus standard of care. The study reported 3% relative improvement in clinic 
attendance and a 7% relative improvement in attending two consecutive clinic visits in 
the intervention group, particularly in young patients with lower baseline biological 
characteristics (35).  
A goal of this dissertation was to add to the existing body of knowledge in further 
exploring what the barriers to care are through a combination of both qualitative and 
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quantitative methods of inquiry. Given the highlighted target points of intervention from 
previous studies (35, 36), this dissertation also aimed at highlighting possible strategies 
for intervention to ensure not only that the current reduction in morbidity continue as a 
downward trend, but that the lives of people living with HIV/AIDS are improved. The 
study was carried out in a rural town in Uganda that is representative of resource-limited 
settings with a high burden of disease. It is important that policies on HIV/AIDS 
management in these settings be guided by a better understanding of the current 
challenges, such that programs are tailored to the specific needs of their users in order to 
achieve long-term success. This study aims at providing insights that could potentially fill 
this present gap. 
 
B. Specific Aims 
 
The purpose of this study is to identify barriers to HIV care in rural Uganda and to 
determine the impact of these barriers on HIV treatment outcomes. A better 
understanding of both the barriers and facilitators of HIV care in rural Uganda will 
subsequently guide interventions for optimal HIV care in resource limited settings.  
 
The specific objectives of this study are as follows: 
Aim 1. To identify the structural and economic barriers to retention in HIV Care in rural 
Uganda 
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Aim 2. To determine the impact of the defined barriers on patients’ HIV treatment 
outcomes 
Aim 3. To develop intervention strategies to ease the impact of structural and economic 
barriers to HIV care in rural Uganda 
 
Hypothesis: Structural and Economic barriers to HIV care in rural Uganda are associated 
with diminished health outcomes through decreased access to and retention in care, 
increased treatment interruptions, increased AIDS-related morbidity and mortality. 
 
For the purpose of this study, barriers to care were initially grouped under two 
main categories; the first being structural barriers, and the second being economic 
barriers. There is need to distinguish between these two factors as they require different 
interventions. Structural barriers include environmental factors such as seasonal changes, 
or geographical obstructions that might affect an entire community regardless of the 
economic status of its members. This definition also includes factors that affect the 
distribution and supply of medications, clinics and clinicians in rural Uganda of which 
the individual patients have no influence. Structural barriers can also be defined at the as 
factor external to the individual’s ability to function regardless of their economic status 
and for which there is no immediate or direct solution. Economic barriers in this study are 
defined as financial factors at the individual level that impede access to HIV care. By 
segregating these two concepts, the appropriate interventions can be tailored to address 
specific problems presented in HIV care and delivery in rural settings. As such, this study 
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will explore both definitions of barriers described above (structural and economic) and 
determine where the greatest burden lies for patients, healthcare providers and the 
healthcare delivery system as a whole.   
Following the qualitative analysis, a constellation of barriers were identified but a 
third category emerged as a leading barrier to care at the individual level, which included 
psychosocial factors such as stigma, depression and the impact of patient-provider 
interactions on care. Internalized stigma presented as a barrier to patients’ accessing care 
or seeking support for their HIV disease, while negative patient-provider interactions, 
centered around rigid clinic policy on missed visits, resulted in missed visits and poor 
retention in care.  
 
C. Background: HIV in Sub-Saharan Africa 
 
 It is estimated that the first epidemic of HIV in Africa occurred in central Africa 
sometime in the 1970s based on genetic evolution studies (37-40) In the early 1980s the 
first cases of HIV were reported in Uganda, as a disease that affected both men and 
women and caused severe wasting. The disease was locally known as ‘slim disease’ 
because of the rapid weight loss and diarrhea that the patients presented with (37, 41). 
The connection was made to AIDS cases in the United States, although the epidemic in 
East Africa was found mainly in heterosexual individuals. Transmission was rampant in 
high-risk groups; sex workers, and migrant laborers(37, 41). The rapid spread of the 
disease was evident in East Africa, particularly in the areas bordering Lake Victoria, due 
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to a combination of factors including high rates of migration for work and ease of travel, 
prevalence of sexually transmitted diseases, coupled with low status of women, and lack 
of male circumcision (37). Truck drivers, trader, miners, soldiers and sex workers were 
the initial drivers of the epidemic and the patterns of infection were seen along major 
trade and transport routes. Uganda was hit particularly hard by the epidemic and by the 
late 1980s the prevalence rate was more than 30% among pregnant women (37, 42). Most 
patients presented to the hospital in the advanced stages of the disease and died due to 
lack of treatment. Because little was known about modes of transmission at the time, 
coupled with the fact that the initial drivers of the epidemic were migrant workers and 
sex workers, HIV was characterized as a ‘disease of prostitutes’, and the stigma 
associated with the disease was born out of this notion. Given the stigma associated with 
the disease, the motivation to get tested in the absence of treatment was low.  
Governments in sub-Saharan Africa responded to the crisis by focusing on prevention. 
Uganda’s prevention efforts were outstanding as the country was able to reverse the 
trends and turn the epidemic around by decreasing its HIV prevalence rate significantly 
by 2000. Backed by strong political will, Uganda’s extraordinary effort resulted in the 
country reducing the adult HIV prevalence rate down from around 14% in the early 
1990s to 8% in 2000, and from a high of 29.5% in 1992 to 11.3% in 2000 in pregnant 
women (42). 
 Although prevention efforts were extremely successful in Uganda, it did not erase 
the need for treatment for those who were living with HIV/AIDS. By 2001, it was 
estimated that about 19 million people had died of HIV/AIDS in sub-Saharan Africa, and 
28.1 million people were still living with the disease (1, 2, 33). Majority of this number 
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were living without access to treatment given its high cost. Concerns about the ability of 
poor, illiterate individuals in resource limited settings to sustain a complicated regimen of 
antiretroviral therapy involving multiple drugs taken at specific times, drove policy in the 
United States and other developed nations to withholding treatment to low income 
countries. The fear was that the inability to sustain the required treatment regimen would 
result in the development of resistant strains of HIV, given the virus’ high rate of 
mutation, and that resistant strains would make the global efforts to control the virus 
without development of resistance, near impossible. There were strong arguments in 
favor of withholding treatment and limiting the response to the HIV epidemic in Africa to 
just prevention. In an article in the Boston Globe on June 7, 2001, Andrew Natsios, 
administrator of the United States Agency for International Development (USAID), was 
quoted as saying that “many Africans don’t know what Western time is. You have to take 
these [AIDS] drugs a certain number of hours each day, or they don’t work. Many people 
in Africa have never seen a clock or a watch their entire lives. And if you say, one o'clock 
in the afternoon, they do not know what you are talking about.” (43). The statement was 
taken as fact and reiterated the notion that withholding delivery of ART to low-income 
countries was justified. 
 
Treatment Scale Up in sub-Saharan Africa 
After much debate and mounting pressure on the pharmaceutical industry to 
reduce ART prices, and following two decades of devastating outcomes of the HIV/AIDS 
epidemic in Africa, treatment was finally made available in 2003/2004. This achievement 
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was made possible by the collaborative effort and funds raised by several countries for 
the multilateral Global Fund for AIDS, Malaria and Tuberculosis (The Global Fund) and 
by the United States government through the United States President’s Emergency Plan 
for AIDS Relief (PEPFAR), which was approved in 2004(13). This rapid expansion of 
antiretroviral therapy (ART) access in Africa made possible by a conglomerate of 
international aid programs such as PEPFAR and The Global Fund, has proved to be one 
of the greatest public health successes of this century.  Equally outstanding is evidence, 
following this expansion of ART, of unexpectedly high levels of ART adherence (20, 44, 
45) in sub-Saharan Africa where the opposite was expected. Early reports indicate 
exceptional adherence to antiretroviral therapy in Uganda and findings of a meta-analysis 
by Mills et al.. showed significantly higher adherence in sub-Saharan Africa when 
compared to rates in North America(45).  
While early ART programs have been successful with increasing the availability 
of ART, the sustainability of this success has been threatened by low retention and other 
socio-economic barriers to care at the individual level. Despite evidence of high levels of 
ART adherence and viral suppression, retention in care and early mortality remain high in 
resource-treatment limited settings (13, 15). Results from a meta-analysis of retention in 
HIV clinics in RLS show that close to 50% of patients initiating ART in HIV clinics are 
not receiving treatment after two years (4) and that the average retention in clinics is 
roughly 60% (11).  
Data from HIV clinics in sub-Sahara Africa have also shown that even when HIV 
treatment is fully subsidized, ancillary costs and logistical challenges such as 
transportation to clinic, as well as food insecurity, become major barriers to sustained 
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treatment adherence and good health outcomes (29, 31, 32, 46-50). Many patients in rural 
Uganda for instance devote up to 30-50% of their income for transportation to the clinic 
to pick up their monthly refills and are unable to fulfill the competing demands of 
adequate nutrition on a daily basis (32, 50). Many HIV patients in rural RLS present to 
HIV clinics when their HIV infection has progressed to advanced stage AIDS (51). At 
this point, many of the patients are no longer physically able to work, have exhausted 
their economic resources at the same time, and are a financial burden to their immediate 
and extended families (31, 52-54). As the stage of disease progresses, the ancillary costs 
needed to sustain treatment of HIV/AIDS increases because of the physical, mental and 
emotional degeneration of the infected persons’ state of being. The insurmountable 
burden on families to overcome these barriers leads to interruptions in care, losses to 
follow up and subsequently result in irreversible ART resistance, clinical failure and 
mortality. Transportation costs therefore remain a common barrier to treatment retention 
and treatment adherence in HIV treatment programs in sub-Saharan Africa.  
Questions about the merits of continued government spending on ART programs 
because of this notion of sustainability and continued economic burden, have led to a 
closer examination of the economic impact of ART. Recent studies by Thirumurthy et al.. 
assessed socio-economic factors that impact HIV care in RLS at the individual and 
household levels have found that being on ART increased productivity and household 
income of adults, and subsequently led to increased school attendance for children in 
these households (55-59). These findings support the argument that the economic returns 
of ART may outweigh the costs of providing ART in RLS and strategies to sustain 
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treatment should remain a high priority even with the underlying climate of diminishing 
funding. 
 
Treatment Scale-Up in Uganda 
ART was introduced in Uganda in 1998 through the Ugandan government’s Drug 
Access Initiative, supported by the the Joint United Nations Program on HIV/AIDS 
(UNAIDS). By this time, the country had already achieved a marked success in reducing 
the adult prevalence from its peak in 1992 at 18%, to less than 10%(42, 60). While the 
exact reasons for the decline are still speculated, the political drive and support of several 
prevention strategies involving campaigns for behavior change, had an impact in 
reducing new infections. The reduction in HIV incidence, coupled with high AIDS-
related deaths, are believed to be the main reasons for the drastic reduction in prevalence. 
By 1998, AIDS related deaths were still high, and over 100,000 people had died of AIDS 
in Uganda , mainly because of the limited access to ART. Although ART was available 
for purchase through the DAI program,  the high cost (over $100 for one month’s dose), 
made it prohibitive for the average Ugandan, and for 5 years that followed, access 
remained limited (60).  
In 2004 no-cost ART became available in Uganda through increased funding and 
support from PEPFAR and the Global Fund. In partnership with the Uganda Ministry of 
Health, and other international develoment partners, the scale-up of ART increased 
access in Uganda from the capital city of Kampala to the rural villages throughout the 
country. The Regional Referral Hospitals were the first points of care and subsequently, 
close to 400 HIV clinics were established in public and private settings across the country 
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to meet the urgent need of delivering free ART to thousands of patients who previously 
had no access . Despite this rapid increase in access, by the end of 2007, there were 
approximately 1 million people infected with HIV in Uganda and only 53% of HIV-
infected people in need of ART were receiving it by the end of 2009 (60).  
 
D. Significance 
 
 
 To date, over 50 billion US Dollars have been spent on HIV/AIDS treatment 
programs in RLS, increasing treatment access to more than 5 million people (1, 2, 33). 
Despite this significant progress, ART coverage has reached only 53% of those in need of 
this life-saving therapy in sub-Saharan Africa. The task of reaching universal access has 
not been accomplished and still presents a huge public health challenge globally.  While 
in line with meeting the goals of universal access, the rapid expansion in antiretroviral 
therapy access has put enormous strains on the infrastructure required to deliver sustained 
treatment in resource-limited settings that were already plagued with weak health 
systems. The challenges of delivering optimal HIV care and treatment in resource-limited 
settings is exacerbated by the two-directional limitations; one within the health systems, 
and the second with the socio-economic burden of managing a chronic illness that 
impacts poverty levels and limits the ability of patients in resource limited settings to 
access care even when it is delivered adequately.  
 
 
CHAPTER 2: REVIEW OF LITERATURE 
 
ART Roll Out and Adherence to ART in sub-Saharan Africa 
 For more than 30 years, the HIV/AIDS pandemic has devastated the lives of 
individuals, families, and communities around the world and its impact has been well 
documented in both developed and developing countries. With 70% of the cases (1), sub-
Saharan Africa continues to be by far the worst affected region in the world, where the 
epidemic has had a profound impact on economic growth and poverty. In the first two 
decades of the epidemic in Africa, much of the effort was put towards prevention, and the 
push to make treatment readily available where it was previously withheld. The 
introduction of ART in 2004 and the subsequent rapid expansion created a new forum for 
discussion around sustainability of the treatment efforts in resource-limited settings. The 
review of literature for this study focuses on the period following the introduction of 
ART in sub-Saharan Africa to the present; describing ART treatment outcomes and the 
challenges and facilitators of HIV care in resource-limited settings. 
Since adherence to ART is the most important predictor of virologic failure (27), 
some of the early studies on treatment outcomes in sub-Saharan Africa focused on ART 
adherence. The initial research questions asked whether or not it was possible for low-
income patients in African to adhere to complicated ART regimens, and whether ART 
could successfully be delivered to rural communities where the needed physical
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infrastructure was limited. One of the first studies on ART adherence was conducted by 
Bangsberg et al. in Kampala, Uganda in 2002. In a sample of 304 HIV positive adults on 
self-pay therapy, from three different clinic sites in Kampala, Bangsberg’s study found 
adherence to be comparable to those in most countries. More than half of the participants 
(68%) reported adherence levels greater than 95%, as compared to developed countries 
where adherence levels reported by patients ranged between 40% and 70% (20).  The 
most commonly cited reason for missed doses in this population was lack of money to 
pay for their prescriptions. A direct correlation between income and adherence was 
observed in this study where participants with a monthly income of less than 100,000 
UGX (~$40) had a higher likelihood of achieving less than 95% adherence.  A second 
study by Bangsberg et al., also in conducted in Kampala between 2002 and 2003, showed 
mean adherence levels of 91%-94% (61) for a population of self-pay participants. Similar 
results were reported in other studies in sub-Saharan Africa and India with ART 
adherence rates above 90% (51, 62), in contrast to what was previously expected. Results 
from a qualitative study conducted by Crane, Bangsberg et al., to better understand the 
findings of high adherence within the self-pay population in RLS, showed that the 
financial burden of purchasing ART was the main barrier to adherence (63). The study 
found that participants were highly motivated to take their medications ‘to live’ and that 
the immediate positive rebound from illness gave them an incentive to adhere to their 
medications (63). The findings from the study suggested that missed doses were as a 
result of ‘failure to access medications’ rather than a ‘failure to adhere’ to medications 
(63).  
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Although the unexpected findings were impressive, there was still some 
speculation as to whether the high rates of adherence observed were due to characteristics 
of highly motivated and self-paying early adopters, or if the same trend would be 
observed when ART was provided at no-cost. It was expected that those who were 
paying for medications at a high cost, would be highly motivated to take their 
medications, and questions remained about the trends in the treatment programs that were 
free. Amidst much skepticism and even on the platform of weak health care 
infrastructure, the roll out of ART in resource-limited settings was launched in 2003. At 
this time, there was a shortage of healthcare workers in Africa (3), limited laboratory 
capacity, and concerns about the feasibility of drug supply to remote areas were 
prevalent, given weakness in the supply-chain management (3). In light of this, the WHO 
set guidelines for HIV care in Africa that were based on a public health approach, which 
was the opposite of the model for patient care in the United States. Given prohibitive 
costs, the US model, which was patient-centered, with specialized physicians and costly 
laboratory monitoring, was not feasible in resource-limited settings. The WHO public 
health approach was designed to cater to the needs of the population, rather than the 
individual, with standardized protocols, so that treatment could be delivered by non-
specialist clinicians in a de-centralized health system. Tools for clinical decision-making 
were simplified into what was called ‘the 4-Ss’. The ‘4-Ss’ referred to a standard 
treatment algorithm that guided clinical decisions on when to: ‘start drug treatment; 
substitute for toxicity; switch after treatment failure; and stop’ (3). The WHO guidelines 
in the public health approach also provided simplified options of ART for both first-line 
and second-line therapy. The first-line recommendation included two options; one with a 
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combination of 3 different nuclease analog reverse-transcriptase inhibitors (NRTI) or the 
second option with 3 different NRTIs combined with one non-nucleoside reverse-
transcriptase inhibitor (NNRTI). The second-line options were given based on what was 
prescribed as first-line therapy and included fixed–dose combinations of either 2 NRTIs 
plus one protease inhibitor (PI), or a combination of one NRTI, one NNRTI, and one PI. 
Production of the fixed-dose combinations in generic formulations enabled the prices to 
drop dramatically (3).  The generic pill burden was subsequently reduced to as few as one 
pill, taken twice a day.  
In 2003, the WHO launched its 3 by 5 initiated, which strived to treat 3 million 
HIV positive people in low-income countries by the year 2005. Although the initiative 
failed to meet its goal by 2005, with only 1.3 million people on treatment (1, 3), it set the 
pace for increased access and shaped national policy on HIV treatment in almost all focus 
countries (3), making it possible for the success of ART scale-up. As with the self-pay 
patients, adherence rates were unexpectedly high in non-paying patients on ART in 
Africa in the initial years (64, 65). In 2009, Ware et al. conducted a qualitative study to 
explain the adherence success experienced in sub-Saharan Africa.  The study spanned 
three countries; Nigeria, Uganda, and Tanzania, and involved 414 in-person interviews 
carried out with 225 HIV-positive adults taking ART, their treatment partners and 
healthcare providers.  This study found that patients were highly motivated to take their 
medications and prioritized adherence to ART despite multiple obstacles and challenges 
to accessing and retaining in care (48). The main driving force behind prioritizing 
adherence was explained not only by a need to improve health, but also a need to fulfill 
responsibility in social relationships. Social relationships were particularly important 
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because through them, patients received tangible assistance to meet their treatment needs. 
In return, patients felt obligated to reciprocate the support from their friends and family 
by adhering to their medication, and staying alive, in order to preserve these relationships 
(48). Ware et al. noted that in resource-limited settings, where formal social welfare 
programs and government/public assistance were absent, consistent goodwill expected 
from social relationships were essential for survival (48). The concept of social capital in 
this case, is described as a resource for prioritizing adherence and overcoming economic 
barriers to care. 
 
Barriers to Care 
Despite the motivation to stay in care, evidenced by high adherence rates, the 
findings in recent literature show that access to care and retention in care continue to pose 
challenges and threaten the sustainability of the initial ART successes. In a qualitative 
study conducted in Uganda in 2009, patients recounted several challenges in making their 
routine monthly clinic visits to pick up medications. Transportation costs emerged as a 
key obstacle, alongside food insecurity, competing demands, alcohol use, and financial 
constraints linked to poverty (32).  Several studies throughout sub-Saharan Africa 
reported similar findings (28, 46, 47, 50, 66-69). Difficulty in meeting transportation 
costs to clinic visits sometimes caused participants to miss visits and have treatment 
interruptions due to an inability to refill their prescriptions in a timely manner.  
Other barriers to accessing care included long waiting times in over crowded 
clinics, coupled with unexpected user fees for clinics that could not afford to deliver the 
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‘free’ medications without a fee for service (46). Many patients continued to feel 
stigmatized and discriminated against. Respondents in a multi-national qualitative study 
involving Uganda, Tanzania and Botswana, reported negative experiences as a result of 
disclosing their HIV status which included loss of jobs, domestic violence or being 
abandoned or treated badly by their partners, and being isolated by community members 
(46, 47, 52, 66).  Medication side effects, especially with the fixed doses that included 
d4T, a common NRTI used in initial formulations, were common and included body rash, 
swollen legs, nausea, headache, increased heart rate, diarrhea and vomiting (46).  
Although direct effects of alcohol consumption on HIV disease progression were not 
sited in the literature, alcohol was found to be a barrier to adherence by impairing 
memory, concentration and physical coordination (52), which most likely lead to missed 
doses.   
The overwhelming numbers at the centers of treatment made it difficult for the 
healthcare providers to administer treatment and the required counseling in a systematic 
flow.  The increase in patient volume was not met by a correlated increase in human 
resources required to manage care. The WHO public-health approach proposed task-
shifting to lower cadre health providers such as clinical officers and nurses, who were 
authorized to prescribe ART and give comprehensive HIV care, but this still did not meet 
the growing patient needs. The quality of pre and post ART counseling within the clinics 
varied by region and in Uganda, the counseling was done mostly by ‘lay counselors’ with 
limited training, who were HIV positive themselves in many cases (46). The poor quality 
of HIV counseling, among other compounded issues of overcrowded clinic settings, 
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made for sub-optimal patient-provider interactions that were frustrating for both parties 
(66, 70).  
Retention in care emerged as a significant challenge in the recent literature (4, 11, 
12, 14, 71). A systematic review of patient retention in care from 2000 to 2007 carried 
out by Rosen et al. in sub-Saharan Africa revealed that by the end of the 2nd year of 
follow-up ART programs had a retention rate of only 60% of their patients (4).  This 
review included 32 publications on 33 patient cohorts totaling almost 75, 000 patients in 
13 countries and found that rates for retention in care ranged from 27% to 77% in the 
clinics studied (4). Forty percent of the patients no longer in care in these facilities were 
either lost to follow-up or dead (4).  A mixed-method study by Roura et al. in 2009, 
aimed at better understanding attrition from ART programs in Tanzania, revealed that 
although patients were highly motivated to stay in care at the individual level, 
programmatic constraints and structural barriers at the community level contributed to 
lowered retention rates (72). Geng et al. also sought to understand attrition using a 
sampling-based approach in an HIV clinic in rural Uganda and found that the main 
reasons for losses to follow-up were lack of transportation or money to return to clinic 
visits, and competing demands at the family level with childcare and work 
responsibilities (11).  This study revealed that mortality was highest following the last 
clinic visit, and the predictors of mortality included lower CD4 T-cell counts at baseline, 
being older, and having lower blood pressure at the last clinic visit (11). Although the 
study concluded that social and structural factors were the main reasons for patients being 
lost from care, much of the attrition was due to patients transferring to other clinics that 
were possibly more conveniently located to their homes (11). This suggests that not all 
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patients who are lost to follow up have poor treatment outcomes and the issues surround 
retention in care are complex, and need further investigation.  
The decline in clinical outcomes for patients who are no longer linked in care (4, 
11, 71, 72) provide the impetus for a shift in focus from not just increasing access to 
ART, but ensuring retention in care to maximize the benefit of increased access (65). 
Recent interventions to improve adherence and/or retention in care have focused in four 
main areas: 1. Use of some form of directly observed ART therapy (DOT) (73-78); 2. 
Use of community-based peers and treatment supporters (6, 9, 79-83); 3. Use of 
community based follow-up systems of mobile clinics (84-87); 4. Use of technology and 
devices such as cellular telephones or alarm systems for monitoring adherence and to 
serve as appointment/regimen reminders (88-90).  
 
Strategies for Mitigating Barriers to Care  
There have been a few other attempts at improving access to health care services 
by provision of vouchers or cash transfers to mitigate the economic barriers to accessing 
care (91, 92). These interventions were not specifically for HIV/AIDS patients in RLS, 
but serve as proof of concept for the intervention. In Nicaragua, a voucher system 
initiated by a public-private sector partnership proved successful at increasing the use of 
STI services by commercial sex workers (91). This incentive to access care had a 
significant impact on the outcome of sexual health in this particular population. In a study 
among HIV-positive methadone patients in San Francisco, voucher reinforcement 
improved medication adherence in a randomized trial (92). Other studies in RLS 
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including Kenya and Cambodia have found that implementing a voucher approach has 
been successful at improving reproductive health behaviors in the studied communities 
(93-96). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 3: METHODOLOGY 
 
A. Overview of Study Design 
 
This study comprised a two part, mixed method approach to better understand the 
barriers to HIV care in rural Uganda and the impact this has on HIV treatment outcomes. 
Data from the two separate sources were analyzed concurrently. 
I. Qualitative Study. A cross-sectional qualitative study was conducted with key 
informant interviews of the Mbarara ISS Clinic healthcare providers and patients 
on ART.  The study took place in a government HIV treatment setting in Mbarara, 
Uganda; the Immune Suppression Syndrome (ISS) Clinic, at the Mbarara 
Regional Referral Hospital (MRRH), from June, 2010 to December, 2011. 
II. UARTO Sub-study. This study comprised quantitative analysis of secondary 
data from the UARTO cohort collected over the first 12 months of enrollment in 
UARTO. The purpose of the quantitative analyses was primarily to describe the 
study population in the study setting; Mbarara, Uganda, and further clarify the 
relationship between structural and/or economic barriers to care and health 
outcomes in HIV positive patients in Mbarara, Uganda. 
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Study Site   
  Mbarara Regional Referral Hospital (MRRH) Immune Suppression Syndrome 
(ISS) Clinic served as the study site for participant recruitment, informed consent, data 
collection and analysis. Mbarara has a population of approximately 65,000 residents and is 
located 275 kilometers southwest of the capital city of Kampala in Uganda. Mbarara lies at 
the cross roads leading either to Rwanda, Congo or Tanzania. Mbarara is one of the fastest 
growing towns in Uganda, although most of the district it is still considered rural, 
representative of the Ugandan population, which is almost 90% rural.  
  The MRRH ISS Clinic is part of the Mbarara University of Science and 
Technology (MUST) Teaching Hospital. This Hospital was built as a district hospital in 
1952 and the University (MUST) was established in 1989. The MRRH has 350 beds and 
the ISS Clinic is an outpatient clinic housed within the hospital premises. The Mbarara ISS 
Clinic serves as the regional referral HIV clinic for the entire Southwestern region of 
Uganda, with a few additional patients from Rwanda, Congo and Tanzania. The Mbarara 
ISS Clinic was started in 1998 and has a total cumulative enrollment of over 20,000 
patients, of which more than half are active to date. The clinic enrolls approximately 150 
new patients per month and an average of 150-200 new and returning patients are seen each 
day. About 7,000 patients are receiving antiretroviral therapy. The clinic has 37 staff in 
total. These include 23 healthcare providers who have direct patient contact: (Physician 
(1); Medical officers (5), Pharmacy dispensers (2); Clinical officers (2); Senior nursing 
officer (1); Nurses (2); Nursing assistants (3); Counselors (3); Phlebotomist (1); Health 
Educators (3)),  and fourteen additional staff that provide care indirectly including: 4 
laboratory personnel, 10 data personnel, 2 administrators, including a clinic director. What 
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about the expert patients or peer counselor? The clinic is open 5 days a week and sees 
patients with confirmed positive HIV status. 
  The Mbarara ISS Clinic is a free government run clinic with a mission of caring for 
the rural population in the community surrounding it. Although it is a government run 
clinic, there are several international collaborators that are affiliated with the clinic. These 
include Harvard University, Massachusetts General Hospital, University of California San 
Francisco, USAID, the CDC, and others. The HIV treatment program at the Mbarara ISS 
Clinic is funded jointly by the Uganda Ministry of Health, The Global Fund, PEPFAR and 
research/donor funds through collaborating institutions.  
 
B. Qualitative Study Methods 
 
Study Design 
A cross-sectional qualitative study was conducted via in-depth interviews with 
healthcare providers (n=14) and a sample of patients (n= 19) at the Mbarara ISS clinic. 
The Mbarara ISS Clinic patients in this study were recruited from a sub-sample of 
UARTO study participants enrolled between June 2005 and June, 2011. At the time of 
this study, the UARTO cohort was still open to enrollment. The study took place at the 
Mbarara ISS Clinic, in Mbarara, Uganda, from July, 2010 to June, 2011. 
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Study population 
This study included two groups of participants;  
1. Healthcare providers at the Mbarara ISS Clinic;  
2. Patients on ART at the Mbarara ISS Clinic, sampled from the UARTO study. 
 
1. Healthcare providers at the Mbarara ISS Clinic 
 The sample of healthcare providers at the Mbarara ISS Clinic consisted of 14 
healthcare providers who were working full time at the clinic. At the time of the study 
there were a total of 20 healthcare providers at the clinic and all of them were invited to 
participate in the study during an informational meeting session about the study. Six of 
the providers were either unavailable at the time of the study, and it was determined that 
the fourteen interviews were sufficient to answer the research questions. No subsequent 
attempt was made to contact the remaining six healthcare providers for interviews. 
Consent was obtained for all who were interested at the Mbarara ISS Clinic, where the 
interviews also took place.  The study investigator and research assistant both conducted 
one-on-one, in-depth interviews, with open-ended questions, with the healthcare 
providers to determine their perceptions on barriers to HIV care as experienced by their 
patients.  
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2. Patients sampled from the UARTO study 
 Twenty UARTO participants were randomly selected from two defined 
communities with ten participants in each community. There were a total of 505 enrolled 
UARTO participants at the time of the selection, of which 463 were active, 63 had died, 
and 39 were lost to follow up. All 505 participants were included in the list of UARTO 
participants from which the qualitative sample was drawn. From a total of 505 possible 
unique numbers representing unique individuals, 20 random numbers were generated 
using an online random number generator (http://www.random.org/). When a randomly 
selected participant was dead, lost- to -follow up or withdrawn from the UARTO study, 
the following participant in the sequence of UARTO enrolment replaced the original 
randomly selected number. The list of 20 potential participants was reviewed to assess 
the geographic location of all participants and the 20 selected participants were sub-
divided by geographic location. The communities were defined by their geographic 
location as measured by a global positioning system (GPS). Although GPS data were not 
collected on all UARTO participants, GPS data were complete for the randomly selected 
participants by chance. The sub-divided groups included 10 participants in each group 
and the first community included participants who lived within ten kilometers of the 
Mbarara ISS Clinic. The second community included participants who lived between ten 
to twenty kilometers of the Mbarara Clinic. The limitation of this method of clustering 
was that we grouped participants together based on geographic locations that did not 
necessarily coincide with natural socio-cultural boundaries of given communities. The 
assumption was that a 10-kilometer radius in each particular region was small enough to 
establish a level of homogeneity within communities to answer the questions posed in 
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this study. The goal of random sampling was to ensure a systematic approach, and to 
enable a wide variety of perspectives. 
 All twenty randomly selected participants were invited to participate in the study. 
Permission to contact the selected participants was obtained verbally by existing UARTO 
research staff during routine UARTO follow-up visits, or via a phone call. Once 
permission was obtained, a research assistant for this study, fluent in Runyankole (the 
local language), and trained in qualitative research methods, approached the participant 
for consent. Consent was obtained either at the Mbarara ISS Clinic or at the participant’s 
home. In-depth interviews were also conducted either in the Mbarara ISS Clinic or the 
participant’s home, depending on the participant’s preference. 
 The study was approved by the University of North Carolina Institutional Review 
Board, the Mbarara University of Science and Technology Institutional Ethical Review 
Committee, and the Uganda National Council for Science and Technology. All 
participants gave written informed consent to participate in the study. 
 
Data Collection  
Data were collected using qualitative methods. One-on-one, in-person interviews, 
with both open ended and semi-structured questions, were conducted by the study 
investigator and a Ugandan research assistant trained in qualitative research methods, 
who was fluent in the local language, Runyakole. The interviews were semi-structured, 
meaning that an interview guide with questions covering the core topics of interest was 
used to guide the interview process.  However, questions to the participants were open-
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ended and the participants were probed to elaborate on certain areas of interest for more 
in-depth understanding of their responses.  The open-ended approach also enabled 
additional themes to our core areas of interest to emerge. The qualitative methodology 
employed allowed participants to freely discuss their opinions whilst being prompted by a 
predetermined course set by the interviewer using the interviewer guide (97). 
The core areas of interest for the healthcare providers included:  1. Concerns 
about how their patients were managing their HIV disease; 2. Challenges they 
experienced in delivering care in this setting; 3. Barriers to care expressed by some of 
their patients.  
Core areas of interest for patients being interviewed were: 1. Disclosure of their 
HIV status and stigma in their communities; 2. Challenges faced with their clinic 
appointments and general HIV care; 3. Their rating of the clinic services and their 
providers; 4. Challenges with food insecurity, childcare, transportation, physical ability, 
and general feelings about their HIV treatment and health. 
The goal of the interviews was to understand barriers to optimal HIV care in a 
rural setting, from both the perspective of the patients and their healthcare providers. All 
interviews were conducted in a private setting with no one outside the research team and 
the study participant present. All healthcare provider interviews were conducted in 
English, and all patient interviews were conducted in the local language, Runyankole. 
Interviews were recorded using a digital audio-tape recorder with permission from the 
participants and lasted an average of one hour per participant. The participants received a 
small snack and drink after the interviews and transportation reimbursements were given 
where applicable. 
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Data preparation and analysis 
 All interviews were stored digitally on a designated, pass-word protected 
computer. Following each interview, a transcript was generated by the researchers from 
the audio-recorded interview sessions. The transcripts captured the exact words of the 
respondents and did not summarize the interview sessions. For the patient interviews in 
Runyankole, the transcripts were translated from Runyankole to English, after they were 
transcribed from the audio-recordings by the research assistant. The transcription and 
translation were verified for completeness and accuracy by a second researcher, who was 
not part of the interview sessions. In addition to the transcribed interviews, interview 
write-ups were generated during and after each interview session to record impressions 
and activities observed during each session that were not captured by the audio-
recordings.  
 Data from the patients and providers were analyzed concurrently. The study 
investigator reviewed the data to identify relevant themes and categories using the long 
table approach (97). Major themes and categories were developed based on the following 
factors: 1. Frequency of occurrence within each participant, and also within the group; 2. 
Specificity of the theme to the core areas of interest; 3. Intensity and extent of emotion 
expressed with the response. The data were sorted, coded with specific text grouped 
under the major themes identified. The data were refined through multiple reviews of the 
transcripts and additional relevant sections of text were extracted and grouped 
accordingly. 
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C. UARTO Sub-Study Methods 
 
Study Design 
 
This study involved analysis of secondary data from a longitudinal cohort study, 
the UARTO study, on HIV treatment outcomes in HIV patients attending the Mbarara 
ISS clinic.  UARTO participants included in this study were enrolled into the UARTO 
study between June, 2005 and June, 2011. For this study, we analyzed data from the first 
twelve months of their enrolment into the UARTO.   
 
Data Source 
Three sources of data were imported into a relational database specifically for this 
study and analyzed using SAS.  The three sources of data included: 
1. Self report data from interviewer-administered UARTO study 
questionnaires collected on all participants at baseline, and quarterly 
thereafter. Summary data were compiled on specific variables of interest 
listed in the data dictionary below. 
2. ART adherence data derived from measures collected monthly during study 
participant follow-up in the UARTO cohort. The adherence measures were 
collected using an electronic pill bottle cap; the Medication Events 
Monitoring System (MEMS), and were downloaded monthly into a ‘MEMS 
database’, from which the data were analyzed. 
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3. Biological data from plasma specimens collected concurrently with the 
UARTO study questionnaires. The variables included in the analysis were 
CD4 cell counts and viral load counts of all participants over the first 12 
months of their enrolment. 
 
Study population: Participants of the UARTO cohort 
Data from all participants of the UARTO cohort were included in this study. 
UARTO participants consist of ART-naïve patients above 18 years of age who live 
within 30 kilometers of the Mbarara ISS Clinic and who were initiating free therapy at 
the same clinic. Initiated in June, 2005, the UARTO cohort is an observational cohort 
study of HIV treatment outcomes (clinical and behavioral) among 505 HIV positive men 
and women attending the Mbarara ISS Clinic in Uganda. It is funded by an NIMH grant 
with Dr. David Bangsberg of Harvard Medical School/Massachusetts General Hospital as 
the Principal Investigator. The primary objective of UARTO is to determine adherence 
levels as well as predictors of virologic failure and ART resistance in HIV positive adults 
initiating therapy. UARTO participants are nested within the larger Mbarara ISS Clinic 
cohort of patients and continue to receive their care at the Mbarara ISS Clinic after 
enrollment in the study.  All eligible patients of the Mbarara ISS Clinic who are ART-
naïve and initiating therapy are invited to participate in the UARTO study and are 
recruited upon consent. All patients initiating ART at the Mbarara ISS Clinic are 
consecutively approached by a study research assistant during the clinic visit to ascertain 
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eligibility and obtain informed consent. Both biological and behavioral data are 
concurrently collected at baseline, and during monthly and quarterly follow up visits.  
 
Biological and Behavioral Measures 
Biological and behavioral data were collected at baseline and quarterly 
afterwards. Biological data include data on CD4 cell count, HIV viral load, viral 
resistance, and immune activation. Behavioral data are obtained from questionnaires 
administered by a research assistant and include information on demographics, socio-
economic status, sexual behavior, drug and alcohol consumption, depression, functional 
status, ARV side effects, health status, quality of life and adherence. Participants are 
offered free transportation to the research site adjacent to the Mbarara ISS Clinic for 
quarterly follow-up visits.  
 
Transportation Assistance 
 Although transportation assistance was not a direct study procedure, retention 
efforts in UARTO included provision of transportation assistance to participants to their 
quarterly study visits. Transportation assistance came in the form of free rides in study 
vehicles from participants’ homes or reimbursement of transportation fares when 
participants came to the clinic for their study procedures. For some participants, 
transportation was provided to the clinic following their monthly adherence visits. For a 
few others, opportunities for free rides to the clinic occurred randomly through chance 
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encounters with study drivers and research assistants in their neighborhoods and 
communities and requests for free rides in these cases to the study team were rarely 
denied. These free rides to the clinic often coincided with clinic visits. 
 
Adherence Measures 
Based on the concept of patient adherence to therapy described by Urquhart and 
Vrijens, adherence measures for this study were defined in terms of persistence and 
execution (98). Persistence refers to the duration on therapy from the time the first dose is 
taken to a time when treatment is discontinued.  Execution is the actual level or degree of 
compliance between the doses the patient takes and what is prescribed. In other words, 
execution refers to how well a patient takes their prescribed medications and persistence 
refers to how long they adhere to a regimen. To understand adherence patterns in this 
study, both treatment persistence and execution were examined. Treatment persistence in 
all individuals initiating therapy in the UARTO cohort was examined to determine their 
mean adherence each month while on therapy. Treatment execution was also examined to 
establish patterns of treatment interruptions over time for each participant.  
Adherence monitoring in the UARTO cohort was done monthly in the first 12 
months via unannounced home visits. Data are collected electronically using Medication 
Event Monitoring System (MEMS). The MEMS includes a standard pharmacy-sized 
bottle cap with an electronic chip that clocks bottle openings in a 24-hour period. This 
objective measure provides information on patterns of adherence, including treatment 
interruptions and missed doses. At the time of enrollment, each UARTO participant is 
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given a MEMS (MEMS Track V, Aardex Ltd.) pill bottle cap equipped with an electronic 
device to monitor the date and time of pill bottle openings. The MEMS pill bottle caps 
are screwed onto the pill bottles into which the prescribed antiretroviral medication is 
placed. The MEMS caps replace the original pill bottle cap and the event of unscrewing 
the MEMS cap to open the pill bottle registers electronically. Data from the MEMS caps 
were downloaded during monthly, unannounced pill count sessions in the participants’ 
homes. The system makes the assumption that each cap opening coincides with a pill 
taken by the participant. 
 
Data collection procedures 
A comprehensive dataset of summary measures was requested from the UARTO 
cohort data management team for participants, who initiated antiretroviral therapy 
between June, 2005 and June, 2011. The dataset included the first 12 months of follow-
up for each participant, and the baseline visit was determined by their ART start date. 
The ART start date served as the defining point at which a participant was included in the 
cohort, therefore, the data file included a cohort of ART starters between June, 2005 and 
June, 2011. 
A SAS file was generated with a set of tables that represented summary measures 
of interest which included: biological data, demographic data including reported cost of 
transportation, travel time to clinic from patient’s homes, ART information, laboratory 
data, disease stage, alcohol use and data on opportunistic infections. Adherence data was 
derived and analyzed from an independent MEMS database. 
 34	  
Predictor Variables  
The predictor variables for the UARTO analysis were: 
1. Travel time to clinic: Duration of travel to clinic was defined by the patient’s 
self-reported total time spent traveling from home to the Mbarara ISS Clinic. 
This variable was analyzed both as a continuous variable and also as a 
dichotomous with 45 minutes set as the limit above or below which 
participants travelled to clinic. 
2. Socio-economic status: This was determined from a combination of variables 
from self-reported data including income, education, job training, literacy, 
marital status and employment type. The data were summarized such that each 
participant fell within a classified socioeconomic position using the Henkel-
Pritcht scale, which groups defined assets and expenditures reported by the 
participant together such that participants fall within a defined level on the 
scale. This was an ordinal variable. 
3. Alcohol and drug use: This was determined from self-reported data. The data 
were collected using a standardized questionnaire that is part of the Alcohol 
Use Disorders Identification Test (AUDIT). The AUDIT is a screening tool 
that identifies patients who are heavy drinkers and have disorders associated 
with alcoholism. The AUDIT-C is a revised version of the AUDIT test which 
scores patients on a scale of 0-12, with a score of 0 reflecting non-use of 
alcohol and 12 reflecting the most hazardous levels of drinking. Scores of 4 
and higher for men are considered positive while a score of 3 or higher in 
women is positive for alcohol use. The AUDIT-C has been validated in this 
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setting and provides the best determination of alcohol use in this cohort. The 
AUDIT-C score was determined for each participant from these data. From 
the AUDIT-C score, each participant’s alcohol use was classified as non-
drinker, moderate drinker or heavy drinker. Data were analyzed using these 
summary measures and the alcohol use variable was ordinal. 
4. Adherence to HIV therapy: This was assessed from MEMS and self report 
data. Mean adherence via MEMS was calculated separately for each 
participant to determine their average adherence per month over time. These 
summary measures classified participants with low adherence, defined by an 
average MEMS adherence measure below 90%, and high adherence, defined 
by an average MEMS adherence above 90%.  
5. Persistence on ART or Treatment Interruptions: Treatment interruptions 
were defined as no pills taken for greater than 48 hours, as recorded monthly 
through MEMS and Self-Report. Treatment interruptions were further 
categorized by duration of interruption into four categories: <7 days, 8-14 
days, 15-30 days and >30 days. The number of times participants interrupted 
their treatment for 7, 14, and 30 days or longer was calculated and the rate of 
treatment interruptions over time was determined for each participant 
quarterly, after their baseline study visit. Treatment interruptions were 
analyzed as a predictor variable for loss to follow up and mortality.  
6. Disclosure of HIV Status: The effects of disclosure of HIV status on 
adherence, LTFU and mortality were measured with disclosure as a standard 
covariate and also as an interaction term with distance to clinic. Disclosure 
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status was obtained from participants’ clinic data that were merged with 
UARTO data, from a single binary variable that indicated whether or not the 
participant had disclosed their HIV status to anyone. The disclosure question 
was asked at the participants’ baseline visit and the variable was analyzed as 
dichotomous. 
7. Internalized Stigma: Internalized stigma was measured using the 
Internalized AIDS-Related Stigma Scale (IARSS) (99). On a scale of 0-6 on 
the IARSS, a higher score indicated a greater degree of internalized stigma for 
each participant. This was an ordinal variable. 
8. Social Support:  Social support was measured using the Functional Social 
Support Scale (100), a modified version of the Duke University-University of 
North Carolina Functional Support Questionnaire (101), which consisted of 
questions on both emotional and instrumental support. Higher scores indicated 
higher levels of social support received by the participants. The effects of 
social support on adherence, treatment interruptions, treatment failure, LTFU 
and mortality were measured with social support as a standard covariate. 
Social support was analyzed as an ordinal variable. 
9. Effects of Seasonality: The effects of rainy season on treatment interruptions, 
treatment failure, LTFU and mortality were measured and also as an 
interaction term with distance to clinic. Rainy season included standard 
months with heavy rain: March –May and October –November. 
The data were adjusted for confounding variables including disease stage, and functional 
status. 
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Outcome Variables 
The main outcome variables were:  
1. Treatment interruptions: Treatment interruptions were defined as no pills 
taken for greater than 48 hours, as recorded monthly through MEMS and Self-
Report. Treatment interruptions were further categorized by duration of 
interruption into four categories: <7 days, 8-14 days, 15-30 days and >30 
days. The number of treatment interruptions or breaks in treatment per 
participant and length of interruption was calculated for each interruption for 
each participant. This variable was analyzed as a dichotomous with data 
points defined by breaks of each participant given length and number of 
breaks of each participant given length. 
2. Patient execution of ART regimen: This was defined by participants’ 
execution of their prescribed treatment while persisting on therapy and the 
mean adherence over time was calculated for each participant.  
3. Treatment failure: Treatment failure was defined as viral load >400 
copies/ml after > 3 months on ARV therapy. Any participant with a viral load 
level greater than 400 copies after the 3-month mark was counted as having 
experienced viralogic failure. Viralogic failure was assessed at 4 quarterly 
intervals over the 12 month follow up period and summarized for each 
participant. Virologic failure was analyzed as a dichotomous variable. 
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4. Mortality: Deaths in the cohort were confirmed by hospital records or 
through key informants. Kaplan Meier survival curves with even rates and 
95% CI were stratified by predictor variables of interest. 
 
Preliminary analyses and data cleaning 
All data were checked for completeness and accuracy. Missing values in the SAS 
relational database were excluded from the analyses and reported as missing.  The 
MEMS data contained several gaps and additional steps were taken to clean the data and 
confirm inconsistencies. The purpose of cleaning the MEMs data was to ensure that all 
missed doses that were identified by the electronic MEMS tool, were accurately 
identified as missed doses and not merely due to equipment mal-function etc. Data from 
the MEMS database were verified by comparing the MEMS results with other adherence 
measures (self report, pharmacy refill data, and unannounced pill counts) that were 
collected concurrently. The process of data cleaning involved the steps outlined below: 
1. A list of all UARTO participants with missed ART doses was generated from a 
review of the MEMS database. The list included all UARTO participants with 
missed doses that occurred between the date they initiated ART, and their last 
known visit time-point. 
2. A missed dose was identified when a MEMS reading was recorded as ‘0%’ for a 
given day in the database. Each participant was expected to have 2 MEMS 
reading recorded each day with a value of 0% or 100%, with 0% representing a 
missed dose and 100% representing a completed medication dose. 
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3. The distribution of gaps was summarized and reported from the MEMS data by 
length and year of occurrence.  
4. The length of each gap by year was determined for each participant as follows: 
i. 0-6 days 
ii. 7-14 days 
iii. 15-30 days 
iv. greater than 30 days 
5. From the summarized list, each missed dose was investigated independently for 
each UARTO participant.  
6. For the purpose of this dissertation, missed doses for all UARTO participants 
identified by MEMS, broken down by length, for the first 12 months of follow-up 
only, were included in the final review to determine the validity of the MEMS 
identified gap.  Four different sources were used to determine whether the MEMS 
identified gaps were true or false gaps; in order of priority: 
a. Adherence Monitoring Uganda (AMU) study visit notes to confirm 
MEMs use, blister pack use, ARV status, definitive comments on gaps for 
missed doses or interruptions 
b. Pill counts (PC) – concurrent adherence measure during period of MEMS 
gap  
c. Pharmacy refill data - confirmation of refill during the time of gap 
d. Self report  (SR) from UARTO questionnaire – patient report of 
interruption and/or adherence in UARTO questionnaire 
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7. An access database was created with the following variable codes that served as 
criteria for confirming whether a MEMS identified gap in medication dosing was 
a true gap or a false gap: 
 
'Notstarted' Some MEMS gaps occur before the participants actually start taking 
medication. "1" in that column meant that this gap happened before the ARV start 
date. 
 
'hadpocketdose' in this column it was recorded whether a participant reported 
taking pocket doses at the time a gap was reported by MEMS. "1" in this column 
meant they had a ‘pocket dose’. Pocket doses refer to pills removed from the pill 
bottles prior to the time when they are supposed to be taken by the participant.  
 
'hastelegap' If the participant reported to have missed taking drugs in the 
teleforms completed at the regular quarterly visits, it recorded as ‘1’ in this 
column.  
 
'haslossgain' in the AMU monthly visit, a "lossgain" was registered if a person 
lost drugs or borrowed drugs. A negative "lossgain" would mean the participant 
lost drugs and it is likely that they missed a dose. A "1" in this column meant that 
the participant reported losing drugs at the time of the MEMS reported gap. 
 
'malfunction' represented times when the MEMS cap recorded a strange date or 
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numerical value that was not recognizable. A "1" in this column meant there was 
a malfunction with the MEMS cap. 
 
'laterrefill'  This column represented pharmacy reports for participants who 
returned to the ISS Clinic pharmacy after their prescribed refill date. The 
assumption was that the participant missed doses in the days following their 
prescription refill date. "1" in this column meant a late visit to the pharmacy, and 
“n/a” for no information from the pharmacy in the time of gap. 
'haddrug' This variable showed whether or not a participant had filled their ART 
prescription, and therefore had their medication in their possession at the time of 
the gap as reflected in the pharmacy database. "1" in this column meant that the 
participant had drugs at the time of the MEMS recorded gap, and “n/a” for no 
information from the pharmacy in the time of gap. 
'AdhPCAdj' This was the adherence value recorded in the AMU database 
calculated from the monthly pill counts. If the adherence was >0.5 then a “No” to 
the gap was recorded in this coloumn. If the adherence was <0.5 then a “yes” to 
the gap was recorded in the column. “n/a” was registered for times when there 
were missed visits and no pill count. 
'VisitNotes' These were notes recorded at monthly AMU visits by UARTO 
research assistants. All visit notes were read to see if the participants mentioned 
anything about missed doses, adherence etc. at the time of the MEMS recorded 
gap. “Yes” in this column meant that the notes confirm there was a gap, “No” 
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meant that the notes clearly state that there is no gap e.g., a note that participant 
had ART prescribed in blister packs, and therefore was not using the MEMS cap. 
“n/a”  meant that  there were not notes written at the time of the MEMS recorded 
gap or that the notes written do not help classify the gap. 
8. A Microsoft Excel spreadsheet was created to summarize the result of the review 
variables with options of yes/no or n/a. To make a definitive statement whether 
gaps were true or false the results of all variables for each participants were 
reviewed. 
A MEMS identified gap was confirmed as a true gap if: 
1. There were corresponding gaps in the  
a. AMU study visit notes 
b. Pill Count  
c. Pharmacy refill data 
For purposes of this study,  true gaps were confirmed and reported if 3 out of 4 
review criteria (AMU study visit notes, PC, Pharmacy refill, SR), were considered true 
gaps and were included as gaps in the MEMS adherence calculations.  
A MEMS identified gap was confirmed as a false gap if: 
1. One or more of the 4 review criteria (AMU Visit notes, PC, Pharmacy refill, SR), 
confirmed that the participant was taking his/her pills at the time of the suspected 
gap including: 
a. Pharmacy refill at the time of gap 
b. Adherence was 50% and above by PC 
c. No missed doses via SR 
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d. Visit notes were also assessed to see if any interruption was reported 
MEMS Data from this group were highlighted as MEMS non-use and not 
included in the MEMS analysis as true gaps. Adherence was calculated in this group 
using the confirmed measures.  
A MEMS identified gap was confirmed as Inconclusive if: 
1. There was insufficient data to determine whether these were true gaps or false 
gaps because  
a. Data from corresponding sources were missing 
b. Visits were missed and visit notes did not exist  
             Data from this group were treated as missing data in the MEMS analyses.  
 
The data cleaning exercise yielded an adjusted MEMS database used in the 
univariate and multivariate analyses of ART adherence and treatment outcomes. 
 
Statistical Analysis 
 
Univariate Analysis:  
The demographic characteristics of all participants in UARTO were summarized 
and described in Table 1. 
Bivariate Analyses:  
The primary analyses examined associations between the predictor and outcome 
variables, while controlling for potential confounders described earlier. These analyses 
included Chi-square and Fisher’s Exact tests to compare categorical variables, and t-tests 
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for continuous variables. Predictor variables that were found to be associated at p<0.25 
with the outcome variables listed above, were retained for multivariate regression 
models.  
Multivariate Analyses:  
Logistic models were used for dichotomous variables and ordinary least squares 
for continuous variables.  
Repeated Measures:  
The SAS GLIMMX procedure for numeric outcomes was used to account for 
within-subject correlation of measurements over time for the outcome variables: 
treatment interruption, and adherence measured over a twelve month period.  
Survival Analyses:  
Survival analyses were used for time-to-event outcomes including loss-to-follow-
up and mortality. For these two outcome variables, Kaplan Meier survival curves were 
generated with event rates and 95% confidence intervals. The curves were stratified by 
the following predictor variables: gender and travel time to clinic with the predetermined 
cut-point of 45 minutes.  
 
D. Ethical Considerations 
 
 
The study was approved by the Institutional Review Boards of University of 
North Carolina Chapel Hill, Mbarara University of Science and Technology and Uganda 
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National Council for Science and Technology. The ethics approvals for the quantitative 
study of secondary data allow for the analysis of de-identified data already collected in 
the UARTO study, therefore no specific written or verbal consent was obtained. Written 
consent was obtained in English for all healthcare providers enrolled in the qualitative 
study, and all patient participants gave written consent in either English or Runyankole, 
the local language in Mbarara, Uganda. 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 4. RESULTS 
 
A. Qualitative Study Results  
 
Demographic Characteristics of the Qualitative Study Participants 
A total of 33 participants were interviewed for this qualitative study including 19 
patients and 14 healthcare providers.  
 
Results of Patient Participants 
 
I. Descriptive Analysis for Patient Participants 
 
Sixteen out of Nineteen (84%) of the participants were women. More than half of 
the participants (53%) were widowed; 32% were either divorced or separated from their 
partner; 1 participant (5%) was currently married; and 2 (11%) had never been married. 
Almost all the participants (95%) were Christian and 1 person was Moslem (5%). The 
majority (90%) had no formal job training and 74% of the participants had received only 
primary education or no formal education at all. The age of the participants ranged from 
33 to 42 years old, with the mean age being 37 years. The average household size 
included 4 members and the mean monthly income for most households was 97,500 
UGX, which is approximately $39 per month. The participants took almost an hour on 
average to travel to the clinic from their homes, and spent an average of 4,250 UGX 
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(~$2) on transportation costs (each way) to the clinic. The mean CD4 cell count at 
baseline was 183 cells/mm and the mean viral load at baseline was 303,275.  
 
II. Key Findings from Patient Participants 
 
Using the long-table approach, the findings were interpreted and organized under 
two main categories: 1. Barriers to Care and; 2. Facilitators of Care.  
Under the category of Barriers to Care, there were three main themes that 
emerged. These include:  
1. Stigma and issues of disclosure of HIV status are major barriers for accessing care 
and sustaining adherence 
2. Financial constraints and resource scarcity are recurring challenges for patients 
managing their HIV disease 
3. Inflexible clinic schedules and delays at clinic are frustrating and challenging 
 
Under the category of Facilitators of Care, the following emergent themes are 
summarized below: 
1. There is a high level of trust in the ability of health providers/clinic to deliver 
good quality care 
2. Positive health outcomes are attributed to a higher being, God, and patients’ 
spirituality is important in sustaining care 
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3. The availability of ART is appreciated and there is a high level of trust in its 
effectiveness 
4. Participants relied heavily on social support to sustain their HIV care and 
for survival 
 
Barriers to HIV Care Reported by Patients  
 
1. Stigma and Issues of Disclosure of HIV Status are major barriers for accessing care 
 and sustaining adherence 
 
Stigma associated with being infected with HIV emerged as a major theme for all 
the participants, although it did not present as a barrier to care for everyone. The fear of 
being ‘stigmatized’ or ‘discriminated against’ presented as a barrier when it prevented 
participants from accessing care, taking their prescribed medications, or seeking social 
and financial support to help them adhere to their care and treatment. Stigma was also 
noted to affect participant’s emotional well-being and self-esteem, ranging from ‘feelings 
of worthlessness’ to actions of attempted suicide in one instance. Overall, the emotional 
well-being of all the participants influenced their ability to ‘cope with’ and ‘manage’ 
their HIV disease effectively. Interviews with the participants revealed that whether or 
not the individual had experienced or perceived acts of discrimination due to their HIV 
disease, they were all aware of its prevalence in their communities and had developed 
different coping mechanisms for dealing with it. About half of the participants had 
experienced or perceived the effects of stigma in their communities and about a quarter of 
them had made conscious decisions not to disclose their HIV status as a result of prior 
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negative experiences. The fear of discrimination, described frequently as ‘what people 
would do’ or ‘what people would say’ to them and the subsequent effect this might have 
on their emotional and psychological well-being was sited as a reason for not disclosing 
their status. A woman in care at the clinic for 5 years, who had disclosed to only a few of 
her friends and family members spoke about disclosure and stigma in the community and 
described specific acts of discrimination and its potential effects: 
Only some of them [in response to whom she had disclosed to] because 
most of our friends are rumor mongers… People are different, there are 
people who discriminate, they don’t want to use a plate or cup an infected 
person has used and this lowers one’s self esteem. Someone was once 
discriminative towards me but I forgave them. (woman in care 5 years) 
 
A female farmer who sells fruit to raise money for her transportation fare to the 
clinic described her experience as having changed over the 5 years she received care at 
the clinic: 
Some people do treat me bad, at first people used to rumor about me how I 
am infected but they no longer do that… My husband was positive so my 
in-laws thought with this disease if they mistreated me I would die of 
stress but I did not. (Female farmer in care 5 years) 
 
Another woman who had been in care for more than 6 years in clinic and had only 
disclosed to family members that live in the same home with her, responded to a question 
about whether or not she had disclosed to people in her village: 
 
No, probably they know since they see me visit the clinic occasionally but I 
never tell them. Even when you talk to them about it as a friend they show 
you a bad attitude, so since I have my strength, I don’t see why I have to 
tell them, they are not health workers nor are they counselors, why should 
I tell them anything? They only laugh at you since they are not affected. 
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(woman in care > 6years) 
[In response to disclosing to her friends] I have told few of them, I trust 
very few with my issues. Isn’t that the reason I was telling I only tell few of 
my friends the close ones, Some of them, you think they are friends but at 
the end of the day they are rumor mongers…. (Woman in care >6 years) 
  
The same participant gives specific examples on how disclosure issues can 
be a barrier to care, as patients take extreme measures to protect the 
confidentiality of their HIV status: 
One barrier is self esteem; people shy away till they are so weak. If they 
find out their colleagues are receiving treatment at the same clinic, they 
stop coming to that clinic. (Woman in care >6 years) 
Another participant, who had fully disclosed her status, and had been a 
patient at the Mbarara ISS clinic for more than 10 years, also commented on the 
same issue: 
Some people have low self esteem if they are found HIV positive. 
Sometimes when they are at the clinic and they see someone they know, 
they leave their medication letters behind and when their time comes to be 
called in, they are nowhere to be seen. (Woman in care 10 years) 
 
A female casual laborer, in care for 4 years and highly motivated to stay in 
care, described a similar situation she believed posed a barrier to care when 
patients forfeit filling their prescriptions at the clinic: 
Some people have weird characters, they don’t want to wait for long in 
queues, and some don’t want to be recognized as infected people. There 
are people I know but when I meet them at this clinic they shy away and 
don’t get their medication. (Female casual laborer in care 4 years) 
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Another woman who had been at the clinic for 4 years, described instances when patients 
find other community members, such as herself, present at the clinic. The unexpected and 
uncomfortable meetings at the clinic lead to patients forfeiting their prescriptions in an attempt to 
hide their status: 
They always think when I get back home I will spread the rumors about 
them since they have been visiting the clinic in secrecy. They leave without 
the drugs to give me the impression they were on their other businesses. 
(Woman in care 4 years) 
 
There were several reports from participants of internalized stigma and feelings of 
shame about their HIV status. In many of these cases, the individuals had not necessarily 
experienced discrimination but anticipated negative judgments from their family, friends 
and community members towards them. For those who had high moral standards, the 
idea of being HIV positive tested their self worth and they worried about how others 
might perceive their character regarding how they contracted the virus. There was a 
general belief by this sub-group of people that HIV was a disease of ‘prostitutes’ and that 
all who were HIV positive were ‘useless’ and had ‘looked for it’. This belief contributed 
to their inability to accept their status, disclose it, and maintain their routine in care with 
the necessary support needed.  One participant describes the emotions about the shame 
felt because of how the disease was contracted;  “So there is nothing more shameful than 
this.” An older woman, recently diagnosed with HIV, after her husband died more than a 
decade prior was not only shocked by her diagnosis, but limited the disclosure of her 
status to just two of her children who were present when she was tested: 
Yes I have another son, but if I told him about my situation, he would tell 
my daughter-in-law who does not like me very much. And then she would 
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say that, “considering that your mother is not a prostitute how did she 
come to contract the virus?” And so I chose not to tell him about it, it is 
only those 3 people who know about my situation….  
It makes me feel very very very ashamed. Seeing that I am an old woman, 
do you think that I should be having HIV? Looking at how old I am, I am 
not one to be falling sick or acquiring HIV. I mean what should be making 
me become infected? Don’t you see that it is embarrassing?  
[In response to a question clarifying what is embarrassing about her HIV 
disease] It is the question of how I might have acquired the virus and 
people coming to question how I might have acquired it. That is what is 
shaming. And so that is what is causing me not to tell people in the village 
about it. No, no I see that it brings me shame because at the age at which I 
am, to find that I have HIV, they would start wondering and thinking that 
how did this one come to contract the disease. And so I decided to leave 
them and keep silent about it. Ehhhhh, you can’t you see how old I am? I 
mean eventually having to die from HIV isn’t that the unthinkable? Yes. 
(Older woman in care less than a year) 
 
For some of the participants, their decision to keep their status private went beyond the 
fear of hurt emotions and translated into the fear of loss of financial support and threats of 
physical violence. These individuals experienced a high level of anxiety about being ‘caught in 
lies’ they created to keep their HIV status hidden. One participant, a 34-year old woman, who 
had not disclosed her status to her husband and father of her two children, noted fear of domestic 
violence as a reason for not disclosing her status to her husband: 
 [In response to why she had not disclosed to her husband] eeh, it’s very 
difficult. (Laughs) aaaaayyyii, it’s not possible. When the man is not 
infected, then you wonder even how you will tell him. eeehhh, I just know 
that it has happened as a big mistake and he can even cut me into pieces 
(laughs). A person like him whose you don’t know, won’t he cut you. He 
can do something terrible to me. (34 year old newly married woman) 
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In addition, she described the intricacies of avoiding discussions of HIV 
with her husband and refusing to get tested jointly with him when the opportunity 
presented. The stress of ‘lying’ and trying to hide medications (ART) from family 
and friends becomes a barrier when it interferes with one’s persistence on their 
treatment regimen or leads to interruptions in their clinic visits. 
You know when you go to test [for HIV]; they tell you that you should go 
the two of you. But every time I dodge him [her husband]. When I am going 
to Mbarara, I tell him that I am going to visit Jennifer (sister) and I will 
test from there. I try and confuse him... I lie to him that am visiting 
Jennifer. (34 year old newly married woman) 
.. Of course when I ask him [speaking of transport money to Mbarara 
town], he says that for you why do you want that money? Where are you 
going? … He has never seen my medical forms, I try very much and hide 
them, like my handbag, he rarely checks in it. [When asked about taking 
her medication] I take them when he is away; the issue of money becomes 
more complicated because sometimes, I really try very much to see that I 
don’t end up badly. (34 year old newly married woman) 
 
This particular account by the 34 year old woman illustrates how stigma is a 
barrier to accessing social support. This is an important concept as stigma is often viewed 
as an emotional/cognitive construct as described above, but can also function as a barrier 
to accessing tangible support to overcome structural-economic barriers. 
It was not uncommon for the participants who had not disclosed their status to face 
challenges in explaining their frequent visits from their villages to Mbarara town to their family 
and community members. It is also likely that this sub-set of participants traveled away from 
clinic facilities closer to their homes, which equally provided ART, and chose to come to 
Mbarara to seek care just to seek more privacy and protect the confidentiality of their sero-status. 
For women who had been pregnant in the past, their ante-natal care provided an excuse for 
monthly visits to the health centers or clinics. However, once their babies were delivered, the 
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challenge of explaining where they were going each month, and for what purpose, resurfaced. 
This placed an enormous emotional burden on the participants. Such was the case of a 34-year 
old mother of two, who described the difficulties of obtaining her transport money to go for her 
monthly clinic visits and having to come up with a valid reason for travelling to Mbarara.  
Yes, because when you see, if you don’t have money, you cannot go to 
Mbarara now, like when am going to the clinic. Because you see, most of 
the things [talking about purchases for the home] he brings them. So he 
will ask that what do you want the money for or he says that tell me what 
you want and I will bring it. So now if you tell him that I want to go to 
Mbarara, he will ask what I want from there. There is no way I can say it. 
If he would give me money, then I would lie that this thing is not there and 
if he still gives me the money while lying, then I would obtain the money 
through lying and I would get it and go immediately. But now he brings 
everything. So now the money for going to Mbarara, I don’t have it in my 
head. So as I see the days drawing near, I go to my brother in Nyakabira, 
though he is a bit difficult, but I also insist until he gives me the money. 
Then, he gives me money for going and then Jennifer [sister] pays my 
transport back. (34 year old woman) 
No, as for him, [speaking of the husband] the money for taking me to 
Mbarara is not part of his pocket. It cannot happen. (34 year old woman) 
 
 
One key finding was that almost all of the participants found it the most difficult 
to disclose to their religious community and even when they did disclose to their church 
community, this was the last community to hear of their status. The responses were 
almost unanimous when asked about disclosing to their church member and leaders in 
particular: 
‘No, I mean going to tell them to I am infected, there is no way’…  
“No and I don’t think I will ever tell them… Definitely there are rumors 
but they are not sure.” 
 
“I have not told the church leaders …” 
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Almost half of the participants had made a conscious decision early in the course 
of the HIV disease to disclose their status and be open about their experience to their 
family, friends, colleagues and beyond. For this group of individuals, they acknowledged 
the positive effects disclosing their status had on their ability to maintain their HIV care 
and treatment. Many of them saw no reason to hide their status as they believed that 
many members of their community were equally infected. Typical responses to questions 
about perceived stigma in the community were: “No, most people are infected, they no 
longer hide their status”.  Another common response on questions about experiencing the 
effects of stigma in the community was: “I have not experienced that, most of the people 
are infected so they don’t discriminate.” For those who responded in this manner, there 
was a general consensus that HIV was a ‘normal’ part of life in their community and 
affected almost everyone. The respondents also reported benefiting from social support in 
dealing with their HIV disease. 
 
2. Financial constraints and resource scarcity are recurring challenges for patients 
   managing their HIV disease 
 
 
All participants reported financial constraints and resource scarcity as a recurring 
challenge in the management of their HIV disease. The cost of transportation to the 
Mbarara ISS Clinic for routine care was prohibitive to many participants. Therefore, 
‘raising’ funds for transport fares required advanced planning with concerted effort, and 
for some, this task consumed their thoughts and actions regularly. A female trader, with a 
higher income level than most of the other participants, still had issues with paying for 
her routine visits to the clinic: 
The only challenge is the funds because I have a lot to cater for. I get 
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problems with funds, sometimes my day comes when I have no money for 
transport and I miss my visits yet I can’t walk; my legs are weak. I failed 
to raise the money for transport. (Female trader) 
Another women reports the same issue: 
There are times I fail to raise transport money, I walk and may be board 
from Kijungu or sometimes I walk the whole journey but when I get home I 
weaken a lot. (Woman in care 6 years) 
Most participants described the issue of transport fares as a ‘problem’ or ‘challenge’ or 
‘difficulty’ that caused them stress. 
The challenge and the only one is money. I may fail to raise the money for 
fares to the clinic. 
The problem really is money; there is no money that is the important 
thing. Because you see someone may owe you money and they say to you 
that, “I will give the money back to you on Monday because you told me 
that you are going to clinic on Tuesday”. And when you get to the person 
they tell you that, “the one who was going to give me the money did not 
show up”. And so you starting looking everywhere for money to make sure 
that you go to the Clinic. 
 
Many participants ‘borrowed’, ‘begged’ or ‘got’ funds from friends or relatives to 
meet the cost of their transportation to clinic in the event that they were unable to raise 
money before their scheduled visit. Borrowing was easier when one had disclosed their 
status and could give a ‘straight-forward reason’ for needing the funds. A female farmer 
who has been a patient at the clinic since 2004 and was highly motivated to stay in care 
because of her children reports: 
 Sometimes I don’t have money; I borrow since I have to go get my drugs.  
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Other participants share the same experience: 
It [transport fare] is not always available, but I find other means. I told you 
about my son who works in town; I get money from him if I can’t raise it 
myself. Sometimes he refuses but lends me money for transport which I 
pay back after some time. It is not enough money really. 
 
Even when transport fares were realized, for some of the participants there were 
additional challenges with getting to their routine clinic visits. Although seasonal, they 
did present significant barriers to accessing care for those involved. For some it was as 
simple as traveling on a day of the week that was busy and transportation options were 
limited, or for others the situation was more complicated. Many individuals worked as 
casual laborers or sold their own crop to raise transportation fares. This strategy of raising 
money was dependent on sufficient crop yield and availability of employment. Given 
seasonal changes, the outcome of the yield as well as need for casual labor varied. It was 
during these times of scarcity that raising transportation fares became daunting. 
May be sometimes I have money for transport but I fail to get vehicles 
going to town which forces me to take a boda boda [public motor bike] 
which are dangerous but since they are the available means I use them.  
Mondays are usually tricky days; I delay a lot on the road because cars 
are not there. I reach the clinic late and sometimes I am told they are not 
receiving more patients.  
No big challenge, maybe one that I may soon face is raising the transport 
fare. During school holidays, there are no jobs because people feel the 
children can work on the farms. To be honest, there are times I fail and I 
have to beg my brother to ride me to the clinic.  
If you say to cultivate crops, yet in Mbarara it is demanded you go every 
month. By the time the crops grow and the month reaches, where will you 
be? If you have cultivated on borrowed land and sometimes the crops fail, 
then you have to first give the yield to the owner of the land and what 
remains is for only for eating in at home.. 
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There is lack of sufficient income, there are times the farming business is 
not booming and you are run with a lot of thoughts that I sometimes forget 
the day I am supposed to visit the clinic. 
 
Walking to clinic, to avoid paying unaffordable transport costs, was an option for 
those whose functional status permitted. 
I walk 15 Kilometers from home then I board to the clinic, boarding a taxi 
to Mbarara costs me Ush. 2000. If I am to use a motor bike, it costs Ush. 
5000. 
Since I have not failed to walk, I find no problem with that. I usually walk 
most especially when I have not found work to do to raise transport… 
No, even if I don’t have transport I make sure I walk to the clinic unless I 
am having a fever that’s when I miss coming to the clinic. 
 
A few participants talked about having to purchase food at their clinic visits when 
they spent long hours waiting for their turn to see their clinicians. It was not uncommon 
for a clinic visit to turn into an ‘all-day’ affair. While the long wait was generally 
expected, purchasing lunch at the clinic canteens went beyond the financial capacity of 
many participants and posed a challenge in their ability to cope during their clinic visits. 
The challenge was exacerbated when there were multiple family members who were 
infected and who received care at the clinic. Some expressed a compounding of factors 
when family members were scheduled to come to the clinic on different days. In such 
cases, coordinating the logistics of travel, food and treatment was overwhelming.  
 
I have a challenge because both I and my wife are on medication and 
different review dates, so I have to look for her transport money and some 
more for some food at the clinic. 
There is also hunger as one sits for long and can’t move anywhere in case 
your name is called out you need to be around. 
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Financial resources were often stretched with large families and difficult choices 
were made to accommodate competing demands. Basic necessities such as food and 
school fees for children, were not often met, and therefore took priority when funds 
became available. School fees for children were typically required three times in a year, 
and it was a difficult but necessary choice to pay the fees for families who wanted a 
brighter future for their children. Because adherence to the prescribed regimen was 
equally important to the participants, the diffusion of resources required additional 
‘borrowing’ and several gave accounts of going further into debt to accommodate all 
their needs.  
When I have raised some money and it’s all gone into school dues, I find 
myself with no transport.  
Because for us you see we have problems and if you look at all the other 
expenses; school fees, rent you find that we end up in debt to make sure 
that we go to the clinic. 
The other challenge is school fees for my children I spend many days with 
little or no food so that they go to school. 
I always have time to go when my day comes, the only problem is when I 
don’t have transport. But there are times my day collides with the market 
day, the market day is really important for me since that is where I earn a 
living so end up not going to the clinic. I go on another day. Of course the 
hospitality is not good. 
 
Food insecurity presented as a competing demand, as has been noted in previous 
studies, but in this case, participants were as concerned about the quality of their nutrition 
as they were with the quantity and availability of food. Participants were conscious of 
being adherent to the advice given by their healthcare providers regarding food. For 
some, getting enough food to eat for themselves and their families was a struggle, but for 
most participants, there was a sense of failure to abide by the instructions of their nurses 
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in eating a balanced and nutritious diet. The clinic counselors emphasized the importance 
of a nutritional diet to functional recovery, and many participants viewed this as an 
essential part of HIV treatment. Knowledge about the types of food needed for optimal 
health as an HIV positive patient was extensive, regardless of the respondent’s level of 
education or socio-economic status. Several respondents described: 
 
To be honest, sometimes I don’t have food but I make sure I swallow my 
medicine whether the food is there or not. It is a problem because I have 
to take the drugs without meals. 
To be honest, food is not enough for me, like I had told you earlier some 
days I go hungry. 
Food in the village is scarce, but we try to have our regular meals only 
that I failed to get the food the nurses recommend. 
I have found it big challenge because in most cases I have insufficient 
food, I eat less. I buy expensively the matooke, which is all I feed on. I 
have failed to feed on Posho. When there is only Posho at home, I take 
water and sleep. I cannot even afford to buy milk. 
 
3. Inflexible clinic schedules and delays at clinic are frustrating and challenging 
 
 Like many other HIV clinics in sub-Saharan Africa, Mbarara ISS Clinic 
experienced a rapid expansion and a 20-fold increase in patient volume. This increase in 
number of patients was equally overwhelming to the patients as it was to the healthcare 
providers. Patients found it difficult and frustrating to navigate a system with thousands 
of patients and very few healthcare providers. In order to limit their length of stay at the 
clinic, some patients came to the clinic 2-3 hours before the start of the clinic to ensure a 
good spot in line, as patients were seen on a first-come-first-serve basis each day. Long 
waiting times at the clinic were expected and many planned for this, but did not look 
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forward to it.  
Since I know people are many, I tell the bike rider the day before to pick 
me at 6am then by 6:30 a.m. I arrive at the clinic. 
I feel I spend too much time at the clinic sometimes I leave the clinic after 
one and other times I spend the whole day there… Sometimes when I delay 
at the clinic I am forced to buy lunch since I don’t take breakfast having 
travelled so early. 
The services are good but there are some things that can be changed. I do 
not know if it is because the number of people increased but you can easily 
sit at the clinic for the whole day. Like when I went there in December, it 
became too much, we were even about to pass out from there. But usually 
[speaking of the past] when we arrive they just treat us and we leave. 
 
In 2009, clinic appointments became a standing order in a clinic that previously 
saw patients on a walk-in basis. Appointments were given to participants for specific 
days, but without specified times, and strict instructions were given to the patients to 
adhere to their appointments. Patients were seen on a first-come-first-serve basis on their 
assigned clinic appointment dates. Although the system was necessary to maintain an 
organized flow of services, many participants found it too rigid in its implementation. 
According to the participants, there was no room for deviations from assigned 
appointments and for those who had challenges meeting their transport costs, or other 
conflicting obligations, they expected that they would not be treated if they came on an 
unassigned day. The consensus among many participants was that the clinic reception 
was hostile when they showed up on an unassigned day, and for some, this prevented 
them from going to the clinic at all. The fear of being ‘shouted at’ or ‘chased’ [being sent 
away] caused many to worry about missing their visits and sometimes they actually did 
miss their visits as a result.  
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The clinic officials insist everyone should come on the assigned day 
because when you appear on a different day you may make those supposed 
to receive drugs that day, miss. I am not sure what happens when you go 
on a day not assigned to you because I have never visited the clinic on an 
unassigned day. I think I might forget one day since I have many thoughts. 
So, when my days pass and I go to the clinic when I am sure I’ll be served 
after all the rest. Even when you explain to them that I failed to raise the 
money for transport they don’t understand.  
 
The reception received by patients who came outside of their assigned clinic visit 
date was often described as ‘rude’ and with ‘no understanding’ of their plight.  
People in records [records room staff] usually disturb us a lot; they don’t 
respect us and it hurts us. 
 
In order to be seen for an unassigned clinic visit, patients had to present valid 
evidence for missing their appointments. It was required for them to obtain letters from 
their local political leaders to verify their reasons for a missed visit. Most of the 
participants viewed this requirement as extremely rigid and representative of a lack of 
understanding of the challenges involved in making their clinic visits. The participants 
describe almost in unison below: 
The care takers here told us that if at all you have a reason why you 
missed to come on your assigned day, you should be able to come with the 
chairman’s letter explaining all the reasons of your absence then that is 
when they serve you on a different day. 
They (at the clinic) said that even though it’s your father-in-law who has 
died and you failed to go there [to the clinic], you have to take the 
chairman’s letter showing the problem that prevented you from coming or 
if you give birth around that time. But you just cannot skip that date 
without bringing solid evidence with you. They cannot accept it.        
If at all I go before or not on my assigned day, they ignore you and treat 
patients meant to be treated on that day first. You have to sit for long 
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hours waiting. 
There are times you receive treatment elsewhere because sometimes when 
you go before your visiting day they are rude to us since we have come on 
a day not assigned to us and you try to explain to them how you are 
feeling sick and that is where we always get treatment, they insist we 
should not appear when our day are not due, we should try other clinics. 
 
In response to questions about their experience with missed clinic visits, two 
participants replied: 
Like twice [referring to the number of missed visits], because there are 
times I feel so sick and I go to the clinic on a day not assigned to me but 
when I realized I will stay unattended to for long hours while am feeling 
weak, I decided I go to some other clinics when I have some money. 
Well, usually it’s [speaking about challenges] transport especially where 
you are a widow. When you miss [clinic visits] that also disturbs because 
when you reach hospital they delay to work on you or you are chased [sent 
away], which is not okay.  
 
For a few participants however, the strictly enforced clinic guidelines on 
appointments served as motivation to plan and get ‘organized’ in preparation for their 
visits, to ensure that they did not miss them. In these cases, the motivation to stay in care 
mitigated all barriers and challenges and the participants expressed a lack of 
understanding for those who could not be as diligent. 
There are people who fail to get transport means, time schedule and some 
don’t know the days they have to pick their drugs so they end up blaming 
the doctors for the bad treatment; yet it is a problem of their own making. 
Some people have transport issues even when they are given ample time to 
look for it, some say they forget their visiting days and they are served late 
on another day which hurts. 
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Facilitators of HIV Care Reported by Patients 
 
 
1. There is a high level of trust in the ability of health providers/clinic to deliver good 
            quality care 
 
The experience of being very ill was not too far in the past for many participants. 
They remembered clearly how their HIV infection had incapacitated them both 
physically and emotionally and did not want to ‘go back to that state’. There was a strong 
motivation to adhere to medications as a direct result of the positive outcome of their 
treatment. But the participants’ description of their healthcare experience went beyond 
the medications and attributed their treatment success to the quality of care of the 
clinicians. Many participants in this category felt that their ‘death sentence’ had been 
reversed as a result the quality of care they received at the Mbarara ISS Clinic. Many 
described the quality of care as good, and detailed the caring nature of their doctors in 
particular. In general, there was a high level of regard for the clinicians and specifically, a 
high level of trust in their ability to deliver good quality care.  
 
They have really cared for us; they are so good. The time I tested I had 
CD4 count of 15, I now have 200 or so, why wouldn’t I appreciate? They 
give us the drugs in time and in good amounts, great counseling, they are 
never rude, we pray, what more can I really ask for? I award them with 10 
[in response to ranking the clinic on a scale of 1-10]. 
 
Because they have given me life, when I look back the point I had reached 
and I compare it to the way I am doing now, it is a great job they have 
done for me. I used to be so sick and weak but I am better now. (Female in 
care for 4 years) 
 
Even it is 100% I can give it to them because for me I was already dead, 
because I was really weak and sick. And look if they managed to get me 
treated and here I am standing by myself again, why shouldn’t I thank 
them? (Male bar tender in care for 5 years) 
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All participants unanimously agreed that the clinic had done an excellent job of 
making sure that they had a steady supply of drugs. More importantly, the patients 
expressed gratitude about the fact that the clinic did not charge additional service or user 
fees, typical in other treatment centers. For some participants who had been patients at 
the clinic at a time in the past when ART was either not available, or was available at a 
prohibitively high cost, the receipt of ART at no cost was particularly well appreciated. 
For many who sacrifice resources to make it to the clinic, the expectation of leaving the 
clinic with medications was motivating enough for them to find ways of making it to the 
clinic. Some remembered the times when clinic visits constituted being on long waiting 
lists in anticipation for ART availability. 
Even their meds do not run out; I have never gone to the clinic and gone 
away without meds. 
They really take good care of us. Long ago we used to be so many and we 
would take so long there till they allocated each of us a day to receive 
treatment and now everyone goes with medication at the end of his visiting 
day. I give them 10 [referring to the clinic rating on a scale of 1 to 10]. 
(Female farmer in care for 5 years) 
 
2. Positive health outcomes are attributed to a higher being, God, and patients’   
            spirituality is important in sustaining care 
 
The Mbarara ISS Clinic was founded in 1998 by an American Baptist Missionary 
doctor, who instilled a religious culture at the clinic for both health care providers and 
patients. Long after the founding doctor left, the clinic has continued to have a strong 
religious foundation, although it is not affiliated with a religious institution. In addition to 
the Mbarara ISS Clinic having a strong Christian religious foundation, participants 
seemed to express a high level of spirituality in their conversation and description of 
experience with regards to their treatment outcomes. A strong theme that emerged, not 
 66	  
previously discussed in other studies was the attribution of positive clinical outcomes to a 
higher being, God. The participants expressed their beliefs about the impact of God on 
their health in two main ways. The first category of responses focused on the participants 
personal belief system and faith in God. They described their personal relationship with 
God and viewed God as the divine healer of HIV. Participants described praying to God 
and expecting healing and positive outcomes as a result of their personal relationship 
with God. There was a feeling that no matter how challenging or insurmountable their 
disease might have presented, that there was a ‘way out’ that was guaranteed by God. An 
older female participants, whose husband died in 2000, and who had previously 
attempted suicide when she found out she had HIV described her relationship with God:  
My faith helps me a lot because I know what God has done in my life from 
that time till now. When I got saved, I now have peace. God helps me deal 
with the daily challenges. 
 
Another female participant: 
There are challenges but I know God will help. They say when God has 
blessed someone, somebody else can delay that blessing on the way but it 
will definitely reach its destination/owner. 
A male participant, who became religious and ‘born again’ after receiving his HIV 
diagnosis, attributes his being alive to his personal relationship with God. 
God had made it possible for me [to live] but all this came as a result of 
being born again because if I was not then I would not have managed. 
 
Other participants describe their relationship with God, and one even attributes the 
decision to get tested as a direct order from God. 
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It has not been easy but I always pray to God to make a way for me. He 
knows I did not go to look for the disease. I have never gone out with men 
for sex, so I tell God to be my husband and provider and he has done that. 
(Female who contracted HIV from her deceased husband) 
God has to make a way for me because I am not getting help from either 
uncles or aunts. (Female participant in care for 3 years) 
I also believe in my medication but I believe in Jesus who advised me to 
go and get tested because if I had continued believing every time I got sick 
it was malaria then I would have died and left my children. It’s not easy to 
wake up one day and you decide to go for HIV testing but to know that 
God is the one that did it. (Female participant in care for 5 years) 
 
In the second category, some participants talked about the healing effect of God 
through their health care providers, and described the healthcare providers as 
‘messengers’ of God in delivering care. They equally described their ART regimen as 
tools used by God to heal them. Almost all of these participants strongly believed that 
faith and medication ‘go hand in hand’ and that God works through the medicine or 
through the hands of the providers. There was a high level of faith in the belief that the 
HIV treatment was delivered from God through the healthcare providers. There was a 
notion that effectiveness of their medication depended on their faith in God. 
I always thank God who has used the care givers/whites to do the 
tremendous job they are doing I pray for more blessings upon them. I 
don’t think I will die, I actually don’t consider AIDS a disease nor do I 
even worry about it. Faith is all that one needs. Medicine in its self cannot 
cure a disease if one does not have faith that the medicine will actually 
work. If one does not love their doctor, their chances of good health will 
be minimal.  Faith that you will get fine heals.  
People who get medication but have no faith are like those that don’t 
receive medication because every challenge they get they go to the bar for 
waragi [locally brewed gin]. This I know because I remember what I used 
to do. 
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I prayed to God to help me take the medication without any side effect. I 
prayed that the medication would do its work and I believed in what I had 
prayed for. Faith is everything.  I have no complaints. 
Well my faith may be more important than the medication because if I had 
not believed and remained in denial I would not have taken the medication 
because I think you have seen people who get it but don’t take it because 
they don’t have faith that the medication will help.  
No, maybe to thank you for the services offered and to God who enables 
the medication to work because others take it but their health still 
deteriorates. 
God is the one that brought this care because if it were not for him we 
would not have accessed this care so God helps us get free care. 
God is a healer of many diseases; he uses many ways he may heal through 
someone or through medication 
 
 
3. The availability of ART is appreciated and there is a high level of trust in its  
            effectiveness 
 
Many of the participants had been in the clinic long enough to experience 
healthcare before and after the introduction of ART. Most of them had close relatives, 
either a spouse or other family member, who had died of AIDS in the era when treatment 
was not available. There was a genuine appreciation of the availability of ART and an 
overwhelmingly high trust in the effectiveness of ART. In that regard, participants 
prioritized their treatment, and sacrificed tremendously to overcome significant structural 
and economic barriers to their accessing care. The positive effectiveness of treatment was 
evident for many participants, who kept accurate count of their progress, especially with 
their CD4 T-cell counts. Many knew their CD4 T-cell counts before they started 
treatment and after, and made the correlation of their positive outcomes to the treatment.  
Yes, I even got 100% because of taking my medication, as I should in 
about 5000 people. I have never forgotten to take my medication because I 
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know how my health was in the beginning and I don’t want to go back to 
that. (Female in care since 2000, and on ART for 5 years) 
So I tell them that if you know you have the virus and you choose to take 
care of yourself, you won’t die. Don’t you remember where I came from? I 
was already dead but I recovered and now I am doing well. (Female, who 
sells alcohol and works as a casual laborer to raise transportation fares) 
 
Health was a priority for many participants, who placed a high premium on life, 
which they believed they gained from effectively taking their medications. The level of 
motivations was high as they forfeited all other activities to ensure that they took their 
medicines.  
I always get the time to go to the clinic, I can never forget because it’s 
important for my health. Even when in have what to do I leave it behind 
and go for my visit. 
I find no challenge, and if at all I am to attend a burial in the 
neighborhood, they say I had better get my treatment first and go burial 
besides that person is dead and am struggling for my life. 
Since life is the most precious thing one has, I can’t fore go my treatment 
to go to the garden. 
I always give up all the activities of that day, I don’t mind the loss. 
 
Prioritizing treatment came at a cost, but many participants felt this was a cost worth 
absorbing. 
Hey, fighting for your life has never been wastage of time. When I have 
made a day a visiting day at the clinic, that is all, nothing else I can fix in 
that time. 
I always know my visiting day, so whatever other business is there on that 
day is postponed. That day one is sure of no other business so you sit and 
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wait to receive your treatment. The time is long but I have to be patient 
always. 
 
4. Participants relied heavily on social capital to sustain their HIV care and for 
            survival 
 
As described in a previous study in 2009 by Ware et al. (48), the importance of 
maintaining relationships played an important role in facilitating access to care, retention 
in care as well as adherence to therapy. Many of the financial barriers that plagued the 
participants were mitigated by social support that served as the foundation of these 
relationships. The social support went beyond emotional support and encouragement to 
take medications on time, but provided a tangible resource that translated into tangible 
‘help’ including getting rides to the clinic visit, help with childcare, and sometimes even 
physical cash to borrow. Participants relied heavily on their social capital not only to 
make it through their HIV care, but also for survival. 
There are times when I don’t have the money and then I talk to my 
neighbors how my hospital day is up, yet I have to buy fuel, they get me 
Ush. 5000. It was only once when it rained a lot, but then I have a 
neighbor who owns a motor vehicle, he brought me to the clinic. 
 
It needs that if you are infected with HIV, you tell someone about it. Well 
if the person is your friend, you tell that I am infected with this disease and 
then they help you. Well the person will always comfort you, counsel you 
and encourage you. It is important to me because even after I told them 
about my situation they continue to encourage me and comfort me and this 
has encouraged me to continue swallowing my drugs. This has helped my 
health improve. 
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Some participants relied on their family and friend to remind them to take their 
medication. 
 
Most of them don’t disclose so that they are not known, they hide when 
taking their medication so even when they forget no one can remind them 
because myself in case I forget to take my medication, even when I am 
asleep they wake me up to take the medication. 
 
           The concept of reciprocity, described in an earlier study (48), was brought up by 
one participant. This female laborer/farmer wanted her neighbors, families and friends, 
who had supported her emotionally to know that she was doing well. She felt a sense of 
responsibility to reciprocate their good will with adhering to her treatment regimen and 
doing what she needed to do to stay healthy.   
Well, remembering how much pain you went through, how sick I was and 
how I looked like, that is why I decided to tell them. What I mean is that I 
was disclosing to them since they had encouraged me that to take my 
medicines that I would be better, I wanted them to know that I was feeling 
and looking better 
 
Another participant talked about being motivated to stay alive because she did not want 
to ‘leave behind additional burden’ on her family. 
That was not a reason to die, where would I leave my children. 
 
Well it’s not good the relatives think you will die and leave behind infected 
children that will disturb them so they are not happy 
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Results of Healthcare Providers 
 
III. Descriptive Analysis of the Healthcare Providers 
 
Fourteen healthcare providers participated in this study, out of a total of 23 
eligible healthcare providers at the clinic. All who were approached gave informed 
consent to participate in the study. Nine healthcare providers were unavailable because 
they were either on study leave or on assignment in other sections of the hospital, and 
were not within the vicinity of the clinic at the time of the interviews, therefore were not 
approached to participate in the study. More than half (57%) of the healthcare providers 
who participated in this study were men. The mean duration of working time for all 
participants at the Clinic was 5.5 years, and the range of service time as healthcare 
providers in the clinic was between 2 and 10 years. Five (36%) of the healthcare 
providers were medical officers; 1 (7%) was a clinical officer; 2 (14%) were nurses; 1 
was a medication dispenser; 2 (14%) were counselors; and 2 (14%) were patient 
educators. One participant (7%) was a physician and director of the clinic. All categories 
of caregivers at the clinic were represented in this study, with the exception of the data 
management team and the laboratory technicians. The data management team was 
excluded from the study because they do not have direct contact with the patients at the 
Clinic. The laboratory technicians also did not communicate directly with the 
participants, and as such were not included in the study. 
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IV. Key Findings from the Healthcare Providers  
 
Using the long-table approach, the findings were interpreted and organized under 
two main categories: 1. Barriers to Care and; 2. Facilitators of Care.  
When interviewing the healthcare providers about barriers to care in their clinic 
setting, they discussed two main approaches to viewing the barriers.  In the first 
approach, the health care providers talked about barriers experienced by their patients, 
which were discussed during clinic visits. The discussions served as a ‘second-hand’ 
account of patients’ experiences recounted by their providers.  In the second approach, 
the healthcare providers discussed challenges they faced as providers directly, while 
working within a health care setting with limited resources. These latter discussions 
centered around how their experiences as healthcare providers, the structure of their 
clinic, and the healthcare system in general in a rural, resource-limited setting, had an 
impact on the patients’ experiences and care. From these two approaches combined, there 
were six main themes that emerged as barriers to care from the prospective of the 
healthcare providers at the Mbarara ISS Clinic. The first two themes below describe 
barriers experienced by patients, but shared with their healthcare providers during clinic 
visits. The last four themes are based on the healthcare providers’ direct experiences from 
treating patients in a rural, resource limited setting. The emergent themes are outlined 
below:  
1. Stigma and issues of disclosure of HIV are a major barrier to HIV care 
2. Poverty and financial constraints area the main barriers to HIV care  
3. A challenging work environment and work overload reduces quality of care 
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4. There are too few centers that offer HIV services, requiring patients to travel long 
distances to access care 
5. Limited drug supply and distribution problems are major ongoing challenges  
6. Challenges with poor ART adherence, routine monitoring, and sub-optimal 
treatment outcomes threaten the sustainability of HIV care 
 
Under the category of Facilitators of Care, the main themes that emerged were: 
1. The efficacy of ART and quality of care at ISS Clinic are recognized and valued 
2. The success of HIV treatment programs in sub-Saharan Africa is dependent on a 
positive global response and continued global support. 
 
Barriers to HIV Care From Healthcare Providers 
1. Stigma and issues of disclosure of HIV are a major barrier to HIV care 
Stigma and issues of disclosure of HIV status are perceived as a main barrier to 
care. The patients’ inability to disclose their status frequently had a negative impact on 
their ability to keep their clinic appointments, subsequently leading to missed visits. 
Some patients were described as having missed doses because they could not find a 
private time to take their medications because they were hiding their status and 
medications from close family members. It was not uncommon for patients to disguise 
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themselves and change their names at the clinic, which made it difficult for the clinic to 
keep track of them. 
And others even do not disclose to their people. They are still having 
stigma in them so somebody tells you, “I couldn’t come” because they 
couldn’t allow her at work. And then we advise them that but you tell 
them, ‘please I am sick, and whenever I want to seek medical help I have 
to move away on this day’, but they don’t want to say that. They fear for 
their jobs some of them (Dispenser, 5 years at the Clinic) 
 
And even some change their names from the real names to new names of 
ISS Clinic names. Those are new names that are used after testing 
positive, in opening the file… I have no problem other than clients giving 
their false names at the clinic and sometimes you read, read at the end of 
the day without getting the owners file when actually he is inside seated. 
Another thing is when following up in their villages; we get problems in 
getting to their homes since they had given wrong names. They can tell the 
clinic the real village, treatment supporter but deceive them their names. 
 (Health Educator, 5 years at the Clinic) 
 
 
Patients still come to the clinic at a huge expense because they are hiding their 
status from the community members. Even when HIV clinics are established close to 
their homes, patients find it difficult to access care within their communities because they 
are afraid of being recognized as HIV positive, and subsequently being discriminated 
against. 
 
But also, another challenge which I have observed is the stigma especially 
if the patient is to get care in an area near their home especially things to 
do with HIV, there is still stigma. That’s what most patients tell us; why 
they cannot get services nearer to their homes. It’s stigma a number of 
patients mention that. (Clinical Officer) 
 
The most difficult thing, personally from my experience; I have found it 
difficult to get them to disclose. It is hard; it is like writing on water like 
people say. You explain to them, the advantages and the good thing about 
disclosure and all that and they will simply come back to you and say; I 
can’t, it is hard. Even when you have told them the beauty of disclosure, in 
them getting support from the people they have disclosed to so that they 
can swallow their pills well. They’ll say yes, all that is good but it is 
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difficult. (MO, 6 years) 
 
 
 
For resource-limited settings where people rely heavily on social support and 
financial assistance from friends and family, not disclosing one’s status may make it 
more difficult to access tangible resources.   
 
You may find that some patients have not totally disclosed to relatives and 
this sometimes has affected them especially where they get support from 
the relatives, may be the husband you might find that the lady has tested 
positive but she fears to disclose to the husband. Especially maybe if she 
gets pregnant because they need special care, so disclosure is important 
because it is a problem that affects the adherence and the support one 
would get from the relatives and the community. (Clinical Officer, 6 years 
at the Clinic) 
 
Maybe social reasons for example couples; if someone is married and they 
are attending clinic and the spouse doesn’t know, they miss the drugs or 
miss appointments for example if your husband is around and you don’t 
want him to know that you are coming to the clinic, you don’t come. Then 
when he has gone that’s when you know, you come. But the social bit is 
mainly for women; you know the cultural bit, everyone has to know where 
you will be. Your spouse, mother in-law, uncles; they all have to know 
where you are going and what you have to see. (Medical Officer at clinic 
for 4 years) 
 
 
The emotional stress experienced by patients when they have not disclosed their 
status was described by many of the health care providers. Having to hide, and carry the 
burden of their status in secret, created additional stress factors for people who already 
had compromised immune systems. 
And then it is also related with stress; because if someone lacks something 
and they don’t get it in time, then his life doesn’t do well. And then others 
are lacking disclosure; they have not disclosed to the family members, so 
the family members are not ready to help that person. So whenever he 
wants to come to the clinic he has to devise other means to see that he gets 
transport in a secret and then he has to come to the clinic. And then others 
are employed and they have not disclosed to their bosses so they fail to 
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make it to the clinic because of lack of disclosure… because they fear to 
be stigmatized and discriminated. (Health Educator) 
 
Another thing that has made people fail to access care it that some women 
come when they are pregnant. They maybe pregnant while swallowing 
their ARVs and the husbands might think that they are pregnancy drugs. 
So when they deliver, they won’t have any more excuse for swallowing the 
drugs or coming for them and thus they will disappear. (Counselor) 
 
 
Two of the healthcare providers were frustrated by the helplessness they felt with 
the fact that there was no legal framework to protect patients from work-related 
discrimination. This presents a challenge to the healthcare providers when they encourage 
patients to disclose.  
 
It is a big problem. It is happening amongst our clients but we don’t have 
a legal framework to help them and so even when it has happened, apart 
from asking them to find legal redress from the courts of law, as a 
clinician or a doctor, I don’t have a way to help them. I don’t have that 
legal framework to say I will do a, b, c; if this happened to help them. The 
only thing I can do as of now is to advise them, for them to take their 
initiative; to go to the courts of law. Otherwise, it is a big problem. (MO, 
6 years)  
 
Some of them have come up with complaints of being discriminated at the 
places of work; some of them have been retrenched because their HIV 
status has been somehow discovered. Someone gets to know, especially 
their bosses get to know that they are HIV positive and they are taking 
drugs and the next thing is; they are sacked. So they come back to us and 
they are like, Dr. you see, you encouraged me to disclose and so forth, 
now I have no job? (MO, 6 years) 
 
Another grave consequence of disclosure was domestic violence, experienced 
almost exclusively by women. As with work related discrimination, the laws protecting 
women are not strongly upheld, and in some instances, the women do not know their 
rights, even when the laws are in place to protect them. In some instances, seeking 
protection from the law required financial commitments and expenditures that the women 
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were not privileged to have. 
 
There is also gender-based violence and I think that also moves along with 
stigma where a man realizes that the wife is getting better care and 
therefore, women are beaten. You can even see these women that come 
here and pick drugs sometimes keep them at there neighbors’ places and 
we have some violent cases reported to police mainly because the woman 
is getting drugs and the husband isn’t. (MO, 10 years) 
 
2. Poverty and financial constraints are main barriers to HIV care  
‘Poverty’ was the word used by almost all the health care providers as the main 
barrier to HIV care for their patients. Poverty affected the patients’ ability to raise 
transportation costs, stay food secure, and manage competing demands effectively in 
such a way that it didn’t affect their care.  
The big word is poverty. Some of them have found it difficult to come back 
to the clinic; some have found it hard to find food to eat. Because we give 
them drugs, them come to the clinic, even when they have been out of 
service for long, or they have not been working for a long time, so they 
virtually have not a single coin. You start them on ARVs and you tell them 
you are going to take these drugs but at the same time you are going to eat 
and drink well. And they will tell you, Dr. I don’t have the food. So it is 
difficult. Others find it difficult to even just maintain the clinical 
appointments; just to have money to transport them to the clinic. So, 
poverty generally has complicated this care; this kind of chronic care and 
it is a big big draw back. (MO, 6 years) 
 
The main problem is social-economic. Ok like economically, most of them 
are peasants. You find most of them, maybe due to their sickness, are not 
able to work and get like transport to come here and obtain their care. 
And also most of them are unable to buy good foods and of course if you 
don’t have what to eat, you become more weak and the more you become 
weak, it hinders your ability to work, and there are no free services like 
outreach to the patients homes and therefore they have to cater for their 
transportation. And the nature of our communities; they are poor, and 
they have big families to support, that one also worsens the situation. So 
it’s mainly the transport problem. (Clinical Officer, 6 years at the Clinic) 
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Patients’ finances played a role in the clinical decisions that were often taken by 
the health care providers, particularly in the length of time given before their next clinic 
visit. 
The commonest thing they share is lack of transport, funds to come to the 
clinic more frequently, some of them say “doctor I would like you to give 
me medicine for four months because I don’t have income that can help 
me come back every month” and that is done by several patients because 
50% of them say “I would like to have medicine for more months” 
because I find it difficult; I stay very far, that’s the scenario they keep 
sharing. (Physician) 
 
 
Social issues, including family burdens, where overwhelming from a financial and 
emotional standpoint for many patients. 
 
I mean like those most of these people come from families where like say 
the head of the family has died and he has left many orphans, so the 
burden is left to the other relatives in the family or the wife. So it becomes 
very hard to support all of them especially when they are all HIV positive. 
(Clinic Officer, 6 years at the Clinic) 
 
Under social I must say the few examples I can give are the people who 
live with discordant couples and relatives where there is a bit of 
misunderstanding when one is positive and the other is negative, the 
feeling they get towards the partner who is positive yet people like women 
have to stay and cope for purposes of the children (Physician) 
 
 
3. A challenging work environment and work overload reduces quality of care 
All the healthcare providers discussed the challenges of working in a congested 
clinic space, with a high patient volume and work overload. The main point of frustration 
expressed was with the government health referral system. With the Mbarara ISS Clinic 
being part of the Regional Referral Hospital system, the clinic serves as the main referral 
 80	  
site for HIV treatment centers and clinics throughout Southwestern Uganda. The 
overwhelming volume of patients seen at the ISS clinic comprises referrals from the 
lower health centers that are ill equipped to manage comprehensive HIV care. The 
respondents were also frustrated by the weak communication lines they had with the 
lower health centers that made linkage in care and tracking of patients problematic. The 
health care providers were often fatigued and tired of ‘doing the same thing over and over 
again’. 
The most difficult thing you need to talk a lot about HIV to patients and to 
some of them they don’t understand what HIV is or what you are actually 
talking about so its always challenging explaining the same things, telling 
them to do the same things and also doing the same thing every day you 
get bored. (Dispenser, 5 years at the Clinic) 
 
 
Limited space presented a constant challenge in the delivery of care and the ISS 
Clinic was often congested and laden with delays. To handle the issue of congestion and 
spread of disease, the Clinic sees patients who are the sickest, with suspected tuberculosis 
or other highly infectious diseases first, to help infection control among patients and 
clinicians within the Clinic.  
 
 There is a lot of congestion in the clinic. We have so many patients and 
the clinic is not as big to accommodate all those patients so you find that 
we are stuck in the corridors and fail where to pass and in the clinic we 
cannot pass. They are planning to destroy the lower area of the clinic and 
we are going next because we are going to get more squeezed in those 
small rooms. It can easily lead to the spread of other infections like TB, 
you know when you stick people together there are those who have TB so 
when you mix them together the others will get it. (Dispenser, 5 years at 
clinic) 
 
No clinician would want to work in a congested place because of the 
increased infection rate like T.B and whatever, so that’s a challenge 
because we have to share rooms both as clinicians and other nursing 
teams. The congestion; yes we are working, but it’s not comfortable when 
you are working someone is coughing right into your face and the room is 
so tight. (Physician) 
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All of the healthcare providers reported that their patient load was too high, 
making it difficult to manage the flow of the clinic, especially when patients came on 
unassigned days. Patients were given follow-up appointments depending on health status 
and where they fell in the timeline of their HIV treatment. The time between 
appointments ranged from two weeks to four months. The clinic patient load was 
managed through an electronic database that kept track of patient appointments and 
projected the number of patients expected each day. Typically, the ISS Clinic sees 
approximately 200 patients a day. Of this number 10 are usually new patients coming to 
the Clinic for the first time, and 170 are returning patients with appointments. However, 
it is not uncommon to have about thirty returning patients shown up in one day, without 
appointments.  
 
Many healthcare providers felt that the patients had unrealistic expectations of 
their healthcare providers and the clinic services. The providers all felt the stress of being 
over worked and a counselor described the work load as one that ‘breaks us down’ and 
makes us ‘loose morale’ because ‘the clinicians cannot handle’. Almost all the providers 
were frustrated with the quality of care they delivered and believed they could deliver 
higher quality of care if given a lighter patient load. 
 
They expect much more than what we are providing and they expect 
heavens and earth. Could we have a cup of tea? Could we have some 
transport given? Could we have a, b, c, d? All that sort of thing, and they 
expect heaven and earth. (Nurse) 
 
Yah. Another problem is the number of patients; with time the number is 
increasing almost everyday and it happens that the number of the health 
workers has remained almost the same. (Clinical Officer) 
 
And then in terms of the amount of work done, sometimes we have more 
patients to be attended to than one can handle and what that one means is 
if you have 200 patients to see yet you have two or three clinicians it 
means the clinicians are over stretched they have to work an extra mile to 
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be able to see all these patients and all that comes with a cost, many are 
attended to but the quality of service given will not be as good as if you 
saw fewer patients, to elaborate on this, if a clinician is given say 30 
patients to see in a day and another is given 100 patients a day, the latter 
will not give them as good the service as the one who has seen 30 patients, 
they are few, you have more time to listen to their challenge, do all the 
examinations, making a consultation at the next door or from another 
clinician as compared to when you have so many patients. (MO, 8 years) 
 
 
There was a general concern about the increasing levels of stress experienced by 
the healthcare providers as a result of treating a chronic disease with no cure. A few 
healthcare providers, particularly the counselors, reported that they were having difficulty 
coping with their work-related stress.  Some providers noted that their heightened 
emotional state resulted to an impatient and negative response to patients at the clinic. 
 
The other challenge is stress at work, the professional stress here is high 
because like me the counselor, I always deal with people who are 
traumatized, they have a lot of issues they raise and then we get more 
stress because we don’t have any stress management policy at this clinic 
and many others. (Counselor) 
The most difficult thing for me as a clinician is seeing patients come back 
when they are stable even when you know you are unable to cure them. 
That to me, I find disturbing most. As a clinician what I hate is to see the 
patients suffering with so many ailments and I can’t put a stop to their 
complaints. (Physician) 
 
Some providers acknowledged that the Clinic was sometimes a hostile 
environment for the patients, and their inability to handle the patient load, especially 
when they had special needs e.g. mental health patients, caused them additional concern. 
Sometimes we bark at them they don’t feel comfortable with us and some 
of the clients who are some how mentally disturbed, we don’t know how to 
handle psych patients and we react poorly towards those patients. (Health 
Educator, 5 years at the Clinic) 
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I can’t say that all could be well with the way health workers always speak 
to the patients, a few have expressed the fact that they may not want to 
come to the clinic more regularly because they may interact with a few 
health workers who may be not kind to them, a few have come to my office 
and even slid small notes under my door saying “so and so who is brown 
and the first name is this” is being rude to us and I would say it’s a draw 
back to a few patients. (Physician) 
 
4. There are too few centers that offer HIV services, requiring patients to travel long 
distances to access care  
All of the healthcare providers agreed that the number of centers that offered HIV 
services was too few. Some patients travelled over 100kms to receive care at the Mbarara 
ISS Clinic, because they did not have a closer clinic to the patients’ homes. Even when 
there were health centers in closer proximity, the quality of services was far less 
comprehensive than the care offered at the ISS Clinic. Many providers were frustrated by 
the limited communication between the lower health centers and the regional referral 
clinics. 
 
The biggest is the referral system is still poor. We don’t link with other 
lower centers so we end up taking everyone and we are carrying a lot 
which we cannot handle. Sometimes that’s why you see so many people 
get lost because somebody is admitted on the ward and you find he is HIV 
positive and they can’t first think of where the person is coming from and 
they refer them to the nearest center but for us on receiving it has become 
difficult   for us to maintain these patients at our care because come in 
from very far they end up getting lost so the major problem is the follow 
up because you can have patients like ten thousand but you find in actual 
sense you have like three thousand. The rest have disappeared. 
(Dispenser, 5 years at clinic) 
 
The loss to follow-up as you know, we have failed to keep good track of 
some of these patients, it’s a bit difficult but because we are in a referral 
hospital, we tend to accept a few more patients who come via the medical 
order and several often find centers where they can access care and we 
don’t officially transfer them out, they self transfer themselves out, and we 
have a problem juggling to know whether somebody has died or self 
transferred out. (Physician) 
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One provider felt that the healthcare providers were not doing enough to reach out to 
patients in the community, and that this may be a common reason for the disconnect 
between the Clinic and the patients. 
This clinic has not reached out to the people; that’s the major challenge. 
It’s a big clinic; it can do a number of things but it is away from the 
people who need the services, so people go through thick and thin to come 
to the clinic. I rather have the service and go to them, but it can’t. Now 
that’s a big time challenge. If there was a way of the service that is 
provided in this place to get to the people, it would be much better. (MO 6 
years) 
 
 
5. Limited drug supply and distribution problems are major ongoing challenges  
Although there were several incidents of drug shortage, the healthcare providers 
managed to bridge these gaps with donor drug supplies so that patients were not aware of 
the shortages. Even with the added resources of donated drugs, some of the providers still 
expressed frustration with their limited access to a wide variety of medications for both 
HIV and other opportunistic infections. 
The most difficult thing that I find in the clinic has been the occasional 
inconsistence of the ARVs availability from the Ministry of Health 
whereby we have to struggle, be on the phone all the time, contacting the 
National medical stores that the drugs are running out of stock, yet we 
can’t let our tension spill over to the patients. (Physician) 
Well, we still have some problems with supply of drugs…, especially with 
the Ministry of Health supplies. Some times they bring one drug with no 
combination, sometimes they bring what you have not ordered for. It 
becomes a challenge to us and patients themselves because we can’t give 
them a drug which is single, not combined. Then also people get lost from 
the clinic and we don’t have any mechanism. Ok, the mechanism is there 
we have but they are not a hundred percent that we can get everyone. 
(Dispenser, 5 years at the clinic) 
The other thing is we do provide drugs free but there are some times when 
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you need to prescribe a specific type of medication that the patient may 
not afford to buy when at the same time you do not have that drug at the 
shelf so in other wards you want to give someone a medication that they 
cannot afford and you also don’t have at a free. (MO, 8 years at the 
Clinic) 
 
While the donor-driven structure for ART supply and distribution was 
appreciated, many of the providers would have preferred greater stability, and ownership 
of HIV managed in general, by the Uganda Ministry of Health. Many providers felt that 
the Ugandan government needed to take more responsibility for managing the health care 
system, particularly with the lower-level health centers that were not empowered and 
equipped, even with human resources, to handle HIV services appropriately.  
The other challenge is about our mother institution owner; mother 
institution I mean Ministry of Health. Much of the work we do here is 
donor driven… it is the development partners who are supporting the 
clinic in terms of ARVs, the labs and paying even majority of the staff in 
the clinic. So Ministry of Health for our country is a bit laid back and 
that’s a big challenge and that’s why, the service cannot go to reach the 
people, to find the people where they are so that they can access the 
service within their areas of reach. Now that’s a big challenge, I may not 
do much about it but it’s the major challenge. You will find that all these 
other problems are coming up because of that. (MO, 6 years) 
 
The donor-driven system has its challenges when there are multiple parties working 
within one system. 
Different projects which have different rules or SOPs to follow sometimes 
we have had some conflicts whereby one project would have loved this to 
happen like that and vice versa, and it becomes a challenge to marry all 
the projects together. But in the long run the fact that it’s one clinic we try 
to compromise and do the best for the patients. (Physician) 
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6. Challenges with poor ART adherence, routine monitoring, and sub-optimal 
treatment outcomes threaten the sustainability of HIV care 
Many of the providers were concerned about ART adherence and did not feel that 
enough was being done by the Clinic to prevent lapses in adherence on the part of the 
patients. They talked about the difficulties they had in monitoring patients with limited 
resources in the Clinic to effectual optimal care. 
The minority; of course not every body is doing well, some fail on their 
drugs; you give them the drugs and they fail to work, others don’t adhere 
to the medication, so eventually they don’t do well clinically. That’s it. So 
they keep getting infections, infections and infections. I think patients not 
keeping their appointments is kind of a bigger problem because it reflects 
on their adherence; if I am not keeping my appointment, maybe am also 
missing my drugs. You understand? Because we are saying that most 
people don’t have the transport, but there are those who have and they 
feel they have other things to do. So if there are so many things going on 
in your mind, maybe will also forget to take your drugs. So it’s kind of a 
problem. (Medical Officer, 4 years) 
 
 
Missed appointments were often made up by patients who ‘feel they can drop in 
at any time’, which disorganized the flow and organization of the Clinic. The providers 
did not welcome this practice. 
…you give them appointments wait for them and they don’t come. Some of 
them come after some many days when they have already missed some 
doses, when they have contracted some other sicknesses which need extra 
care and maybe to be admitted on the ward, and with those challenges 
they can not be admitted at the ward because there is no one to care for 
them. So it becomes a big problem. And then others shift from one place to 
another. You wait for someone to come, he isn’t coming; when you trace 
for that person, he’s not at home and the people at home can’t allocate 
where he is and when they allocate where he is, you can’t reach there. It 
becomes a problem because you can’t tell whether that person has died or 
he still exists, or whether he still gets any medication. And then after some 
time, you see him coming back. He tells you; you see, I got a job 
somewhere, I was working and they couldn’t let me come. Then you just 
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have to go through counseling again; heart counseling which takes some 
time, so to improve the life of such a person again becomes a problem.   
(Health Educator) 
 
There those who think spend a lot of time at the clinic because when they 
come here they want to be worked first but the queue as you see today so 
they have to bear with us as the principle is first come first served so some 
feel it’s a barrier to them then they tend to dodge their return dates and 
when some forget their return dates, they think when they come here some 
health workers will be harsh on them so they tend to stay away and may 
be come when we send our tracker to look for them. (Counselor) 
 
Management of HIV is changing and becoming more complex for the already 
overburdened clinicians. Despite the long lines, and the growing patient population, in 
2010, the clinicians decided to have an administrative day to have continuing education, 
discuss difficult cases and have management meetings to better manage the Clinic needs. 
Maybe another thing we observe are the difficult cases, we are seeing 
more complicated cases in HIV management where by you can get stuck 
and you find that you cannot do much for the patient. Especially things to 
do with treatment failure, resistance; because we are seeing patients 
nowadays who are failing on second line and yet the options we have, 
which are available are limited. (Clinical Officer) 
 
It’s the workload really, because when you have so much work, by 5pm 
you are so tired, you can’t read and it’s so hard to keep up to date 
because you know HIV keeps changing; the drugs keep changing, new 
things keep coming up so you kind of lag behind. So you find that you have 
only weekends to catch up and after 5pm when you are so tired. (Medical 
Officer at Clinic 4 years) 
 
Poor ART adherence and sub-optimal treatment outcomes were of major concern to 
almost all the providers. 
The one I would consider as most challenging is not being able to ensure 
patients have maximum adherence to therapy when we do not have the 
abilities to improve the adherence, for instance when someone comes with 
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poor adherence, all we can do is to counsel them but remember when you 
counsel, you are only going to help the person who will have developed 
poor adherence due to reasons say if someone was forgetting. Then you 
can tell them to use an alarm. If one had a source of income but has been 
wasting that money, that one can improve, but one who had absolutely no 
source of income and was depending on another’s funds and that other 
person doesn’t give them the funds, in that case it is very difficult to 
improve on that person’s adherence because they will repeatedly have the 
same problem. (MO, 8 years) 
 
Getting these people to swallow their drugs is a major challenge. Some of 
them have been bold enough to tell us that they get tired, fatigued; they get 
tired of swallowing the drugs/pills so they tell us. Others because we 
monitor; we do monitoring for that; we want them to take their drugs. So 
you discover it and then you ask them; what is happening, why are you not 
taking your drugs? So it is either way, some of them will tell you, others 
you simply find out as you do the monitoring. (MO, 6 years) 
 
 
Facilitators of HIV Care from Healthcare Providers 
 
1.  The efficacy of ART and quality of care at ISS Clinic are recognized and valued 
Almost all the providers talked about the efficacy of ART and described the 
positive effect of the successful treatment outcomes on patients’ motivation to stay in 
care and adhere to their prescribed regimen. Many of the providers were equally 
encouraged by the visible improvement in clinical and physical symptoms experienced 
by their patients. 
What I see mainly in these patients is the improvement they get when they 
start at because previously most of them used to come when they are very 
sick, and like when they start and adhere to their treatment they really 
improve and that one gives us joy seeing them improve on their treatment. 
(Clinical Officer, 6 years at Clinic) 
 
Basically, majority of the patients are doing very well. The simplest way I 
can put this is patients come to the clinic when they are having repeated 
infections, when they have lost weight, when they are not eating well, 
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they’ve lost appetite, they have infections like wounds in the mouth and 
they are not able to eat and when you initiate them to Anti-retroviral 
therapy and after a period of time you begin to see them when they have 
no complaints in other words they are able to take their drugs as they 
carry out their routine work well and they only come to me when they 
want medication without any complaints which is a good indicator that 
they are faring well with their medications. (MO 8 years) 
They are improving on their health, because when people are started on 
ARVs, eventually I see them coming up becoming productive getting back 
to their normal lives and doing their normal activities.  Ideally, we have 
seen people go back to school, those who thought will never get married 
are now married, couples are giving birth that is basically what I meant 
by doing well. (Counselor 2 years) 
 
 
 
2. Success of HIV treatment programs in sub-Saharan Africa is dependent on a 
positive global response and continued support 
 
There was a general consensus that the success of the HIV treatment programs 
was as a result of a concerted effort by international partners working together with 
Ugandans to respond adequately to the crisis. 
But I think all has been running well because we have other stakeholders 
and other projects which have been helping us that is the Harvard, the 
MJAP; they have all been to our support and buffering the stocks we have 
from Ministry of Health but without those other projects, buffering the 
stocks would have been so difficult to handle the loads of patients we have 
who are on ARVs because they are about 5500 patients on ARVs. So if all 
of the drugs went out of stock from one project and we had no one to 
buffer, it would really be so difficult. (Physician) 
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B. UARTO Sub-Study Results 
 
I. Descriptive Analysis of the UARTO Study Participants 
 There were a total of 505 UARTO study participants included in this analysis, of 
whom 360 (70%) were female. Majority of the participants were Christian (91%) and 9% 
were Moslem. Almost one quarter (20%) of the participants were not literate with 12% 
having no formal education. More than half of the participants (62%) had received 
primary and 26% had received some secondary education or higher. More than half were 
either unemployed or worked as subsistent farmers. Ages ranged from 18 to 75 years and 
the median age was 35 years. Only 26% of the participants were married, with 22% 
widowed, 25% separated or divorced and 8% were never married. A little less than three 
quarters (67%) had a household size consisting between 2 and 8 members. The median 
CD4 cell count at baseline was 152 and viral load was 4.9 log copies per mm3. Mean 
adherence was 94% over 12 months of follow-up and participants had an average of 2 
treatment interruptions greater than 48 hours, with each interruption averaging 17 days 
long. 
 
Public transportation was the main mode of travel to clinic for 82% and included 
public buses, taxis and motorbikes and the average travel time was 52 minutes. 
Participants spent an average of 4,250 UGX ($2) per trip to the clinic. Only a few (6%) 
participants reported depression but 63% scored between 1 and 6 on the Internalize 
AIDS-Related Stigma Scale, indicating some level of internalized stigma. Baseline 
summary statistics are described in Table 1. 
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Table 1. Characteristics of UARTO Participants (N=505) 
 
Characteristics Mean 
or N 
(%) or  
95% CI 
Missing 
Observations 
Gender     
   Female 360 (69.9) 6 
Religion    8 
   Christian 466 (90.9)  
Literacy   9 
  Cannot read sentence 104 (20.2)  
Education    37 
   No Education 56 (11.6)  
   Primary Education 300 (62.0)  
   Secondary and above 108 (26.4)  
Marital Status    9 
   Never married 41 (8.0)  
   Divorced/separated 126 (24.6)  
   Widowed 112 (21.9)  
   Married 134 (26.2)  
Means of transport to clinic    233 
   Walking or Bicycle (private means) 50 (17.7)  
   Public Transportation  236 (82.0)  
Internalized AIDS Related Stigma    324 
   No Stigma 73 (37.1)  
   Stigma (ranked 1-6 on IARS scale) 124 (63.0)  
    
Age (years) 35 (34.0, 35.4) 7 
Monthly Income (UGX) 93081 (73540,112622) 182 
Travel time to clinic (Minutes) 52.3 (48.5,56.2) 7     
Cost of travel to clinic (UGX)  4248.6 (3780.2,4717.0) 237 
Mean MEMS Adherence (% over 0-12 
months)  
93.6 (89.9,97.3) 47 
Mean CD4 cell count at Baseline 152.0 (142.235,161.762
) 
13 
Mean log Viral Load at Baseline 4.9 (4.8,5.0) 22 
Number of Treatment Interruptions >48 
hours (among those with interruptions)  
1.9 (1.5,2.3) 35 
Average length of Treatment 
interruptions (# of days among those 
with interruptions)  
16.8 (14.076,19.498) 35 
FP Asset Index   -0.012 (-0.195, 0.171) 11 
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II. Predictors of High Adherence (greater than 90%) Using MEMS 
 
Mean adherence in this population was high at 94% over 12 months. However, 
when stratified by quarter adherence levels were varied; mean adherence was 98% in the 
first quarter (3 months), peaked at 100% in the second quarter (6 months) and by the third 
and fourth quarters, a decreasing trend was observed with mean adherence at 94% and 
84% respectively. See Figure 1. Increased age was associated with higher MEMS 
adherence in the univariate analysis, but these results were not statistically significant in 
the multivariate analysis. Higher scores on the internalized stigma scale were associated 
with lower adherence in both univariate and multivariable regression model. Results are 
summarized in Table 2.  
 
Table 2. Predictors of High Adherence (>90%) using MEMS                  
 
Univariable 
 
Multivariable Variable 
OR (95% CI) OR (95%CI) 
(excluding 
IARSS) 
OR (95% CI) 
(with IARSS 
only) 
Gender (ref = male) 1.14 (0.89,1.45)           
Age 1.02 (1.00,1.03)*         1.01 (0.99, 1.02) 1.00 (0.98, 1.03) 
Travel Time  1.00 (1.00, 1.01)          1.00 (1.00, 1.00) 1.00 (1.00, 1.01) 
Asset Index        0.97 (0.91,1.02)            0.99 (0.93, 10.5) 0.94 (0.85, 1.03) 
Stigma  0.88 (0.80, 0.98)*  0.90 (0.81, 0.99)* 
Travel Cost  1.00 (1.00, 1.00)             
Disclosure       1.01 (0.73, 1.39)   
Social Support 0.87 (0.60, 1.23)            
Rainy Season  1.13 (0.90, 1.42)            
Alcohol Use per 
AUDIT-C        
1.07 (0.54, 2.11)             
Distance to Clinic 
(KM)       
1.01 (0.99, 1.02)             
 
* denotes statistical significance at the p<0.05 levels 
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Figure 1. Mean MEMS Adherence by Quarter (3, 6, 9 and 12 months) 
 
 
 
 
 
 
III. Predictors of High Adherence (greater than 90%) Using Self-Report 
 
Increasing age and internalized stigma were both associated with higher Self-
Reported adherence in the univariate analysis and both were statistically significant in the 
multivariate analysis. While alcohol consumption (defined by having a positive AUDIT-
C score) was associated with lower odds of high adherence, the results were not 
statistically significant in the multivariate analysis (p=0.06). Higher scores on the 
internalized stigma scale were associated with lower adherence in both univariate and 
multivariable regression model. Results are summarized in Table 3.  
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Table 3. Predictors of High Adherence ( >90%) using Self Report 
 
 
* denotes statistical significance at the p<0.05 levels 
 
Proportion of Participants maintaining high levels of adherence, stratified by quarter:             
When stratified by quarter, to assess adherence trends over time, Figure 2. below 
illustrates that more than 90% of the participants retain high levels of adherence 
throughout the 12 months, with a slight decrease to 88% at 12 months. Self-reported 
Univariable 
 
Multivariable Variable 
OR (95% CI) OR (95%CI) 
Excluding 
IARSS and 
distance) 
OR (95% CI) 
With IARSS 
only 
OR (95% CI) 
With distance 
only 
Gender (ref = 
male) 
0.99  
(0.67, 1.46) 
   
Age 1.08 
(1.05,1.10)* 
1.01 
(0.99,1.02)* 
1.06 (1.03,1.10)* 1.06 (1.03,1.09)* 
Travel Time  1.00  
(1.00,1.00) 
   
Asset Index        0.97  
(0.88,1.07) 
   
Distance to 
Clinic   
1.03  
(0.99,1.06) 
 0.99 (0.96,1.03) 1.02 (0.99,1.05) 
Travel Cost  1.00  
(1.00,1.00) 
   
Disclosure  1.21  
(0.76,1.90) 
   
Social Support  0.96  
(0.57,1.60) 
   
Rainy Season  
 
0.85  
(0.60,1.22) 
   
Alcohol Use  0.45 
(0.21,0.95)* 
0.48 
(0.22,1.04) 
0.44 (0.17,1.13) 0.46 (0.20,1.05) 
Internalized 
Stigma  
 
0.89 
(0.78,1.01)* 
  0.89 (0.81,0.99)* 
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adherence is lower overall and is more variable by quarter with the proportion of 
participants reporting high levels of adherence being 75% at 3 months, 82% at 6 months, 
81% at 9 months and 68% by 12 months. The trend stays the same for both measures. 
 
Figure 2. Mean MEMS and SR Adherence by Quarter (3, 6, 9 and 12 months) 
 
 
 
IV. Predictors of Treatment Interruptions (7, 14, and >30 days): 
 
On average, participants had 2 episodes of treatment interruptions with an average 
of 17 days for each interruption. When examining any interruption, Asset index was the 
only variable associated with an interruption in the univariate analysis, but this was not 
statistically significant as with other variables in the multivariate analysis.  
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Interruptions of 7- Days or shorter:  
Higher asset index was protective of interruptions lasting 7 days or less in both 
univariate and multivariate analyses. Increased travel time as a continuous variable was 
associated with a decreased odds of interruptions lasting 7 days or less. Summarized in 
Table 4. 
 
Interruptions of 8-14 Days:  
Gender and Age were associated in 14 day breaks in the univariate analysis but 
not in the multivariate analysis when asset index, age and gender were added to the 
multivariable models. Summarized in Table 5. 
 
Interruptions of 30 Days or longer:  
Increased travel time was associated with decreased odds of interruptions lasting 
30 days and longer. Summarized in Table 6. 
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Table 4. Predictors of Treatment Interruptions lasting 7 days or shorter 
Univariable 
 
Multivariable  
Variable 
OR (95% CI) OR (95%CI) 
 
Gender (ref = male) 0.97 (0.53,1.77)  
Age 0.98 (0.95,1.01) 1.0 (0.96,1.04) 
Travel Time  0.99 (0.99,1.00)           0.99 (0.98,1.00)* 
Asset Index        0.81 (0.68,0.98)*           0.74 (0.61,0.91)* 
Distance to Clinic  0.99 (0.94,1.04)           
Travel Cost  1.00 (1.00,1.00)            
Disclosure 1.00 (0.48,2.09)      
Social Support  0.66 (0.21,2.08)            
Rainy Season  1.06 (0.59,1.88)            
Alcohol Use  per AUDIT-C  0.62 (0.08,4.60)           
Internalized Stigma  
 
0.85 (0.61,1.18)           
 
* denotes statistical significance at the p<0.05 levels 
 
 
Table 5. Predictors of Treatment Interruptions lasting 8-14 days  
 
Univariable 
 
Multivariable  
Variable 
OR (95% CI) OR (95%CI) 
 
Gender (ref = male) 2.51 (1.03,6.14)* 1.25 (0.54,2.88) 
Age 0.95 (0.91,0.99)* 0.98 (0.94,1.03) 
Travel Time  1.00 (0.99,1.00)            
Asset Index        0.87 (0.71,1.06)         0.87 (0.71,1.06) 
Distance to Clinic  0.96 (0.89,1.03)           
Travel Cost  1.00 (1.00,1.00)            
Disclosure 1.09 (0.48,2.09)      
Social Support  1.44(0.50,2.37)            
Rainy Season  0.67 (0.33,1.36)            
Alcohol Use  per AUDIT-C  <0.00 (0.00,0.00)           
Internalized Stigma  
 
1.11 (0.81,1.50)           
  
* denotes statistical significance at the p<0.05 levels 
        
 98	  
Table 6. Predictors of Treatment Interruptions lasting longer than 30 days 
 
Univariable 
 
Multivariable  
Variable 
OR (95% CI) OR (95%CI) 
 
Gender (ref = male) 0.81 (0.33,2.03)  
Age 0.95 (0.88,1.01) 0.97 (0.91,1.02) 
Travel Time  0.98 (0.96,1.00)*           0.98 (0.96,1.00)* 
Asset Index        0.85 (0.64,1.14)            
Distance to Clinic  0.95 (0.86,1.05)           
Travel Cost  1.00 (1.00,1.00)            
Disclosure 1.08 (0.36,3.24)      
Social Support  0.91 (0.20,4.20)            
Rainy Season  0.91 (0.37,2.24)            
Alcohol Use  per AUDIT-C  <0.00 (0.00,0.00)           
Internalized Stigma  
 
0.94 (0.59,1.50)           
 
* denotes statistical significance at the p<0.05 levels                                       
 
 
Proportion of Participants with Treatment Interruptions, stratified by quarter:  
When stratified by quarter, to assess treatment interruption trends over time, 
Figure 3. below illustrates that treatment interruptions of 30 days or longer are 
experienced in 20% or less of the participants in all quarters. Close to half of the 
participants experience interruptions of 7 days or shorter in all quarters, and both 7 and 
14 day breaks assume a U-shaped trend with the highest proportions experiencing these 
breaks at the first and last quarters.  
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Figure 3. Proportion with Treatment Interruptions by Quarter (3, 6, 9, &12 months) 
 
 
 	  	  
V.  Predictors of Treatment Failure Defined by Viral Load less than 400  
 
The proportion of participants with a VL less than 400 increased within the first 
quarter from 88% at 3 months, to 92% at 3 and 6 month, and to 94% at 12 months. 
Increased MEMS and Self-Reported adherence were associated with decreased odds of 
treatment failure in the univariate analysis. Higher internalized stigma was consistently 
associated with decreased odds of treatment failure in both univariate and multivariate 
analyses. Although not significant in the univariate analysis, the multivariate analysis 
showed that women were less likely to have a treatment failure when included in the 
model that was restricted to only participants with data on distance to clinic. Women 
have 0.5-decreased odds of a treatment failure as compared to men, while adjusting for 
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distance to clinic, alcohol consumption and MEMS adherence. See Table 7. 
The associations between travel time, social support, stigma, serostatus disclosure 
and treatment failure (VL>400) were not statistically significant for any of the 
multivariate models.  
 
Social Support and Travel Time:  
In the multivariate model with travel time and social support as independent 
variables of treatment failure, the findings show a trend of travel times shorter than 45 
minutes having a 1.7 increase in the odds of treatment failure while social support had 
slightly decreased odds of treatment failure. There were no significant interactions 
between social support and travel time.  
 
Internalized Stigma and Travel Time:  
In the multivariate model with stigma and travel time as independent categorical 
variables of treatment failure, the findings show a trend of lower internalized stigma 
having a 2.8 increased odds of treatment failure, while travel times shorter than 45 
minutes having a 2.8 increase in the odds of treatment failure. There were no significant 
interactions between internalized stigma and travel time.  
 
Any Disclosure and Travel Time:  
In the multivariate model with disclosure and travel time as independent 
categorical variables of treatment failure, the findings show a trend of disclosure having a 
2.2 increased odds of treatment failure, while travel times shorter than 45 minutes having 
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a 3.1 increase in the odds of treatment failure. There were no significant interactions 
between disclosure and travel time. See Table 8. 
 
Difference between participants with high levels of stigma versus low levels of stigma:  
Interaction between stigma and social support were not significant in the analysis. 
Further assessment of differences between participants with high levels of stigma, 
defined by those having IARS scale scores of 3 and above, versus those with low levels 
of stigma, defined by scoring below 3 in the IARS scale, showed that there were no 
differences between the groups when social support was included in the model. See table 
9. Depression, however, was the only significant variable in the stratified stigma table 
below. 
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Table 7. Predictors of Treatment Failure (Outcome = >400 VL at 6, 9, or 12 months)      
 
* denotes statistical significance at the p<0.05 levels 
 
 
 
 
 
 
Univariable 
 
Multivariable Variable 
OR  
(95% CI) 
OR 
(95%CI) 
 
OR (95% CI) 
Excludes 
IARSS, distance 
OR (95% CI) 
With distance 
only 
Gender (ref = 
male) 
0.77  
(0.49, 1.20) 
0.65 
(0.34,1.23) 
0.69 (0.42,1.11) 0.50 (0.28,0.89)* 
Age 0.99 
(0.96,1.01) 
   
Travel Time  1.00 
(0.99,1.00) 
1.00 
(0.99,1.00) 
  
Asset Index        0.97 
(0.87,1.08) 
   
Distance to 
Clinic   
1.02 
(0.99,1.05) 
  1.03 (0.99,1.05) 
Travel Cost  1.00 
(1.00,1.00) 
   
Disclosure  0.75 
(0.40,1.40) 
   
Social Support  0.72 
(0.33,1.61) 
   
Rainy Season  
 
1.02 
(0.67,1.56) 
   
Alcohol Use  1.77 
(0.67,4.67) 
1.29 
(0.36,4.66) 
1.88 (0.70,5.04) 2.09 (0.75,5.81) 
Internalized 
Stigma  
 
0.77 
(0.59,1.00)* 
0.77 
(0.59,1.01)* 
  
MEMS 
Adherence  
0.30 
(0.13,0.69)* 
 0.99 (0.98,1.0)* 0.99 (0.98,1.00) 
SR Adherence 0.96 
(0.94,0.98)* 
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Table 8. Predictors Treatment Failure and Interactions between Support, Travel 
Time, Disclosure and Stigma  
 
Outcome viral load>400 OR (LCLM, 
UCLM) 
P 
Social Support (continuous) 0.99 (0.31, 3.14) 0.99 
Travel Minutes Categorized (<45=1,≥45=0) 1.72 (0.23, 12.64) 0.59 
Interaction Social Support*Travel        0.89 (0.21, 3.76) 0.88 
    
Outcome vl>400 OR (LCLM, 
UCLM) 
P 
Stigma Categorized (≥3=0,<3=1) 2.84 (0.63, 12.92) 0.17 
Travel Minutes Categorized (<45=1,≥45=0) 2.87 (0.57, 14.47) 0.20 
Interaction Stigma*Travel        0.38 (0.065, 2.20) 0.28 
    
Outcome viral load >400 OR (LCLM, 
UCLM) 
P 
Any Disclosure (1=disclosure,0=no 
disclosure) 
2.16 (0.57, 8.11) 0.25 
Travel Minutes Categorized (<45=1,≥45=0) 3.08 (0.79, 11.97) 0.10 
Any Disclosure*Travel        0.31 (0.06, 1.55) 0.15 
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Table 9. Difference Between Participants with High and Low Stigma Levels 
 
 
 
 
 
 
 
 Stigma Category (Missing=324) 
 High Levels of Stigma with 
IARS score ≥3(n=52) 
Low levels of Stigma with IARS 
Scores <3 (n=145) 
Variable n mean lclm uclm n mean lclm uclm 
Age 52 33.6    31.0      36.3 145       34.8       33.4     36.3 
Asset 
Index 
52 -0.1      -0.7        0.6 145 -0.2       -0.5     0.1 
Depressed 52 0.80        0.6        1.0 145 0.3       0.1      0.5 
Baseline 
CD4                            
50   157.0     117.1    196.9 144 164.9     147.0      182.9 
Baseline 
log viral 
load                   
49 4.9        4.6       5.2 143 4.7      4.6       4.9 
Social 
Support 
49 1.4        1.2        1.6 131 1.3      1.3       1.4 
Household 
Size 
52   3.5        2.7       4.3 145   3.3        2.8       3.7 
Travel 
Cost 
52 3625.0          3008.7         4241.3 145 4631.0          4082.7      5179.4 
Adherence 
(12 month 
mean) 
        
MEMS 43 86.5       81.2       91.90 130 87.7       80.3       95.2 
Visual 
Analog 
47 94.4      91.9      96.81 127 95.7      94.3      97.0 
 105	  
VI. Predictors of Being Lost to Follow Up from Clinic: 
 
Age was the only variable that was significant in both univariate and multivariate 
analysis with younger participants having higher odds of being lost. After adjusting for 
the effects of rainy season and travel costs, the findings show that increase in age has 
decreased odds of being lost to follow-up in the clinic. Summarized in Table 8. 
 
 
Table 10. Predictors of Being Lost to Follow-up from Clinic  
Univariable 
 
Multivariable Variable 
OR (95% CI) OR (95%CI) 
(excluding travel 
cost) 
OR (95% CI) 
(with travel cost) 
Gender (ref = male) 1.15 (0.69,1.91)           
Age 0.97 (0.94,1.00)*         1.01 (0.99, 1.02)* 1.00 (0.98, 1.03)* 
Travel Time  1.00 (1.00, 1.01)           
Asset Index        1.00 (0.89,1.11)             
Distance to Clinic  0.98 (0.93, 1.04)   
Travel Cost  1.00 (1.00, 1.00)            1.00 (1.00,1.00) 
Disclosure       1.01 (0.55, 1.87)   
Social Support 1.17 (0.90, 2.28)           
Rainy Season  1.44 (0.90, 1.42)          1.42 (0.89,2.28) 1.56 (0.84,2.92) 
Alcohol Use per       0.83 (0.45, 1.52)             
Internalized Stigma       0.99 (0.81, 1.22)            
 
* denotes statistical significance at the p<0.05 levels 
 
 
VII. Survival Analysis 
 
When travel time was assessed as a categorical variable, with the cut-point of less 
than or greater than 45 minutes, travel times longer than 45 minutes were associated with 
increased mortality. Gender was equally associated with mortality as men had increased 
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odds of mortality. Being female was protective of mortality within the first year of 
enrolment and follow-up in the study. Summarized in Figures 3 and 4.  
 
 
Figure 4. Survival by Gender  
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Figure 5. Survival by Travel Time to Clinic  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 5. DISCUSSION 
 
The findings from this study demonstrate that multiple economic and structural 
barriers exist with HIV care in rural Uganda for both patients and healthcare providers. 
The findings further illustrate how these barriers could threaten the sustainability of HIV 
treatment programs and diminish the positive impact of the recent successes experienced 
with treatment roll-out in resource-limited settings. However, the data also point to the 
strength of several facilitators that serve as mediators to counteract the barriers. These 
facilitators may provide insights to possible interventions strategies to improve HIV care 
in rural settings. 
 
Summary of Results 
Similar to previous findings (31, 32, 48, 72, 102), the qualitative findings show 
that patients attending the Mbarara ISS Clinic in Uganda experience barriers to accessing 
care related to poverty. Participants consistently reported difficulty with accessing care 
because of the additional cost of routine transportation to the clinic for medication refill 
and clinician’s visits. The added cost of waiting for long hours at the clinic, hunger and 
food insecurity were sited as added burdens to resources that were already fully 
maximized by competing demands. Although the level of motivation was high to adhere 
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to medications, financial constraints contributed to the patients’ inability to access care 
and medications, which contributed to treatment interruptions. As previously described 
(29, 30, 63), treatment interruptions were mostly due to an inability to access medications 
rather than a function of missed doses of medications in the patients’ possession. This 
finding is consistent with the notion that the Achilles’ heel of HIV treatment in rural 
settings is the challenge of structural and economic barriers that make it difficult for 
patients to access care and retain in care (29).  
The exception to this conclusion is the finding related to the prevalence of stigma 
as a barrier to patients. The high prevalence of stigma reported in the qualitative data was 
unexpected and the extreme measures taken by participants to hide their HIV status was 
even more astounding. Although the UARTO study findings suggest otherwise, both 
enacted and internalized stigma were cited in the qualitative study as reasons for 
withholding disclosure of HIV status. The process of serostatus disclosure was 
complicated and potentially enabled behaviors that influenced adherence to medications 
and/or clinic attendance. Disclosure also had the potential to ease the burden of asking for 
and accepting social support to mitigate barriers to care. Also consistent with previous 
studies (48), social support translated not only to emotional support from friends and 
family, but served as a resource that could be drawn from to mitigate financial constraints 
that prevented access to care as well as retention in care. Social support in this instance is 
a tangible material resource necessary for survival as opposed to an emotional 
phenomenon only. Disclosure did not always lead to increased social support and ease of 
emotional burden. For some participants, the potential consequences, including loss of 
employment, marital status and violence or abuse, were too grave to allow for disclosure. 
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These findings highlight the need to address stigma and HIV-related discrimination as a 
crucial step to engaging and keeping HIV patients in care and improving their quality of 
life in general. 
A new finding from the qualitative data highlighted the difficulties patients’ faced 
in navigating inflexible clinic schedules. The availability of no-cost ART in many sub-
Sahara African clinics, coupled with expanded testing, led to a rapid and overwhelming 
increase in the number of patients at each treatment site. However, the increased demand 
in services did not necessarily translate into increased human and financial resources at 
the health centers and clinics. The Mbarara ISS Clinic was not an exception to this trend, 
and as with many other clinics, found it difficult to manage their rapidly increased patient 
population. The overwhelming volume of patients, coupled with inadequate staffing, 
forced the clinic to adhere to strict pre-determined schedules and remain inflexible in 
changing patient appointments.   
From the perspective of the healthcare providers, patients who returned for clinic 
visits without appointments disrupted the flow of the clinic and only added to their 
already insurmountable workload. In turn, patients were disillusioned by the rigid 
requirements to justify their reasons for missing appointments or returning without 
appointments. They equally complained of the hostility of the clinic and negative 
treatment received when they returned without appointments, particularly from the non-
clinician care givers. Some participants were so frightened of the reception and treatment 
they would receive at the clinic that they missed appointments or sought care elsewhere. 
Due to poor communication lines between all health centers providing HIV care 
throughout Uganda, this scenario presented multiple opportunities for patients to be lost 
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or for linkage in care to be broken. These findings were not evident in the UARTO data, 
in which age was the only significant predictor of loss to follow up from clinic. This 
finding was of particular interest because it still presented as a barrier to care despite the 
reported high levels of trust in healthcare providers at the clinic and general satisfaction 
with the quality of care received at the clinic. The hostility of the clinic described by 
patients was exclusively related to missed appointments or returning patients without 
appointment. It is possible, therefore, that the patients who experienced hostility in the 
clinic were more likely to have other concurrent challenges to accessing and retaining in 
care that caused them to miss their appointments in the first place and return to the clinic 
on days that were not assigned to them.  
A main facilitator of care is that ART effectiveness and improved treatment 
outcomes serve as motivating factors for retention in care. Patients consistently reported 
the motivating force of the ‘Lazarus effect’ of ART and there was a strong unwillingness 
to revert to bed-ridden and dysfunctional disease states experienced prior to treatment. 
The UARTO analysis illustrates near-perfect adherence (94%) at the 3 –month follow-up 
visits, which improved to 100% at the 6-month mark. This trend suggests an additional 
motivation to adhere to treatment once treatment success was experienced. After the 6-
month time point, however, this trend slowly begins to wane and by 12 months, mean 
adherence declines significantly in this population from close to 100% to 84%. 
Examining the proportion of participants achieving more than 90% MEMS adherence by 
quarter, however, illustrates that most participants (90%) remained highly adherent 
(above 90%) to their medications throughout 12 months. This finding suggests that the 
few (less than 10%) individuals who achieved less than 90% mean MEMS adherence 
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probably had complete treatment interruptions or very low levels of adherence, which 
significantly reduced the mean adherence at the 12 month time point. These data suggest 
that possible adherence interventions should be targeted at time points of 6 months and 
later from treatment initiation. Further study is needed to understand the reasons for 
declining adherence beyond 6 months of treatment initiation. 
The patients described a high level of trust in their healthcare providers as a 
reason for continuing with their prescribed treatment regimen and returning to clinic. The 
quality of care was ranked equally high by all patients who were appreciative of the 
constant supply of ART. Although the healthcare providers noted the frequency of 
inconsistent drug supply, the clinic implemented alternative back-up systems with the 
help of collaborating partners to bridge these gaps and prevent treatment interruptions. 
Hence, patients did not experience gaps in their medication refills once they returned for 
their clinic visits. An evaluation of patients starting ART at Mbarara ISS Clinic in 2010 
by Geng et al... found that between April, 2009 and May, 2010 contributions of 
PEPFAR-funded ART programs fell significantly and affected the supply of ART in 
many clinics in resource-limited settings. During this time, the diminished ART supply in 
the Mbarara ISS Clinic was largely covered by a small private donor funded foundation 
(103). Many healthcare providers questioned the sustainability of such efforts in long-
term care. There was consensus among healthcare providers that the global response to 
HIV/AIDS made it possible for international partners to support HIV treatment programs 
and fill unmet needs, but questioned the sustainability of this approach in general. Some 
healthcare providers discussed the need for the Ugandan Ministry of Health to take on 
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more responsibility in proactively managing the epidemic in light of recent diminishing 
international funding and support. 
Spirituality emerged as a strong coping mechanism for HIV positive patients in 
this setting. While other studies have cited facilitators described earlier, there are very 
few published studies that have explored in depth the relationship between spirituality 
and HIV treatment outcomes or retention in care in resource-limited settings. A few 
studies in the United States have found that increased spirituality as a coping mechanism 
for HIV positive individuals has a positive impact on improved health and emotional well 
being (104-106). In 2010 Trevino et al... examined the relationship between religious 
coping and spiritual struggle with biological, behavioral and emotional outcomes in a 
study of 429 HIV positive patients. The study found that greater religious coping and 
lower levels of struggle with spirituality were associated with small improvements over 
time, and that positive outcomes were correlated with higher levels of religious coping, 
while negative outcomes were correlated with spiritual struggles (105). Another US-
based longitudinal study by Ironson et al... in 2006 assessed how changes in 
spirituality/religiousness after HIV diagnosis affected disease progression. The study 
found that almost half (45%) of the participants showed an increase in 
religiousness/spirituality after their HIV diagnosis and this group preserved their disease 
status (CD4 and VL) at a higher rate than other participants.  The study concluded that 
there is an increase in spirituality and religiousness after HIV diagnosis, which is 
associated with slower disease progression. Some studies in sub-Saharan Africa have 
reported spirituality as a coping mechanism for dealing with the psychological stress that 
accompanies HIV/AIDS (107, 108). The qualitative findings in this study corroborates 
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previous research in both sub-Saharan Africa and the United States in describing 
spirituality as a resource that enabled participants to deal with their problems, including 
their HIV disease.  
In addition to viewing spirituality as a coping mechanism, participants affirmed 
their belief in divine intervention with regards to the healing effect of a supreme being in 
their HIV treatment. This sub-set of participants expressed their strong faith in God’s 
direct and indirect positive impact on their improved health status. The belief was that the 
healthcare providers and the effective medications were instruments of God’s work. One 
participant attributed his behavior change in stopping alcohol use, to his faith, and 
described the uplifting emotional effects of belonging to a religious group. Beyond 
behavior change, it seemed that increased spirituality was linked to increased social 
support, and decreased levels of depression or greater optimism. Although this was not 
assessed in the quantitative analysis, Moskowitz (109) describes possible pathways by 
which positive affect predicts lower risk of AIDS mortality in a 2003 study looking at the 
relationship between depression and disease progression. Because spirituality as an 
independent variable only emerged with the qualitative study and was not included in my 
initial list of variables of interest, quantitative evaluation of the impact of spirituality on 
behavior change, disease progression and mortality went beyond the scope of this 
dissertation. It is possible that spirituality might have a positive effect on disease 
outcomes through behavior change and risk reduction, decreasing psychological burdens 
such as stress and depression, and increasing social support. The relationship between 
spirituality and stigma was not explored in this study and it could be that spirituality may 
modify the effect of stigma on outcomes such as treatment interruption. However, an 
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interesting finding was that all participants including those reporting increased spirituality 
after their HIV diagnosis, noted that their religious community was the last and most 
difficult to disclose their HIV status to. Most participants had yet to disclose their status 
to either their church members, religious leaders or both. It seemed that although HIV 
diagnosis was a catalyst for positive change as previously described in other studies (104, 
110), the positive affects of this change did not include a decrease in internalized nor 
enacted stigma.  
Both healthcare provider and patient participants described the main motivating 
factor that facilitates HIV care is the patients’ placing a high premium on health and life. 
This was evident in patients’ description of their need to stay alive for their families and 
children in particular. Maintaining relationships with community members, families and 
friends, especially for those who had disclosed their status, was extremely important. As 
previously described by Ware et al..., the relationships served as an important resource 
and social capital necessary for survival (48). 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 6. CONCLUSION AND TRIANGULATION OF QUALITATIVE AND 
QUANTITATIVE DATA 
 
Interpretation of the Qualitative and Quantitative findings 
 
 Through a two part, mixed-method approach, this study aimed at exploring the 
following questions: 
1. What are the barriers to HIV care in rural Uganda? 
2. How do these barriers affect treatment outcomes? 
3. What are possible facilitators of HIV Care in rural Uganda that could 
guide interventions to optimize care, and subsequently improve the quality 
of lives of those living with HIV in resource-limited settings? 
 
The hypothesis was that structural and economic barriers to HIV care in rural Uganda are 
associated with diminished health outcomes, increased treatment interruptions, increased 
AIDS-related morbidity and mortality. 
 
The qualitative findings both corroborated and added to existing research findings 
and identified barriers and facilitators to care in a rural, resource-limited setting outlined 
in the table below. Many of the barriers to care reported by both patients and healthcare 
providers were related to issues of poverty, which supported our hypothesis that many of 
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the barriers are structural and economic as opposed to behavioral. The exception to this 
was the finding on stigma, which was cited as a major barrier to health-seeking 
behaviors, often contributing to increased emotional and psychological stress. However, 
stigma also provided motivation for those who had not disclosed their HIV status to 
maintain an image of good health. Therefore these individuals were highly motivated to 
stay in care to protect themselves from the consequences of enacted stigma and 
discrimination.  
The quantitative findings however, did not support the above hypothesis 
completely. An unexpected finding was that increased travel time to clinic was associated 
with decreased odds of treatment failure. An explanation for this could lie in the fact that 
participants who travel greater distances to seek care had other compounding factors such 
interfered with their ability to thrive. More research is needed to understand this 
particular phenomenon. Consistent with previous studies, the quantitative analysis 
showed that adherence is high in this population with an average of 94% over 12 months, 
although the mean adherence begins to decline after 6 months of follow-up. Also as 
expected, increased travel time to clinic (greater than 45 minutes) was associated with 
mortality, as was being male. Increased age was consistently a predictor of improved 
treatment outcomes.  
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Table 11. Barriers and Facilitators of HIV Care in rural Uganda 
  
Barriers to Care 
 
Facilitators of Care 
  
Patients 
 
Healthcare Providers 
 
Patients 
 
Healthcare 
Providers 
 
1. Stigma and issues 
of disclosure of 
HIV status 
Stigma and issues of 
disclosure of HIV status 
among patients 
 
Trust in healthcare 
providers 
Social 
support of 
patients by 
family and 
community 
members 
2. Financial 
constraints and 
resource scarcity 
that affect 
transportation costs, 
food insecurity and 
competing demands 
 
Poverty and financial 
constraints experienced 
by patients 
Strong belief in a 
higher being, God, 
and high levels of 
spirituality as a 
coping mechanism 
and for inducing 
positive affect 
Treatment 
(ART) 
success and 
high quality 
of care given 
to patients 
3 Inflexible clinic 
schedules and long 
delays at clinic 
Challenging work 
environment, work 
overload, and reduced 
quality of care 
Treatment (ART) 
success and 
subsequent 
prioritizing of  ART 
adherence and health 
 
Global 
support of 
HIV as a 
disease 
4.  Difficulties with 
healthcare delivery in a 
regional referral 
healthcare system with 
few treatment centers 
 
Social support, use 
of social capital and 
maintaining 
relationships for 
survival 
 
 
5.  Limited drug supply and 
distribution  
 
  
6.  Challenges with poor 
ART  
adherence, routine 
monitoring and sub-
optimal treatment 
outcomes 
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Following the literature review, I further hypothesized that Internalized stigma 
and lack of disclosure of HIV status are associated with poor health outcomes and that 
social support could mitigate these poor outcomes. I expected that alcohol use, decreased 
socio-economic status, distance to clinic would be equally associated with poor health 
outcomes including treatment failure, adherence, treatment interruptions, loss to follow 
up and mortality. The data suggest that even though stigma was associated with lower 
levels of adherence, and adherence was a predictor of treatment failure, decreased stigma 
was not associated with treatment failure, nor any other poor health outcome. This 
finding was contrary to what was expected. One possible explanation for this finding is 
that individuals who have higher levels of internalized stigma have a greater motivation 
to adhere to their medications as a mechanism for hiding their HIV status. Another 
plausible explanation lies with the fact that the data on stigma were collected on only a 
subset of the cohort because they were collected at a later date (2 years later). Without, a 
complete dataset on this variable, it is difficult to extrapolate the findings to the entire 
cohort. 
Similar to the findings on stigma, lack of disclosure was not associated with poor 
treatment outcomes, nor was it associated with positive or improved health outcomes. 
Because the question analyzed for this variable asked about any disclosure, it made it 
difficult to tease out the effects of disclosure on specific groups or individuals that could 
have impacted behavior or retention in care, thus treatment outcomes.  
Contrary to the hypothesis, social support was not associated with improved 
health outcomes and therefore did not mitigate the barriers to care as expected. These 
data were also collected at a later date and were available on only a subset of individuals. 
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Because the data on stigma and social support were collected 2 years after the study 
began enrolment, it could also be the case that the characteristics of the study population 
changed so that those recruited two years later may have different experiences with 
stigma and social support. However, this is an assumption that is not supported by the 
analysis of other baseline characteristics of the cohort, which show limited variability 
within the study population. Another plausible explanation can be deduced from the 
findings of a recent study by Alamo et al. looking at reasons for loss to follow up in a 
community-based ART program in Uganda, which showed that people start to miss pills 
and clinic visits after they start to feel well and want to feel 'normal' again (16). In this 
retrospective cohort of patients lost to follow up between 2001 and 2012, the study 
further showed that wanting a ‘normal life’ was the commonest reason for loss to follow 
up(16) and that this finding most commonly occurred after 2 and 3 years of follow up in 
care(16). Given the quantitative analysis for this dissertation focused on only 12 months 
of follow up, the findings could have been limited for key outcomes of interest such as 
loss to follow up, treatment failure and mortality.  
It is likely that the tangible support provided by the UARTO study, especially in 
the form of free transportation to clinic, complicates the interpretation of some of the 
obscure findings in the quantitative analysis. As the support was an indirect consequence 
of study retention procedures, and not included as an intervention, support rendered by 
the UARTO study was not measured nor studied as an independent variable, yet these 
data suggest that the impact of the this unintended intervention may have been significant 
enough to introduce bias in the relationships between predictor variables such as stigma 
and social support. 
 121	  
A mixed-method approach, combining quantitative data from a 500-person cohort 
collected independently, with qualitative data from both patients and their healthcare 
providers, provided an opportunity to triangulate information from multiple sources to 
gain a deeper understanding of the barriers associated with HIV care and treatment in 
rural Uganda. The amalgamation of the qualitative and quantitative data did not produce 
uniform findings, particularly in assessing the relationship between stigma and social 
support. Further study is needed to understand the factors that reduce stigma as a barrier 
to sustained HIV care in rural settings. 
 
Limitations of the Study 	  
Use of Secondary Data 
The use of secondary data that were collected for purposes other than my study 
limited the ability to target my specific research questions. This limitation was partly 
overcome by the mixed-method approach where primary data collected using qualitative 
methods allowed for my specific research questions to be addressed, which filled the 
unanswered gaps from the quantitative analysis. However, the sampling methods for the 
qualitative study allowed for participants in care beyond 12 months, while data analysis 
in UARTO included only the first 12 months of follow-up. This difference may have 
accounted for some of the discrepancies in triangulating the qualitative and quantitative 
data. Given the complexities of the longitudinal data in UARTO, it was not feasible to 
conduct analysis beyond the first 12 months of follow-up for the purpose of this 
dissertation. The recent findings from the study in Uganda by Alamo et al.. suggest that 
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key outcome variables such as loss to follow up, could better be examined with longer 
follow times of two years and longer. This is explained through the observation that most 
losses to follow up in the ten-year study occurred after the 2nd and 3rd years of follow up 
when patients generally started to feel ‘normal’ post ART and changed their health-
seeking behavior accordingly in ways that compromise their care(16). 
 
Adherence Monitoring and Hawthorne Effects in UARTO 
 
It is possible that intensive adherence monitoring as well as other follow up 
measures that are associated with being in the UARTO study may alter adherence as well 
as other outcomes (Hawthorne effect) in the quantitative analysis. While this cannot be 
excluded, I expect that this was a small effect was outweighed by the advantages of using 
data collected by objective measures, including less measurement error and bias to 
answer the specific questions.  
 
Incomplete Data on Key Variables 
 Data on key variables of interest, such as social support, internalized stigma and 
disclosure were collected at a later date in the follow-up timeline in the UARTO study. 
The UARTO study started enrolment in 2005, however, questions on social support, 
stigma and disclosure were added to the study questionnaire two years later in 2007. As 
such, these data were not collected on more than half of the UARTO cohort. The analysis 
included both complete datasets and sub-sets of data restricted to only those with key 
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variables of interest. There was no systematic attempt to limit all analysis to only those 
with complete data. This important issue may have made it difficult to generalize the 
results of the data on internalized stigma, social support and disclosure. 
 
 
Relevance of Disclosure Data  
 
 Disclosure of HIV serostatus was measured with questions that asked whether or 
not study participants had disclosed their HIV status to a neighbor or family members at 
their baseline study visit. Given the requirements of having a treatment supporter 
accompany patients to their HIV clinic visits, it was impossible to have a situation where 
a patient at the Mbarara ISS Clinic had not disclosed their status to a close friend or 
family member who would likely accompanied them to their clinic visits. Nearly all 
participants had disclosed to a family member at baseline. As such, this variable probably 
did not provide sufficient variation to assess correlation with the outcomes of interest. 
The relevance of the disclosure variable to the UARTO study analysis could have been 
strengthened if data were available on specific individuals or groups to whom the 
participants had disclosed their status; such as employees, religious groups or specific 
family members.  The other question that could have been asked is whether the patients 
disclosed their HIV status to anyone other than the mandatory treatment supporters. The 
qualitative findings from this study indicate that the participants made conscious 
decisions about whom to disclose their HIV status to, and that these decisions were 
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linked to expected outcomes regarding their HIV care and treatment. However, data were 
not available to explore this phenomenon in the quantitative analysis. 
 
 
Combining Results of Complete and Incomplete Datasets in the Quantitative Study 
 
 The UARTO analyses combined data that were complete for some variables and 
incomplete for other key variables of interest. As such, some of the analyses were 
restricted to only participants who had complete data e.g. internalized stigma, social 
support and distance to Clinic. Self-reported travel time was used as a variable in 
instances where data on GPS measured distance to clinic were not available.  Travel time 
and distance to Clinic were interpreted interchangeably in the analysis, when they do not 
necessarily correlate as a proxy for patients’ access to the clinic and measure of 
remoteness of the homes in proximity to the clinic. Analyses involving key variables that 
were incomplete probably contributed to the data not supporting the study hypothesis in 
the quantitative analysis, and not correlating with the qualitative findings particularly in 
the assessment of the associations between social support, stigma and disclosure on 
outcomes such as treatment failure and adherence. Even for the statistically significant 
findings, the associations were weak. 
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UARTO Study Procedures Probably Mitigated Barriers 
 
Because the UARTO study provided transportation, meals and guidance through 
clinic visits for study visits that coincided with clinic visits, some of the barriers to care 
experience by patients were mitigated by these study incentives. Another limitation to 
studying the UARTO population is that the patients had been in care at the clinic for a 
relatively long period of time and probably received prescriptions longer than the 
standard 1-month dose. However, the effects of this would have been more notable 
beyond the first year of follow up. Standard Clinic procedures allow for longer times 
between prescription refills for patients who have been in the Clinic longer than 6 months 
with stable disease staging.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 7: POLICY IMPLICATIONS AND PLAN FOR CHANGE 
 
Policy Implications 
Significant progress has been made over the last decade in expanding HIV 
treatment access in resource-limited settings, but the global burden of disease remains 
high. The United States government between 2003 and 2008 spent $15 billion dollars 
combating HIV/AIDS in Africa PEPFAR and other initiatives. The initial goals of 
PEPFAR were to treat 2 million HIV infected individuals, prevent 7 million infections 
and support care for 10 million people in resource-limited settings(111). In July, 2008 the 
US government renewed PEPFAR as the "Tom Lantos and Henry J. Hyde United States 
Global Leadership Against HIV/AIDS, Tuberculosis, and Malaria Reauthorization Act of 
2008" with an additional $48 billion commitment through 2013 for HIV/AIDS in 
resource-limited settings.  
After meeting it first goal of treating 2 million people, the renewed PEPFAR 
goals were to treat 3 million people, prevent 12 million new infections and care for 12 
million HIV-infected individuals, including 5 million orphans. This is the largest 
financial commitment to a single disease worldwide, though several other global 
multilateral partners including the Global Fund to Fight AIDS, Tuberculosis and Malaria 
and the United Nations program on AIDS (UNAIDS), as well as private foundations such 
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as the Bill and Melinda Gates Foundation and the Clinton Foundation, have also 
committed substantial funds to combat the pandemic. Between 2003 and 2010, the focus 
for HIV treatment programs was on care and increasing the number of people on ART.  
In 2007, UNAIDS reported that although the global target to treat 3 million HIV-
infected individuals in middle to low-income countries by 2005 was not met, significant 
progress had been made towards achieving universal access of HIV care and treatment. A 
key limitation to HIV program implementation in Uganda included an overreliance on 
external resources, capital and expertise, without sufficient integration with local systems 
and expertise. Lessons learned from evaluation of several PEPFAR funded programs and 
program implementation reports with UNAIDS point to the need to ‘maximize results’ by 
collaborating with in-country agencies and institutions to improve impact, build on 
existing platforms within countries, and use innovation to ensure positive outcomes (2, 
33). A recurring challenge with multi-national programs in resource-limited settings is 
the bridging of both cultural and economic gaps, present with resource-rich and resource-
poor setting partnerships that have sometimes resulted in one-directional approach to 
public health interventions that are not often sustainable. The current UNAIDS strategy 
for ‘getting to zero’ 2011-2015 aims at improving prevention efforts, increasing 
nutritional and social support and increasing human rights through gender equality. The 
platform for implementing these initiatives relies heavily on strengthening health systems 
so that programs are nationally owned and that the response to the epidemic within each 
country is sustainable. 
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The findings from this study support the current strategy proposed by the 
UNAIDS ‘getting to zero’ initiative. The following policy options are proposed to enable 
the achievement of the proposed goals. The table below represents seven plausible 
options considered to mitigate the barriers to HIV care in resource-limited settings: 
 
Table 12. Analysis of Policy Options 
OPTIONS PROS CONS SUPPORT RISKS 
Build 
additional 
clinics and 
expand access 
to care in 
remote areas 
-Increases 
access to 
healthcare 
-Limits 
transport 
challenge 
-Expensive 
-Difficult  
 staffing 
-Stigma an  
  issue 
-Drug stock 
and  supply  a  
  challenge 
 
 
- Healthcare 
providers and 
patients 
would support 
this option 
-Waste of 
resources if 
facilities are not 
utilized  
-Clinicians 
would be 
reluctant to 
relocated to 
these areas and 
staffing facilities 
would be 
challenging 
 
Use of mobile 
clinics that 
bring testing 
and care to 
the homes of 
individuals 
- Convenient 
for patients 
-Relatively  
 inexpensive 
-Could reach a 
wide audience 
if combined 
with other 
clinics – 
diabetes, heart 
disease, 
malaria, etc. 
- Assumes no 
  stigma  
-Logistically  
 challenging 
for providers 
 
-Patients 
-Community 
and family 
members of 
patients 
-Patients who 
have 
disclosed 
their status 
 
-Implementation 
is challenging 
-May not work 
in communities 
with high levels 
of stigma 
-Logistical 
challenges of 
fuel, 
maintenance of 
vehicles and 
transporting staff 
and supplies may 
be difficult to 
overcome 
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OPTIONS PROS CONS SUPPORT RISKS 
Provision of 
vouchers or 
cash transfers 
to mitigate 
financial 
burden 
associated 
with accessing 
care 
-May resolve  
 transport 
burden 
- A straight-
forward 
solution to 
transportation 
and food 
insecurity 
burdens 
 
 
- Vouchers 
may 
   be cashed 
and 
   diverted 
-Difficulty 
with 
 
implementation 
-May not be 
accepted by all 
vendors  
-Stigma issues 
may reduce use 
-May not  
 alleviated  
 levels of  
 poverty at the  
 household 
level 
-Short term  
  solution 
 
- Patients 
-Community 
and family 
members of 
patients 
-Patients who 
have 
disclosed 
their status 
-Healthcare 
providers 
 
 
-Funds may be 
diverted to other 
use with high 
competing 
demands 
-May be difficult 
to implement if 
distribution of 
cash in involved 
-Safety and 
security at points 
of distribution in 
resource-limited 
settings is in 
question 
-Flat rate 
distribution 
versus graduated 
depending on 
financial need? 
How is need 
determined? 
 
Training of 
Non-
physician 
clinicians to 
increase the 
clinician to 
patient ratios  
- Can handle 
the patient 
load problem 
much faster 
-In line with 
public health 
approach to 
HIV care in 
RLS 
 
-Quality of 
care may be 
reduced 
-Sustainable 
 
-Political 
leadership 
-Patients  
-Providers 
with heavy 
work load and 
high patient 
burden 
-Surplus of non-
physician 
clinicians  
-Increased 
responsibility of 
staff without 
adequate training 
in cases where 
there is no 
physician within 
radius of 
operation 
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OPTIONS PROS CONS SUPPORT RISKS 
Poverty 
reduction and 
empowerment 
of  women 
-Should have 
a positive 
impact on 
HIV risk 
reduction 
-Extremely 
time intensive 
-Requires 
commitment 
from several 
sectors of 
society  
-Difficulty 
changing 
existing 
cultural norms 
-Strong 
political 
support 
_Patients 
-Providers 
-Very difficult to 
accomplish and 
may prove to be 
an unattainable 
goal in the short 
term. 
-Lack of 
immediate 
results may 
discourage 
momentum 
Build local 
capacity and 
re-engage 
local 
leadership 
- Sustainable  
- Culturally 
relevant 
solutions to 
public health 
problems.  
-Requires 
political buy-in 
and 
collaborative 
effort 
-Time 
intensive 
-Strong 
Political 
support 
-Providers 
-Local leaders 
-Difficult to 
sustain if local 
capacity is lost 
through ‘brain 
drain’ 
Reducing 
Stigma at 
both the 
individual 
and 
community 
levels by 
engaging 
religious and 
other 
community-
based leaders 
 
-Will enable 
sustainability 
of public 
programs 
-Improve the 
lives of people 
living with 
HIV/AIDS 
-Reduce the 
burden of 
emotional and 
psychological 
stress factors 
contributing to 
disease 
progression 
 
 
 
-Requires a 
complete 
change in 
cultural 
perceptions 
and attitudes, 
which is 
difficult 
-Patients 
-Providers 
-Change may 
take a long time 
to occur and lack 
of short term 
results may 
discourage 
efforts 
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Table 13. Evaluation of Policy Options for Improving HIV Care in Rural Uganda 
 #1 #2 #3 #4 #5 #6 #7 
Public 
Health 
Protection 
High High Moderate High High High High 
Economic 
Cost 
High Moderate High Low Low High Low 
Implement
ation 
Feasibility 
Low Moderate Low High Low Moderate Low 
Political 
Feasibility 
Low Low Low Low High High Low 
 
Key for Table 13. Policy Options 
#1 = Increase number of HIV clinics 
#2 = Use of mobile clinics 
#3 = Vouchers and cash transfers 
#4 = Increase the number and use of non-physician clinicians 
#5 = Poverty reduction and empowerment of women 
#6 = Building local capacity 
#7 = Reducing stigma and engaging religious leaders 
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Policy Recommendations  
Based on the findings of this study, barriers to sustained HIV care in a rural 
resource limited setting include a combination of factors that are structural, economic, 
and psycho-social, which act independently or through complex interactions. It is logical 
to state that the characteristics listed above are all linked to poverty and it can be argued 
that alleviating poverty may provide sustainable solutions. Such a herculean task may be 
impossible to achieve in a century and can bring on its own set of complications as can be 
seen in wealthy societies with poor health indicators. However, it is safe to assume that 
strategies to improve HIV care in resource-limited settings should aim at targeting all 
three components of the barriers outlined, while strengthening health care systems and 
building local leadership remain the foundation for sustained success. 
 
Policy Recommendation #1 
Given feasibility, public health impact and economic cost, my first policy 
recommendation would prioritize building local capacity and re-engaging local 
leadership as a first step to mitigating barriers to HIV care in this setting. This 
recommendation is based on the assumption that building local capacity in resource-
limited settings will result in the engagement of leaders who have the potential to develop 
and sustain all other viable policy options listed in the above table. In his 2004 U.S. 
World and News Report article “Does leadership really matter?”, David Gergen 
concludes by stating that America’s progress hinges on the “quality and number of those 
who lead” (112). Likewise, it is the quality and number of those who lead the health 
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systems in Uganda that will influence the progress of the state of health of its population. 
These leaders will inevitably guide the process of change by propelling their colleagues 
to change, by articulating the health problems as well as their solutions such that they are 
clearly understood and by setting the examples for others to follow, a difference will be 
made. Outlined below are three key legislative steps that could be taken to both build  
and sustain the capacity of local public health leadership. 
 
1. Implement a mandatory service corp as a component of the medical 
training that requires doctors and nurses to serve in their home country 
for a period of 2 years upon graduation. This component of the medical 
training would be implemented at the national level via a joint effort between 
the Ministries of Health and Education. The mandate to provide paid 
community service within Uganda upon completion of training would allow 
the country to realize an immediate return on their investment in their citizen’s 
medical education. The mandate could include at least 50% of the service to 
be carried out in the rural regions of the country. 
2. Create a national training and retention program for local health leaders 
under the Ministry of Health to both develop health leaders and increase 
incentives for the leaders to stay in their home country to lead efforts. The 
majority of the health workers who depart from their countries do so in search 
of better opportunities for themselves and their families. Recognizing that 
developing countries cannot match the compensation and opportunities 
provided by the wealthier countries, it is critical to create other incentives that 
 134	  
would compete favorably with compensation. Such incentives include career 
advancement  and health leadership training opportunities that would pave the 
way to leadership roles in the health sector within country. Such a program 
would be tagged on to the afore-mentioned service corp program that would 
create further incentive for medical graduates to complete the mandatory 
service corp.  
3. Require a component of capacity building of local health leaders for 
foreign institutional collaborations with local Ugandan institutions. 
Uganda is one of the countries that have been worst hit by the HIV epidemic 
in the world. Since 2003, following global initiatives from the WHO and the 
PEPFAR program, there has been a surge of activities to combat the public 
health crisis. This influx of funding, resource, and people presents an 
opportunity to leverage resources and maximize the benefits of collaboration. 
Many foreign institutions conducting research and implementing public health 
programs in Uganda have access to more resources than their counterpart 
institutions in Uganda. The impact of these partnerships on capacity building 
of local health leaders could be multiplied if the foreign partner institutions 
were required to allocate a portion of their activities towards development of 
local health leadership. The specific activities could include exchange of 
ideas, training and mentorship opportunities in the health sciences. 
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Policy Recommendation #2 
My second policy recommendation would prioritize reduction of stigma at the 
individual, community and institutional levels. Given the strength of the stigma finding as 
a barrier to care in the qualitative study, coupled with the quantitative finding that stigma 
is associated with reduced adherence levels, this barrier to care needs to be addressed 
with a sense of urgency that identifies it as a barrier to care with dire long-term 
consequences. For psychosocial issues such as stigma, it is important to get a better 
understanding of the underlying issues that are perpetuating the beliefs and drive actions. 
In the case of HIV/AIDS in rural Uganda, drivers that negatively influence stigma at the 
individual level can be broadly grouped under lack of awareness and fear, detailed in  the 
following points:  
• Lack of awareness on both issues of stigma being a barrier to successful HIV 
care and treatment, and HIV as a disease may drive individuals to make 
negative assumptions that may not be based on fact. 
• Individual fears of acquiring HIV as an infection and having to live with it for 
life may drive individuals to act in discriminatory ways or induce feelings of 
shame for those already infected. 
• Fear of rejection and social isolation following HIV infection may drive 
individuals to internalize these feelings when they are infected, and act them 
out when otherwise not infected. 
• Fear of dealing with economic problems that may be compounded by 
infection. 
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Having outlined the possible drivers of stigma above, it is evident that raising 
awareness is key to resolving issues that are associated with lack of awareness and also 
alleviating fears about HIV as a disease. Raising awareness of negative underlying 
attitudes and beliefs has the potential to change them. Raising awareness begins with 
creating recognition of stigma and highlighting mutual benefits of reducing it. The forum 
for information dissemination should be broad, with audiences including patients, 
healthcare providers, religious group members, policy makers and academia. My specific 
plan for change with regards to reduction of stigma shall begin with the publication of 
findings from this dissertation for academic settings. Following this, I intend to 
disseminate the findings to clinic populations beginning with the Mbarara ISS Clinic.  
 In order for awareness issues to be fully effective, addressing stigma reduction at 
the institutional level through legislation must accompany awareness efforts. Clinicians at 
the Mbarara ISS clinic reported frustrations with their repeated attempts at helping 
individual patients deal with internalized stigma by encouraging them to disclose their 
status. Yet, once patients disclosed their status, they were not protected by enforced laws, 
and faced grave consequences as a result. A second step towards reduction of stigma 
would be to push for more strict enactment and enforcement of legislation that defines 
discrimination against HIV in countries like Uganda as a punishable criminal activity.  
 
Policy Recommendation #3 
HIV care in RLS should include a comprehensive care package to mitigate 
barriers to accessing and retaining in HIV care in addition to providing ART. Food 
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supplements, transport vouchers, cash transfers are proven strategies in RLS in both 
developed and developing countries for improving access to care as well as retention in 
care, and overall treatment outcomes. My plan for change would also include prompt 
dissemination of the findings in this study that show that resource constraints threaten the 
success of ART programs.  
 
Policy Recommendation #4 
My final policy recommendation prioritizes the implementation of programs 
aimed at poverty reduction, empowerment of women, and education. While there is no 
direct plan for change that addresses this, it is expected that information dissemination of 
findings from this dissertation could guide program development to target specific areas 
that would impact poverty, and the empowerment of women. One addition that could be 
immediately implemented is the recommendation for the use of HIV patients within the 
clinic as ‘expert patients’ involved in the information dissemination to peer patients.   
 
Plan for Change 
In July, 2012 the Uganda National Council for Science and Technology (UNCST) 
held its fourth annual National Research Ethics Conference in Kampala, Uganda. The 
conference was organized in collaboration with the World Health Organization (WHO), 
the Uganda National Drug Authority (NDA) and the Uganda National Health Research 
Organization (UNHRO) with the theme “Responsive Research to Community Needs: An 
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Ethical Dilemma”, and had a goal of addressing the responsibility of researchers in 
Uganda to respond to community needs. Two main points were raised as areas requiring 
further action for researchers in Uganda:  
1. There is a lack of involvement of community members in the research 
process, both prior to and during the implementation of studies, and also after 
data have been analyzed and findings disseminated. 
2. Reporting of research findings has been limited to just positive results, but 
should include dissemination of negative research findings, which provide an 
opportunity for change.  
The concluding message from the conference called for public health researchers 
to make their research findings more relevant to the communities they study and to have 
a ‘plan to act’ based on their findings beyond academic publications in media that are 
often inaccessible to the general public. In other words, there is an urgent need to include 
a plan for change following the research process that fulfills the responsibility of 
researchers and leaders to improve the public’s health. This call to action serves as the 
impetus for my plan for change. 
Target Points of Intervention 
  Based on the findings of my research there are several possible target points of 
intervention highlighted from both the qualitative and quantitative studies that could 
improve the public’s health. These include: 
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1. Reducing the hostility felt by patients at the Mbarara ISS Clinic, with regards 
to the providers’ rigidity and negative attitudes towards missed appointments, 
which in turn affects patient retention in care 
2. Raising the incentive for providers to stay motivated in a challenging and 
overwhelming work environment 
3. Reduction of stigma associated with HIV at individual, community and 
institutional levels 
4. Increasing access to care for patients 
5. Reduction of poverty and financial constraints that prevent patients from 
managing their HIV care and treatment 
6. Increasing social support, spirituality, ART success and trust in healthcare 
providers as strong facilitators of HIV care 
7. Improving ART adherence beyond 9 months of treatment initiation 
8. Building local capacity and leadership to both drive and sustain solutions to 
identified problems and challenges with HIV care in rural Uganda 
 
Proposed Plan of Action 
Some of the target points outlined above have been addressed through my policy 
recommendations. The policy changes recommended above however, are more global 
and involve long-term strategies for implementation and evaluation. My ‘plan for change’ 
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therefore shall be focused on the first three target problems outlined above, for which I 
intend to act immediately. I propose a plan to communicate the findings of my research to 
both the healthcare providers and patients highlighting the challenges experienced by 
both groups. I intend to create a sense of urgency on the issues raised and build consensus 
among stakeholders to address the issues, and subsequently develop a guiding coalition to 
resolve them collaboratively. The end result of my plan for change therefore, is to 
improve the quality of care for patients and improve the conditions of service for 
providers at the Mbarara ISS Clinic in an attempt to mitigate key barriers to care 
highlighted in my research.  
 
Key Steps in the Plan for Change 
1. Build consensus and get buy-in of key individuals such as the director, 
administrators and clinicians at the Mbarara ISS Clinic, on the importance of 
disseminating my research findings to the clinic community and acting on the 
findings. This step will enable the creating of an integral vision to propel 
actions that are directed towards a common goal of improvement and 
development. 
2. Proposal to clinic administration for inclusion of research findings in health 
education talks at the clinic to enable dissemination of research findings to 
patients. Brief documents highlighting research findings, which are translated 
into the local language would serve a useful purpose of creating awareness for 
patients who participate in research as well as those who do not. Brief 
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presentations could also be made for patients who may not be literate, 
highlighting key findings that are relevant to the Mbarara ISS Clinic 
population. I would recommend this change to the Director of the Mbarara 
ISS Clinic and the administrative bodies that determine clinic processes and 
policy. 
3. Create a communication strategy in collaboration with key stakeholders at the 
clinic that will hone in on the target areas for intervention and create a sense 
of urgency with the healthcare providers in particular to address the issues of 
hostility experienced by patients. Likewise, a communication strategy for 
patients would highlight the volume of patients at the clinic and give the 
patients a better understanding of the reasons behind some of the rigid 
structures viewed in the clinic operations. The communication strategy should 
be clear, with an articulated vision of resolving specific issues identified. 
4. Communication of research findings with healthcare providers via a formal 
presentation to create awareness on the barriers to care experienced by both 
healthcare providers and patients of the Mbarara ISS Clinic.  There are several 
opportunities to present the findings of my research during weekly Mbarara 
ISS Clinic meetings and continuing education sessions.  
5. Communication of research findings with patients via a formal presentation, 
disseminated in the local language by the study research assistants. There are 
two options for dissemination of these findings; the first would be through an 
organized symposium for patients of the Mbarara ISS clinic, and the second 
would be through the routine health education sessions that occur daily in the 
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Mbarara ISS clinic. While the latter forum is meant for health education talks 
including ways in which patients can prevent infection or live positively with 
HIV etc., brief sessions on research findings could be included in this routine 
process at the clinic.  
6. Collaborate with key decision makers at the Clinic to come up with 
intervention strategies for change. During this process, I would recommend 
the creation of a concrete plan to meet the needs of patients who are unable to 
meet their prescribed clinic appointments as a routine process in the clinic and 
that this plan be communicated with the patients accordingly. For the 
challenges of working in an overwhelming environment, I would recommend 
a performance-based incentive structure for healthcare providers that could be 
tied to patient evaluations. 
7. Assess the understanding of the research findings and elicit ideas for 
improvement through meetings and focus group discussions with providers 
and patients. This would enable the process of asking the appropriate 
questions and identifying the root of the issues at hand to lead changes to a 
more relevant direction. While this process could be achieved with the 
healthcare providers during routine clinician meetings, discussions with 
patients would need additional approvals for implementation. 
8. Implement recommendations elicited from healthcare providers and possibly 
patients, through collaborative efforts.  
 143	  
9. Celebrate successes and create a reward system to acknowledge the 
contributions made by all involved in the change process to keep participants 
motivated to sustain the change efforts.  
10. Evaluate change process and re-assess successes and challenges to guide 
continued improvement in the Clinic. 
 
Timeframe for implementation 
The proposed plan for change would be implemented over a one-year period. The 
first two months would be spent soliciting for support for the proposed plan at the local 
leadership level. The following six months would be spent strategizing and 
communicating research findings, plans and ideas. The impact of the proposed changes 
could be evident as early as 12 months after implementation. The expected outcome 
would be a change in attitudes of both healthcare providers and patients about clinic 
appointments and a reduction in the level of rigidity required by the clinic in accepting 
patients who miss appointments evidenced by a clear plan to handle patients who show 
up outside of their prescribed clinic appointment schedule. The number of patients lost to 
follow up could be measured following the change implementation and the changes could 
potentially impact this number. 
 
Conclusion 
This action-based approach to change management is described in detail by John 
P. Kotter in his 1996 book ‘Leading Change’. Kotter outlines an eight-step process of 
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leading change with starts with ‘creating a sense of urgency’ to jump-start the change 
process and ends with ‘anchoring new approaches in the culture’ to sustain the change 
efforts and make them ‘stick’ within an organization or community (113). This 
framework guides the plan for change I outline above and incorporates a leadership 
process that is not linear but circular, involving constant movement between personal and 
global, providing an opportunity to implement change through collaboration but with a  
leader compelling and motivating others to act together towards a common goal.  
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APPENDIX I: SAMPLE KEY INFORMANT INTERVIEW GUIDE 	  
Participant ID number: 
Gender: 
Date: 
 
 
Introduction 
 
Good afternoon ______________. and thank you for accepting to participate in 
this study to better understand the barriers to HIV care faced by the patients in the 
Mbarara ISS clinic. As you know, my name is Nneka Emenyonu and I am a student in 
the Doctoral program in Public Health at the University of North Carolina Chapel Hill 
School of Public Health. I am conducting this study as a requirement for my thesis 
towards a DRPH degree.  
The purpose of this study is to get your views on the barriers to HIV treatment 
and care here at the Mbarara HIV Clinic. You are being asked to participate because you 
are either a healthcare provider or a patient at Mbarara ISS Clinic. I appreciate your time 
and honest assessment of the questions I will be asking you in a few minutes. Your 
answers shall be kept confidential and you shall not be identified in the course of my 
publication of the data. Your answer will be pooled together with those of other 
participants to better understand the barriers to HIV treatment HIV care in this region. 
I would like to spend the next hour or so asking you some questions about your 
affiliation with the Mbarara ISS clinic, followed by some questions regarding the barriers 
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to HIV care experienced by you or your patients and finally, I would like to ask you some 
questions on how these barriers have impacted your HIV treatment outcomes or those of 
patients in your clinic. 
 
Question guide (for healthcare providers) 
1. How do you feel your patients are doing with the management of their HIV 
disease? 
2. Have any of your patients expressed difficulties with managing their HIV 
disease? What are they? 
3. For you, what is most difficult about treating patients living with HIV/AIDS? 
How so? 
 
4. What are some of the barriers that have been expressed by your patients? Please 
Feel free to give specific examples. 
5. What do you feel are the most important challenges to delivering HIV care and 
treatment in your clinic? 
6. What do you see as the biggest issue or problem the clinic is currently facing? 
Why is that a problem? Anything else? 
7. How would you rate the services of the clinic on a scale of 1-10 with 10 being 
excellent? 
 
8. Is there anything else you would like to share or add to what you have talked 
about during this session? 
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Interview Guide (for UARTO cohort participants) 
1. How long have you been a patient at Mbarara ISS Clinic and for how long have 
you been on ART? 
2. Have you disclosed your HIV status? To whom have you disclosed your status 
a. Immediate family 
b. Extended family 
c. Friends 
d. Co-workers 
e. Members of my community (church, school, etc.) 
3. How often do you come to the clinic for a routine visit and/or to pick up your HIV 
medication? 
 
4. How did you get to the clinic? [Probe about transport, costs, process for acquiring 
money, how long the distance is etc.]  
 
5. How would you rate the services of the clinic on a scale of 1-10 with 10 being 
excellent? 
 
6. Do you face any challenges in coming to the clinic for your care? 
7. Which one of these do you think is the most difficult challenge to overcome: 
a. Having sufficient food to meet the demands of your treatment 
b. Having enough money for routine transportation to the clinic 
c. Having childcare available when you come for your clinic visits 
d. Issues of stigma in your community 
e. Your physical ability to travel to clinic 
f. Seasonal changes in weather – e.g. rainy season 
g. Time available in your schedule to go for your clinic visit 
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h. Amount of time spent at the clinic during your visit 
i. The quality of care your get at the Mbarara ISS clinic 
8.  Is there anything else that you would like to talk about regarding barriers to your 
HIV care and treatment? 
 
Conclusion 
 I want to sincerely thank you again for your time in participating in this study. 
Your input is invaluable and will guide efforts towards improving the HIV care status in 
rural settings such as Mbarara. I assure you that your answers will remain confidential. 
You shall receive a copy of my study results upon completion of my study.  
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APPENDIX II: CONSENT FORM FOR PATIENTS 	  
Consent to be a Research Subject 
 
Mbarara University of Science and Technology, Mbarara, Uganda 
University of North Carolina Chapel Hill, USA 
 
Barriers to HIV Care in Rural Uganda 
 
Background/Purpose 
Nneka Emenyonu of Mbarara University of Science and Technology and 
University of North Carolina Chapel Hill is conducting research to learn about 
barriers to HIV care in rural Uganda and to determine the impact of these barriers 
on HIV treatment outcomes that you experience. 
 
I am being asked to participate in this study because I am an active UARTO 
cohort participant living in one of two selected communities in Mbarara within 
10-20 kilometers of the Mbarara ISS Clinic. 
Procedures 
If I agree to participate in the study, the following will occur: 
1. My participation in the study shall require a one time, one-on-one 
interview with the study investigator that should last about 1-2 hours 
in total. There will be no follow up visits after this interview.  
 
2. I shall be interviewed one time by the study investigator. The 
interview will take place immediately following my consent to 
participate in the study and will last 1- 2 hours. Interviews will take 
place in a private room at the study offices in Mbarara or in another 
location that we will identify. Interviews will be conducted in my 
language of choice (English or Runyankole). The interviewers are not 
medical professionals and will not be able to answer questions about 
my health or my health care. However, I may consult health care 
practitioners at the Mbarara Regional Referral Hospital HIV Clinic for 
additional information about your HIV care at any time. 
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3. The interview is informal, like a conversation. We will talk about my 
perceptions regarding barriers to HIV care and treatment that I 
experience. The questions I am asked are not defined in advance. If I 
am asked any question that I do not want to answer, I can simply say, 
"I do not want to answer that."  
 
4. With my permission, the interviewer will audiotape the interview. The 
recordings will be used for research purposes only. The recordings will 
be kept until the study is complete; then they will be erased.  Declining 
to be audio-taped will not affect my eligibility to participate in this 
research study. 
 
5. The researchers will not share any of the information from my 
interview with anyone outside the research team. I am completely free 
to choose not to take part in this research. My decision will have no 
impact on my care nor the services I receive at Mbarara ISS Clinic. 
 
Risk/Discomforts 
 
The risks of participating in this study are minimal. It is possible that I might get 
tired during the interview. I may find some of the questions uncomfortable or hard 
to answer. If this happens, we can (a) discuss the situation, (b) take a break, or (c) 
stop. If I choose to stop, we can either finish the interview another day or I can 
end my participation in the study. Though unlikely, there is always a chance of a 
breach in confidentiality when taking part in a research study. The researcher will 
make every effort to protect me from this risk.  
There may be uncommon or previously unknown risks.  I shall report any 
problems to the researcher. 
Confidentiality 
 
• My privacy is protected as a participant in this study. This means that 
my identity will never be released in a way that can be connected with 
me. There will be a number rather than my name on copies of my 
interviews. All of the interviews, research documents and audio 
recordings will be kept in a locked office of research study personnel 
in Mbarara. Computer files will be protected with a password.  
 
• Only the people involved in the research will be able to get this 
information. None of the information I give you will be shared with 
my providers at the HIV/AIDS clinic, my family members or anyone 
else outside the research project. My name will not be used in any 
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written reports or articles that result from this project. Every effort will 
be made to ensure that descriptions of individual participants are not 
identifiable in any way. 
 
• Participants will not be identified in any report or publication about 
this study. Although every effort will be made to keep research records 
private, there may be times when federal or state law requires the 
disclosure of such records, including personal information.  This is 
very unlikely, but if disclosure is ever required, UNC-Chapel Hill and 
Mbarara University of Science and Technology will take steps 
allowable by law to protect the privacy of personal information.  In 
some cases, my information in this research study could be reviewed 
by representatives of the University, research sponsors, or government 
agencies for purposes such as quality control or safety. 
 
• At any time point during the interview, I may request that the audio 
recorder be turned off. 
 
_____ OK to record me during the study 
_____ Not OK to record me during the study 
 
If there is need to have an interpreter during the interview, the person shall be a 
member of the research team and shall keep all the information regarding my 
study participation private.  
 
Benefits 
Research is designed to benefit society by gaining new knowledge.  You may not 
benefit personally from being in this research study. 
Alternatives 
I may choose to not participate without the risk of losing my current healthcare or 
medicines.  
 
Cost 
There shall be no monetary costs to me for being in the study. However, I will 
need to devote 1-2 hours of my time to participate in the study, for which I shall 
not be compensated with cash per Mbarara University of Science and Technology 
guidelines on research.  
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Reimbursement 
I shall be provided with transportation home in the form of a free ride home or 
transport cost reimbursement after completing the interview if I decline the free 
ride home. 
Questions 
This study has been explained to me and my questions have been answered.  If I 
have any additional questions, I can call the Study Principal Investigator, Ms. 
Nneka Emenyonu at 0782027158. If I have questions for the Institutional Ethical 
Review Committee at Mbarara University of Science and Technology, I can call 
048520851. 
Consent 
I have been given a copy of this consent form.   
 
PARTICIPATION IN THIS RESEARCH IS VOLUNTARY.  I have the right to 
participate or withdraw at any point in this study without the risk of losing my 
medical care.   
 
If I wish to participate I should sign below. 
______________________________ ___________________ 
Subject’s Signature     Date 
 
______________________________ ___________________ 
Staff person obtaining consent   Date 
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APPENDIX III: CONSENT FORM FOR HEALTHCARE PROVIDERS 	  
Consent to be a Research Subject 
Adult participants ( health care provider) 
 
Mbarara University of Science and Technology, Mbarara, Uganda 
University of North Carolina Chapel Hill, USA 
 
Barriers to HIV Care in Rural Uganda 
 
Background/Purpose 
Nneka Emenyonu of Mbarara University of Science and Technology and 
University of North Carolina Chapel Hill is conducting research to learn about 
barriers to HIV care in rural Uganda and to determine the impact of these barriers 
on HIV treatment outcomes that you experience. 
 
I am being asked to participate in this study because I am a health care provider at  
Mbarara ISS Clinic) 
 
How many people will take part in this study? 
If you decide to be in this study,  you will be one of the approximately 40 people 
in this research study 
 
How long will your participation in this study last? 
Your participation in this study shall require a one –on-one interview with the 
study investigator that should be about 1-2 hours in total. There will be no follow 
up visits. 
Procedures 
If I agree to participate in the study, the following will occur: 
6. My participation in the study shall require a one time, one-on-one 
interview with the study investigator that should last about 1-2 
hours in total. There will be no follow up visits after this interview.  
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7. I shall be interviewed one time by the study investigator. The 
interview will take place immediately following my consent to 
participate in the study and will last 1- 2 hours. Interviews will take 
place in a private room at the study offices in Mbarara or in another 
location that we will identify. Interviews will be conducted in my 
language of choice (English or Runyankole).. 
 
8. The interview is informal, like a conversation. We will talk about 
my perceptions regarding barriers to HIV care and treatment that I 
experience. The questions I am asked are not defined in advance. If 
I am asked any question that I do not want to answer, I can simply 
say, "I do not want to answer that."  
 
9. With my permission, the interviewer will audiotape the interview. 
The recordings will be used for research purposes only. The 
recordings will be kept until the study is complete; then they will be 
erased.  Declining to be audio-taped will not affect my eligibility to 
participate in this research study. 
 
10. The researchers will not share any of the information from my 
interview with anyone outside the research team. I am completely 
free to choose not to take part in this research. My decision will 
have no impact on my employment at Mbarara ISS Clinic. 
 
Risk/Discomforts 
The risks of participating in this study are minimal. It is possible that I might get 
tired during the interview. I may find some of the questions uncomfortable or hard 
to answer. If this happens, we can (a) discuss the situation, (b) take a break, or (c) 
stop. If I choose to stop, we can either finish the interview another day or I can 
end my participation in the study. Though unlikely, there is always a chance of a 
breach in confidentiality when taking part in a research study. The researcher will 
make every effort to protect me from this risk.  
There may be uncommon or previously unknown risks.  I shall report any 
problems to the researcher. 
Confidentiality 
• My privacy is protected as a participant in this study. This means that 
my identity will never be released in a way that can be connected 
with me. There will be a number rather than my name on copies of 
my interviews. All of the interviews, research documents and audio 
recordings will be kept in a locked office of research study personnel 
in Mbarara. Computer files will be protected with a password.  
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• Only the people involved in the research will be able to get this 
information. None of the information I give you will be shared with 
other providers at the HIV/AIDS clinic, my family members or 
anyone else outside the research project. My name will not be used in 
any written reports or articles that result from this project. Every 
effort will be made to ensure that descriptions of individual 
participants are not identifiable in any way. 
 
• Participants will not be identified in any report or publication about 
this study. Although every effort will be made to keep research 
records private, there may be times when federal or state law requires 
the disclosure of such records, including personal information.  This 
is very unlikely, but if disclosure is ever required, UNC-Chapel Hill 
and Mbarara University of Science and Technology will take steps 
allowable by law to protect the privacy of personal information.  In 
some cases, my information in this research study could be reviewed 
by representatives of the University, research sponsors, or 
government agencies for purposes such as quality control or safety. 
 
• At any time point during the interview, I may request that the audio 
recorder be turned off. 
 
_____ OK to record me during the study 
_____ Not OK to record me during the study 
If there is need to have an interpreter during the interview, the person shall be a 
member of the research team and shall keep all the information regarding my 
study participation private.  
Benefits 
Research is designed to benefit society by gaining new knowledge.  You may not 
benefit personally from being in this research study. 
 
Alternatives 
I may choose to not participate without the risk of losing my current healthcare or 
medicines.  
Cost 
There shall be no monetary costs to me for being in the study. However, I will 
need to devote 1-2 hours of my time to participate in the study, for which I shall 
not be compensated with cash per Mbarara University of Science and Technology 
guidelines on research.  
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Reimbursement 
I shall be provided with transportation home in the form of a free ride home or 
transport cost reimbursement after completing the interview if I decline the free 
ride home. 
Questions 
This study has been explained to me and my questions have been answered.  If I 
have any additional questions, I can call the Study Principal Investigator, Ms. 
Nneka Emenyonu at 0782027158. If I have questions for the Institutional Ethical 
Review Committee at Mbarara University of Science and Technology, I can call 
048520851. 
Consent 
I have been given a copy of this consent form.   
PARTICIPATION IN THIS RESEARCH IS VOLUNTARY.  I have the right to 
participate or withdraw at any point in this study without the risk of losing my 
medical care.   
 
If I wish to participate I should sign below. 
 
______________________________ ___________________ 
Subject’s Signature     Date 
 
______________________________ ___________________ 
Staff person obtaining consent   Date 
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APPENDIX IV: DATA DICTIONARY FOR QUANTITATIVE ANALYSIS 	  
No Variable Description Variable 
type 
Values Location 
  Demographic 
Information 
  UARTO 
study 
Demo-
graphic 
question-
naire 
1 Gender Gender Dichoto-
mous 
Male = 1 
Female = 2 
Pg1 
2 Height Record Height 
(centimeters) 
Continuous Range 0-99 Pg1 
3 Age What is your 
age? 
Continuous Range 18-77 Pg1 
3a Date of Birth Date of birth 
day? 
Nominal DD/MM/YR Pg1 
4 Tribe What is your 
tribe? 
Nominal 1-5 Pg1 
5 Religion What is your 
religion? 
Nominal 1-7 Pg1 
6 Education Highest Level 
of school 
completed 
Ordinal 1-p1-p6 
2-p7 
3-s1-s3 
4-s4 
5-s5 
6-s6 
7- Vocational 
8-University 
9-Postgraduate 
0-No school 
Pg2 
7 Job training Any other type 
of job training  
Categorical Yes =1,  No =0 Pg2 
8 Literacy Can you read 
this sentence? 
Ordinal 1-Cannot read at all 
 
Pg2 
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8 
cont. 
Literacy Can you read 
this sentence 
Ordinal 2-Able to read only 
parts of the sentence 
3-Able to read whole 
sentence 
4-No card with 
required language 
 
9 Source of 
income 
What is the 
main activity or 
Job you do to 
provide for 
family/ 
household? 
Ordinal 1-Teacher 
2-Student 
3-Technician/ 
artisan 
4-Military/ 
Police/ 
Security 
5-Business person 
(other than selling 
goods) 
6-Construction 
worker 
7-Housekeeper 
8-Farmer (agro, 
animal husbandry, 
etc) 
9-None/ 
Unemployed 
10-Local brew 
seller/bar or 
restaurant attendant. 
11-Selling goods 
(direct interaction 
with customers) 
12- Trucker/ 
Driver/ 
Conductor 
13- 
Government/Clerical
/ 
Secretarial 
14-Mechanic 
15-Health care 
worker 
16-Sex worker 
17 Trader 
18-Other 
Pg2 
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18 Income What is your 
income? 
Continuous  Pg5 
 Socio-    
economic 
status 
Summary  
of socio-
economic 
measures 
Categorical Scale of 1-10 
1 – lowest status 
10 – highest status 
Entire 
socio-
economic
section  
22a Marital status Are you 
currently 
married, 
widowed, 
divorced or 
separated? 
Categorical 1-4 Pg6 
22b Spouse HIV 
status 
Is your spouse 
or partner 
infected with 
HIV/AIDS? 
Categorical 1-Yes 
0-No 
8-Do not know 
status 
Pg6 
22c Spouse ARV 
status 
Is your spouse 
or partner 
currently using 
antiretroviral 
therapy? 
Categorical 1-Yes 
0-No 
8-Do not know 
status 
Pg6 
40 Travel time 
to clinic  
How long it 
takes to travel 
from house to 
clinic in 
minutes 
Ordinal 1- Less than 30 
minutes     
2- Between 30 and 
60 minutes    
3- Between 1 and 2 
hrs          
4- More than 2 hrs   
Pg11 
42 Cost of travel 
to clinic 
Cost of 
traveling from 
house to clinic 
and back 
Continuous  Pg11 
44 Means of 
transport to 
clinic 
Primary means 
of transport to 
clinic 
Categorical 1-walking 
2-bicycle 
3-public bus 
4-motobike 
7-public taxi 
6-special hire taxi 
5-car own by you 
or member of 
household 
Pg11 
 160	  
1-23  Alcohol/ 
Drug use 
  UARTO 
Alcohol/ 
Drug Use 
Question-
naire 
1 Alcohol use Alcohol use 
calculated via 
AUDIT score 
Ordinal 0-Non drinker       
1-Light drinker       
2-Moderate drinker  
3-Heavy drinker 
Standard-
ized 
AUDIT 
question-
naire  
17 Current 
drinking 
status 
Last date of 
alcohol use 
 DD/MM/YR Pg 3 
27 Drug Use Recreational 
drug use 
 
Dichoto-
mous 
Yes = 1,  
No = 0 
Pg 6 
  Distance to 
clinic 
  UARTO 
GPS data 
 Distance, 
route and 
mode of 
travel to 
clinic 
Distance, route 
and mode of 
travel to clinic 
mapped on a 
GPS  
Continuous   
  Biological 
variables 
  Lab data 
 CD4 cell 
count 
Laboratory 
results at 
Baseline and 
quarterly 
thereafter on 
CD4 cell count 
Continuous Range –  
0 - >1000 
 
 Viral load Laboratory 
results at 
Baseline and 
quarterly 
thereafter on 
viral load 
Continuous <400 copies - 
>10,000 copies 
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